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Abstract
Over the years, HIV infection has become a manageable disease with marked 
reduction in mortality from AIDS. However, major comorbidity due to the virus 
itselt and its treatments has become important. This includes development of 
lipodystrophy (LD) and cardiovascular disease (CVD). Up to 40% of HIV 
positive patients on antiretroviral therapy develop LD. CVD now accounts for 
up to 10% of deaths in these patients, with combination antiretroviral therapy 
being independently associated with a 26% relative increase in the rate of 
myocardial infarction per year of exposure during the first four to six years of 
use.
The aims of this thesis were to investigate the factors known to predispose to 
the development of LD and CVD namely blood lipids, insulin resistance and 
cytokine derangements such as tumour necrosis factor-a, interleukin-6, 
adiponectin, leptin, resistin and visfatin; to assess the levels of pre-existing 
conditions known to increase the risk factors of CVD; the actions taken by 
physicians in managing these conditions and to summarise the possible 
interactions between drugs used to treat dyslipidaemia and protease inhibitors. 
A population of 64 HIV-positive patients on antiretroviral therapy was studied 
over a 12-month period. Three groups were evaluated: those taking a 
thymidine based regimen (group 1), those taking a non-thymidine based 
regimen (group 2) and those who switched from a thymidine to a non­
thymidine based regimen (group 3). Two audits were carried out involving the 
review of a total of 179 case-notes. A systematic review was conducted to 
summmarise the drug-drug interactions between protease inhibitors and 
statins, which are commonly used to treat dyslipidaemia.
In the longitudinal studies, the patients were virologically and immunologically 
controlled. Antiretroviral drugs such as thymidine analogues (stavudine and 
zidovudine) and protease inhibitors such as ritonavir boosted lopinavir were 
still being commonly used at the time the studies were conducted. LD was 
common, both as perceived by the patient or diagnosed and documented in 
the case-notes by clinicians. Pre-existing risk factors of CVD were common, 
with high smoking rates (up to 59%), high calculated CV risk over 10 years or 
pre-existing CVD (up to 15%), high lipids (up to 61%), high glucose levels (up 
to 13%), high blood pressure (up to 11.5%) and family history of premature 
ischaemic heart disease (up to 21%). Patients on abacavir showed a 
worsening of their calculated CV risk over 12 months. Glucose tolerance and 
insulin resistance were not significantly different between the three groups. 
TNF-a levels were higher in all groups (4.6-6.3pg/ml) than has been 
documented in HIV negative individuals (1.8pg/ml). IL-6 levels increased over 
the study period in group 3 and group 1 (2.6 pg/mL and 0.3 pg/mL 
respectively) and did not change in group 2. Adiponectin levels declined by 
32% in group 1 and 22% group 3; leptin levels declined by 29% in group 1
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while resistin levels increased by 37% in group 1 and 57% in group 3. Visfatin 
was undetectable in all patients.
The audits showed that in typical HIV clinics, CVD risk factors are common. In 
North Manchester, smoking rates amongst patients were up to 60%, 
dyslipidaemia was found in up to 61% of patients. Up to 21% of patients were 
at high risk (>20%) of developing CVD over a period of 10 years. Patients on 
abacavir were nearly twice as likely to have a moderate risk (10-20%) of 
developing CVD than those that were not on the drug (31% vs. 15.8% 
respectively) and also more likely to be at high risk of developing CVD than 
those not on the drug (33% vs. 20% respectively). Patients were on the whole 
appropriately investigated and managed to correct the abnormalities identified. 
However, in some instances, documentation was not complete, with up to 21% 
of case-notes having incomplete information so that CV risk percentage could 
not be calculated; which may have underestimated the true level of CV risk in 
this population. Additionally, some patients that required high levels of 
interventions according to existing guidelines were not managed accordingly.
The systematic review demonstrated that the pharmacokinetic changes of 
statins when concommittantly administered with Pis mostly depend on the 
extent to which the statin is metabolised by the cytochrome (CYP) P450 
enzyme system. Simvastatin, being extensively metabolised by this system, 
rises to very high concentrations in the presence of Pis (AUC,3000%; Cmax, 
500%), while atorvastatin, which is less extensively metabolised by CYP450, 
shows moderate increases (AUC,70%; Cmax, 122%). Rosuvastatin and 
pravastatin are metabolised by non-CYP pathways and therefore not expected 
to have any interactions with Pis. However, rosuvastatin levels rise (AUC, 
200%; Cmax, 600%) while pravastatin levels drop (AUC and Cmax, 40-50%) 
when coadministered with some Pis. These unexpected changes could be due 
to interaction at the level of efflux drug transporters in the intestine and liver 
such as organic anion transporting polypeptides (e.g. OATP1B1), P- 
glycoprotein, multidrug resistance-associated protein (MRP2) and breast 
cancer resistance protein (BCRP). These interactions could result in reduction 
of the efficacy of statins, or predispose to toxicity which has resulted in deaths.
In conclusion, LD and CVD are common in HIV patients. Understanding the 
underlying mechanisms will help the development of management strategies 
for these conditions. Physicians treating these patients need to be aware of 
guidelines for treating these conditions, be vigilant for drug-drug interactions 
due to the polypharmacy that is necessary in these patients, and adopt a 
multidisplinary approach to manage these complex patients.
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CHAPTER ONE
GENERAL INTRODUCTION
1.1 HIV AND AIDS
1.1.1 History and epidemiology
The acquired immunodeficiency syndrome (AIDS) was first described in 1981 
in gay men in California in the USA who presented with opportunistic infections 
such as Pneumocystis jiroveci pneumonia or PCP (previously called 
Pneumocystis carinnii) (Gottlieb et al. 1981). The Centres for communicable 
Disease Control established a case definition of AIDS in 1982 (CDC 1982) and 
the virus was identified in 1983 (Barre-Sinoussi et al. 1983). Since 1981, the 
virus has rapidly spread through most countries of the world reaching 
pandemic proportions, with the brunt of the disease being borne by countries 
in Sub-Saharan Africa. The pandemic is thought to have peaked in 1999 and 
appears to have reached a plateau in 2007 (figure 1-1 Panel a~b). There are 
now fewer new infections, a decline of 19% since 1999. This is thought to be 
because of increased provision of antiretroviral therapy (ART) and change in 
behaviour including increased condom use resulting in reduction in 
transmission of the disease (Montaner et a/.; Shelton et al. 2006; UNAIDS 
2010). There are now 33.3 million people living with the disease as of 2010; 
and two thirds of cases being in Sub-Saharan countries (figure 1-2) (Shelton et 
al. 2006; UNAIDS 2010).
The advent of highly active antiretroviral therapy (HAART) has turned HIV 
infection from an almost uniformly fatal disease to a manageable chronic 
illness. Indeed deaths from HIV or AIDS are declining due to the scale up of
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the provision of ART, particularly in developing countries (figure 1-1 Panel c) 
(UNAIDS 2007; UNAIDS 2010).
Figure 1-1: Epidemiology of HIV/AIDS
Panel (a)
Global HIV trands, 1990 to 2009
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Figure 1-2: HIV prevalence by region
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Figure 1-3: HIV Structure
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1.1.2 Pathogenesis of HIV Infection
HIV is an RNA virus (Figure 1-3), a member of the human ientivirus family 
which has a propensity to infect cells of the immune system (Haase 1986; 
Fauci 1988; Haase et al. 1990; Levy 1993). There are two types of HIV: HIV 1 
is widespread throughout the world and is more virulent; and HIV 2, which 
causes a less severe disease and is confined to West Africa. Co-infection with 
both viruses does occur and is common in West Africa (Whittle et al. 1994).
HIV is acquired via sexual intercourse or parenteraiiy via intravenous drug use 
or blood products. HIV gains entry into the host cell via attachment of its 
surface glycoprotein (gp120) to the CD4 receptor on cells bearing this receptor 
namely the helper T lymphocytes, follicular dendritic cells (in lymph nodes), 
monocytes, macrophages and antigen presenting cells such as dendritic cells 
(in blood and mucous membranes) and langerhans cells (in skin) (Pope et al. 
1994). The virus also uses chemokine coreceptors namely CCR5 and CXCR4 
to attach to the target cells (Figure 1-4) (Ray and Dorns 2006; Sierra et al. 
2007). Within the cell cytoplasm the virus uses its reverse transcriptase to 
transcribe its RNA into double stranded DNA which is then integrated into the 
host chromosomes using viral integrase enzyme within the host cell nucleus 
(Figure 1-5). Once the provirus DNA has integrated, the cell machinery is then 
used to produce viral polyproteins. Viral protease enzyme cleaves the large 
Gag-Pol polyprotein to yield definitive components of the virus which are then 
assembled and the mature virus buds out of the host cell (Figure 1-6) (Gotte et 
al. 1999; Van Maeie and Debyser 2005; Vandegraaff and Engelman 2007;
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Basu et al. 2008; Delelis et al. 2008). The virus initially multiplies within the 
mucosal membrane, e.g. the genital tract or rectum, spreads to and multiplies 
within regional lymph nodes followed by systemic spread within 6-10 days 
(Miller et al. 2005; Morrow et al. 2007) (Figure 1-7).
Figure 1-4: HIV entry
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Figure 1-5: HIV Integration
PIC: preintegration complex; Adapted from www. ciinicaloptions. com/novelclasses
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Figure 1-6: HIV lifecycle
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Figure 1-7: Mucosal transmission of HIV
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and traffic virus to the subepithelial compartment. Virus bearing DCs can migrate to lymph nodes 
and transmit virus to permissive T cells leading to virus dissemination. Activation of Tregs (Tr) may 
limit virus-specific immune responses. Although both R5 and X4 HIV possibly cross the epithelial 
barrier there seems to be preferential amplification and dissemination of R5 HIV. HSV-2: Herpes 
simplex virus-2. Picture taken from Morrow et al (Morrow et al. 2007)
1.1.3 Natural course of HIV disease
Figure 1-8 depicts the natural course of HIV infection in the absence of 
treatment.
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Figure 1-8: HIV time line
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1.1.3.1 Primary HIV infection or seroconversion illness
This occurs within days or weeks after the initial infection and patients that 
develop this are likely to be fast progressors than those that don’t (Lindback et 
at. 1994; Vanhems et ai 1998). It can manifest as:
• “Glandular fever-like” syndrome: fever, pharyngitis, lymphadenopathy and 
malaise.
• Dermatological: erythematous maculopapular rash, urticaria, and mouth 
ulceration.
• Gastrointestinal: nausea, diarrhoea, and candidiasis.
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• Neurological: headache, meningoencephalitis, peripheral neuropathy, and 
Guillain-Barre syndrome (Tindall etal. 1988; Schacker etal. 1996).
1.1.3.2 Chronic HIV infection
With continuing destruction of CD4+ effector cells, significant 
immunosuppression eventually develops over years and the patients succumb 
to opportunistic infections and malignancies such as Kaposi’s sarcoma and 
lymphomas amongst others resulting in death. Chemotherapy with 
antiretroviral drugs dramatically changes the outlook of this disease, with 
restoration of immune function and suppression of viral replication.
1.1.4 Treatment of HIV infection
Treatment guidelines for the management of HIV have been established. 
Treatment guidelines recommend that patients be administered a combination 
of at least two to three active drugs from at least two different classes, and that 
the goal of therapy for all patients should be to control virus replication, as 
measured by a plasma viral load below the quantification limit of current 
available assays, i.e. 50 or 40 HIV RNA copies/mL (Gazzard 2008; DHHS 
2009; EACS 2009; Thompson et al. 2010). This aims to minimise the 
development of mutatipns in the virus. Starting treatment depends on the 
stage of disease.
1.1.4.1 Primary HIV infection (PHI)
The aims of treating PHI are:
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(1) Preservation of specific anti-HIV immune responses that would otherwise 
be lost, and which are associated with long-term nonprogression in untreated 
individuals.
(2) Reduction in morbidity associated with high viraemia and CD4 depletion 
during acute infection.
(3) Reduction in the risk of onward transmission of HIV.
Situations in which treatment may be beneficial include
- neurological involvement 
any AIDS-defining illness
- a CD4 cell count persistently below 200 cells/mL (i.e. for 3 months or 
more).
However, the benefits of treating this stage, often using a finite course of ART 
are not well established, with only short term improvements in immunological 
markers, viral load and CD4 lymphocyte count (Hecht et al, 2006; Fidler et at. 
2007). More recently this approach was shown to produce some benefit with 
modest delay in progression to requiring therapy in those offered treatment 
compared to those deferring treatment (Hogan C 2010). However, new 
treatment guidelines recommending earlier treatment initiation and 
complications associated with treatment interruption in the SMART study 
(increased opportunistic diseases and death in those interrupting treatment) 
means this approach may not be applicable (Lundgren et al. 2008a; DHHS 
2009).
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1.1.4.2 Chronic HiV infection
It is recommended that treatment is started when the CD4 count falls below 
350cells/mm3. This is based on the fact that studies have shown increased risk 
of both death and disease progression as well as mortality from non-AIDS 
illnesses (e.g. malignancies and CVD) associated with lower CD4 ceil counts, 
though there is no specific clear threshold at which risk increases (Opravil et 
al. 2002; El-Sadr et al. 2006; Phillips et al. 2007). Instances where treatment 
may start early when the CD4 count is above 350cells/mm3 include
- AIDS diagnosis (e.g. Kaposi’s sarcoma); any HIV-related comorbidity
- Hepatitis B infection, where treatment of hepatitis B is indicated
- Hepatitis C infection in some cases, where treatment for hepatitis is 
deferred
- Low CD4 percentage (e.g. 14%, where PCP prophylaxis would be 
indicated)
- Established CVD or a very high risk of cardiovascular events (e.g. 
Framingham risk of CVD >20% over 10 years) (Gazzard 2008).
1.1.4.3 Special situations requiring ART
WHO recommends that pregnant women with confirmed HIV serostatus initiate 
ART for their own health if the CD4 cell count <350 cells/mm3, irrespective of 
WHO clinical staging; or if in WHO clinical stage 3 or 4, irrespective of CD4 cell 
count. Provision of HAART to pregnant women not needing ART for their own 
health is recommended for the prevention of transmission of the virus to the 
baby perinatally starting from 14 weeks of pregnancy or as soon as possible 
when women present later in pregnancy or in labour or delivery until one week
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after all exposure to breast milk has ended. Additionally, WHO recommends 
that infants (breast-fed or otherwise) born to HIV-infected women receiving 
ART for their own health should receive ART in the form of monotherapy with 
either NVP or AZT for 4 to 6 weeks and those born to mothers taking ART 
prophylaxis for prevention of mother to child transmission (PMTCT) receive 
daily NVP from birth until one week after all exposure to breast milk has ended 
(WHO 2009). ART reduces the transmission from mother to child from an 
average of 26% to 1% (Lyall et al. 2001).
Post-exposure prophylaxis is ART given to prevent HIV transmission after 
sexual intercourse or occupational exposure to bodily fluids e.g. needlestick 
injury. It is reserved for exposures that are associated with a credible possibility 
of HIV transmission, usually considered to be at least a 0.1% risk of 
transmission from a source patient who is known to be HIV-positive or a source 
patient whose serologic status is unknown but who is at high risk for HIV 
infection (Landovitz and Currier 2009). Prophylaxis with zidovudine alone has 
been shown to reduce the risk of seroconversion after occupational exposure 
by 81% (Card© et al. 1997). Current PEP guidelines recommend PI based 
HAART for 4 weeks started within a few hours up to a maximum of 48 hours of 
exposure (Tsai et al. 1998; EACS 2009).
Preventing acquisition of HIV in HIV negative people has received much 
attention lately. Early treatment of HIV positive partners in serodiscordant 
couples regardless of CD4 count levels has been shown to be effective in
16
preventing transmission of HIV to the HIV negative partner, showing a 96% 
reduction in transmissions (Cohen et al. 2011). Pre-exposure prophylaxis with 
ART in HIV negative people at high risk of acquisition of HIV has also recently 
been studied, with two studies showing effectiveness in this intervention. Grant 
et al in the iPrEx trial showed a 42% reduction in transmission of HIV with daily 
oral truvada (tenofovir and emtricitabine) vs. placebo in HIV negative men 
having having sex with men (MSM) and transgender women taking, but this 
was very much dependent on the level of adherence to treatment (Grant et al. 
2010). Intravaginal tenofovir (1%) gel applied before and after sexual in 
women has shown an overall 39% reduction (54% reduction with high gel 
adherence) in acquisition of HIV infection compared to placebo (Q.A. Karim et 
al. 2010). However a study currently undergoing closure has reported interim 
results revealing equal numbers of infection in the treatment arm (TDF and 
FTC) and placebo groups (FHI 2011). Based on the MSM study, the US 
Centres for Disease Control and Prevention has issued interim guidance for 
clinicians to support daily oral truvada in high risk MSM (CDC 2011). The 
British HIV Association (BHIVA) and British Association for Sexual Health and 
HIV (BASHH) have jointly recommended that at the present time pre-exposure 
prophylaxis be offered in the context of clinical research studies (Fidler 2011).
1.1.4.4 Monitoring of treatment
CD4 cell count and plasma viral load are used as surrogate markers of 
success of treatment with ART. Reduction in viral load leads to a rise in 
peripheral blood CD4 cell count, with greater rises being seen in those with 
greater and more sustained viral suppression. However the CD4 cell count is a
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better indicator of the immediate risk of AIDS-defining diseases than the viral 
load in those on ART (Staszewski et a!. 1999; Ledergerber et al. 2004; 
Gazzard 2008).
1.2 ANTIRETROVIRAL DRUGS 
1.2.1 ART classes
The first antiretroviral drug to be licensed for use against HIV was zidovudine 
(AZT) in 1987 (Ezzell 1987). Since then, there are now many licensed 
antiretroviral drugs which attack the virus at different levels of its replication 
cycle. The need to develop new drugs is driven by several factors, namely to 
overcome the effects of resistance mutations in the virus, to improve the 
toxicity profiles of the drugs and to reduce the pill burden which would impact 
on compliance with treatment. Table 1-1 lists the ART drugs currently licensed 
for use in the UK.
Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs, NtRTIs) are 
analogues of natural nucleosides and so act as alternative substrates for DNA 
polymerases. NRTIs are inactive as administered, reqy$ng anabolic 
phosphorylation within target cells to achieve their antiretroviral effects. All 
NRTIs are converted to nucleoside triphosphates, which serve as the active 
metabolites (the NtRTI, TDF, only requires conversion to the diphosphate 
form) (Piliero 2004). Because NRTIs lack a hydroxyl group in the 3'-position 
(required for the addition of the next nucleotide onto the primer) their
18
incorporation causes termination of the growing DNA strand (Cherry and 
Wesselingh 2003).
Table 1-1: Antiretroviral drugs licensed in the UK
Reverse transcriptase inhibitors Protease
inhibitors
Entry inhibitors Integrase
inhibitors
Nucleoside Nucleotide Non­
nucleoside
Fusion
inhibitors
CCR5
inhibitors
Zidovudine Tenofovir Efavirenz Ritonavir Efunvirtide Maraviroc Raltegravir
Stavudine Nevirapine Lopinavir
Lamuvudine Etravirine Saquinavir
Emtricitabine Indinavir
Abacavir Atazanavir
Didanosine Fosamprenavir
Tipranavir
Darunavir
| Nelfinavir
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are polycyclic 
compounds that show chemical diversity. They inhibit RT by binding to a site 
near its catalytic site. The interaction with RT induces conformational changes 
that impact the catalytic activities of the enzyme. NNRTs are active against 
HIV 1 only, and not other retroviruses like HIV 2 (Sluis-Cremer et al. 2004; de 
Bethune 2009).
Protease inhibitors (Pis) work at the level of viral maturation by blocking the 
cleaving of the Gag-Pol polyprotein by viral protease enzyme (Dau and 
Holodniy 2009).
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There are a number of new drugs that have been approved in recent years 
targeting the virus at different levels of its life cycle. Entry inhibitors include the 
fusion inhibitor efunvirtide (T20) which bind to the viral transmembrane fusion 
peptide gp41 preventing the viral membrane from fusing with the host cell 
membrane; and CCR5 co-receptor antagonists which block the binding of the 
virus to the CCR5 receptor, blocking cell entry. Maraviroc has recently been 
approved in this class while vicriviroc’s development was halted in 2010. 
Integrase inhibitors are a new class of antiretrovirals that inhibit HIV proviral 
DMA integration into the host genome. Raltegravir is a new drug that inhibits 
the strand transfer in the integration process. Elvitegravir is in advanced 
clinical trials (Pommier et al. 2005; Dau and Holodniy 2009).
1.2.2 Adverse effects of antiretroviral drugs
The use of a combination of drugs in HAART means that adverse effects are
common. The adverse effects may be due to the individual drugs. Adverse 
effects of HAART are considerable and may be severe, having both short and 
long term impact on outcome of the disease. Adverse effects can occur early 
at start of therapy, consisting of side effects that are common to most drugs in 
clinical use such as gastrointestinal effects (nausea, vomiting and abdorpinal 
pain) and headache. Liver toxicity and skin rashes can occur with nevirapine 
(NVP) particularly in the first 6 weeks of therapy which can occasionally lead to 
life threatening hepatitis in 3% of patients and toxic epidermal necrolysis or 
Steven-Johnson syndrome in 0.3% of patients (Pollard et al. 1998; Popovic et 
al. 2009). Neuropsychiatric problems are the commonest early adverse effects
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of efavirenz (EFV), manifesting as vivid dreams and/or nightmares, sleep and 
mood disturbance, drowsiness, dizziness and disorientation. These are mostly 
mild but may be severe enough to warrant discontinuation of the drug and drug 
switch (Boly et al. 2006; BSM 2011). EFV may also be teratogenic; there have 
been six retrospective reports of neural tube defects in mothers taking 
efavirenz in the first trimester; and in a prospectively reported ART Pregnancy 
registry, one of 14 of 501 live births (first trimester exposure) was a neural tube 
defect as of July 2009. Flowever, the relative risk of efavirenz use in early 
pregnancy remains uncertain (BSM 2011). Treatment guidelines recommend 
that women of childbearing potential be warned about becoming pregnant 
whilst on efavirenz and wherever possible EFV should be avoided in women 
who may contemplate pregnancy (Gazzard 2008; EACS 2009).
Late adverse effects of HAART have become the subject of interest lately due 
to their impact on the success of HAART, adherence and non-AIDS related 
mortality such as from cardiovascular disease (CVD), The long term effects 
caused by the three classes of drugs, i.e. the NRTIs, the NNRTIs and Pis, 
which form part of HAART in regimens in common use at present, are 
discussed. The long term effects include lypodystrophy, hyperlipidaemia, 
insgljp resistance with resultant glucose intolerance or diabetes and 
cardiovascular disease.
1.2.2.1 HIV lipodystrophy
Lipodystrophy (LD) refers to body fat redistribution, it comprises peripheral 
lipoatrophy (LA), localized fat accumulation or lipohypertrophy (visceral,
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breasts, back of neck and lipomata). The LD syndrome is a combination of 
these morphological changes and hyperlipidaemia, insulin resistance and 
hyperglycaemia (Chen et al. 2002). The prevalence rate of LD in patients on 
highly active antiretroviral therapy (HAART) is reported to be up to 40% (Chen 
et al. 2002; Kinlaw and Marsh 2004). The prevalence of the condition 
increases with time on therapy, and changes usually become clinically 
apparent only after several months (Veny et al. 1998). The frequency of LD, 
not unexpectedly varies with the drugs used. Nucleoside reverse transcriptase 
inhibitors (NRTIs), particularly thymidine analogues (AZT and D4T), have been 
associated with extremity fat loss (Moyle et al. 2006), while protease inhibitors 
(Pis) have been associated with localized accumulation of fat (Behrens et al. 
1999). Since the drugs are often used together as part of highly active 
antiretroviral therapy (HAART), clinical data suggest that they act 
synergistically in causing LD. The virus itself is thought to contribute to 
development of LD, though changes continue to worsen despite virological and 
immunological control in patients that are followed up after starting ART 
(Mallon et al. 2003). The body changes of LD are distressing and can be 
stigmatizing for sufferers (Figure 1-9).
The mechanism of LD is complex. In studies involving HIV patients, 
lipodystrophic patients show morphological alterations of the adipose tissue 
with abnormal expression of adipocytokines (such as adiponectin) and pro- 
inflammatory cytokines such as tumour necrosis factor-a (TNF-a) and 
interleukin 6 (IL6), as well as adipocyte transcription factors (Lagathu et al. 
2004). Patients have elevated circulating levels, and increased tissue mRNA
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expression, of TNF-a and IL-6 (Lihn ef a/, 2003; Vigouroux et al. 2003; Jan et 
a/. 2004). Lipoatrophic fat from patients has also been shown to have reduced 
adipogenic transcription factors such as sterol regulatory element-binding 
protein 1c (SREBP-1c), CAAT enhancer-binding protein-a (C/EBP-a) and 
peroxisome proliferator activated receptor-gamma (PPAR-y), which are all 
involved in adipocyte differentiation (Kannisto ef al. 2003; Jan et al. 2004,
Jones ef al. 2005c). Additionally, lipodystrophic HIV patients also have 
reduced mRNA expression of adiponectin and leptin, and decreased levels of 
these proteins (Vigouroux ef al. 2003; Jan ef al. 2004; Lagathu ef al. 2005). 
Taken together, all these changes probably account for the increased 
apoptosis, and decreased differentiation, of adipocytes seen in these patients, 
which ultimately lead to lipoatrophy (Jan ef al. 2004).
The metabolic effects of the LD syndrome namely the dyslipidaemia, glucose 
intolerance and insulin resistance are traditional risk factors for cardiovascular 
disease in the general population (Stamler ef al. 1986; Wilson ef al. 1998).
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Figure 1-9: Various Appearances of HIV Lipodystrophy
1. Facial lipoatrophy; 2. Lipoatrophy of leg; 3. Lipoatrophy of buttocks; 4. Increased abdominal 
girth secondary to visceral adiposity; 5. Buffalo hump; 6. Lipoma
1.2.2.2 Mitochondrial toxicity
Mitochondrial toxicity occurs through inhibition of mitochondrial DMA (MtDNA) 
polymerase-y leading to hyperlactataemia and organ-based toxicities involving 
the liver, pancreas, peripheral nerves and skeletal muscle in particular (Walker 
2003). Walker et al (2001) have also shown a link between peripheral 
lipoatrophy and mitochondrial toxicity in that patients with lipoatrophy had more 
pronounced mitochondrial depletion in biopsies from subcutaneous 
lipoatrophic tissues. The degree of mitochondrial toxicity depends on the drugs 
used, with in vitro studies using HepG2 human hepatoma cells showing the 
worst effects with zalcitabine (DDC, which is no longer in clinical use), DDI and
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D4T in reducing order. TDF and 3TC show minimal or no mitochondrial 
toxicity. AZT, FTC and ABC impair cell proliferation and increase lactate and 
lipid production but show no mitochondrial depletion. Combinations of the 
drugs show that they act synergistically to cause mitochondrial toxicity, with 
pyrimidine combinations (such as DDC and D4T) being the worst offenders 
(Squires 2001; Walker et al. 2002; Walker 2003; Venhoff etal. 2007). The level 
of affinity of the active metabolites of the drugs for mtDNA polymerase-y is 
thought to underlie these differences (Squires 2001).
1.2.2.3 Insulin resistance
Insulin resistance occurs when there is a reduction in the ability of circulating 
insulin to induce uptake of glucose into cells. Insulin stimulates its cell surface 
receptor, which sets up a phosphorylation cascade, firstly of insulin receptor 
substrate-1 (IRS-1) which in turn initiates a number of further phosphorylation 
reactions. These eventually result in translocation of the glucose transporter 4 
(GLUT4), from the cytosol to the cell surface where it facilitates glucose entry 
into the cell (Samaras et al. 2007).
Insulin resistance underlies many of the metabolic diseases including obesity, 
type II diabetes, atherosclerotic heart disease and hyperlipidaemia (Reaven 
198?; Samaras et al. 2Qp7). Dysfunction of adipose tissue may be involved in 
the pathogenesis of insulin resistance. The adipocyte has been shown to be 
actively involved in energy homeostasis by secreting hormones^or proteins-that 
have collectively been termed adipocytokines (such as adiponectin, leptin, 
resistin, visfatin and vaspin) (Fasshauer and Paschke 2003; Rajala and
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Scherer 2003; Fukuhara et al. 2005). Adipocytes also secrete pro-inflammatory 
cytokines such as TNF-a and IL-6 (Rajala and Scherer 2003; Lagathu et al. 
2004). These cytokines are known to affect glucose and lipid metabolism and 
may also alter body habitus; derangements in the levels of these cytokines 
result in insulin resistance (Fasshauer and Paschke 2003; Rajala and Scherer 
2003; Lihn et al. 2005). Obese and type II diabetic patients have raised levels 
of TNF-a, IL-6 and leptin; they also show reduced levels of adiponectin while 
levels of resistin have been variable (Lagathu et al. 2004). Altered levels of 
adipocytokines and pro-inflammatory markers have also been demonstrated in 
in vitro (in murine and human adipocyte cell lines) and in vivo studies with the 
use of NRTIs (particularly AZT and D4T) and Pis in HIV patients (Janneh et al. 
2003; Jones et al. 2005b; Lagathu et al. 2005; Kim et al. 2006; Noor et al. 
2006). Pis led to the following changes in these studies:
• A reduction in lipid accumulation in adipocytes.
• Increase in adipocyte apoptosis leading to a reduction in cell numbers.
• Induction of insulin resistance by:
o Inhibition of insulin-stimulated glucose uptake via inhibition of the 
glucose transporter (GLUT-4), 
o Induction of IL-6 and TNF-a.
o Reduction in-gene expression and secretion of adiponectin. 
o Increased lipolysis.
The ability of Pis to induce these changes varies between the individual drugs,
with LPV, RTV, SQV and NFV being the worst offenders (Janneh et al. 2003;
Jones et al. 2005b). The PI ATV has a much reduced effect (Kim et al. 2006;
Noor et al. 2006). IDV did not have much effect on cell viability or lipogenesis
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but inhibited glucose uptake to a greater extent than the other Pis (Janneh et 
a/. 2003; Jones et al. 2005b). With regard to NRTIs, Jones et al. and Janneh et 
al. showed in murine adipocyte cell lines (3T3-L1 and 3T3-F442A) that AZTand 
D4T were not cytotoxic, did not affect adipogenesis or induce lipolysis and did 
not up-regulate the expression of IL-6 and TNF-a. However, Lagathu et aL 
working with the same murine cell lines found that AZT and D4T raised levels 
of IL-6 and TNF-a (Lagathu et al. 2005). These two thymidine analogues also 
reduced the levels of adiponectin, which could contribute to insulin resistance 
(Lagathu et al. 2004; Jones et al. 2005b). Pacenti et al. also found that AZT 
and 3TC, either alone or in combination, did not significantly alter the viability 
and adipogenesis of 3T3-L1 cells (Pacenti et al. 2006). The differences in 
findings in these studies may be due to differences reasons. For example, 
drug concentrations used were different; Janneh et al and Jones et al used 
20pM of Pis while Lagathu et al used 10pM, while for NRTIs, Janneh et al 
used 1pM, Jones et al used 20pM and Lagathu et al used 10pM. Sources of 
the drugs, cell lines and assays used such as for ELISA tests were sourced 
from different suppliers with attendant different methodologies. Additionally, 
different methods were used to determine cell viability and adipocyte function
were different.
Large cohort studies in HIV patients on ART have shown development of 
insulin resistance in these patients with resultant glucose intolerance or 
diabetes (Brown et a/. 2005; Rosso et al. 2007; Tien et al. 2008).
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1.2.2.4 Dyslipidaemia
Lipid disorders are common in HIV-infected patients. Deranged lipids have 
been demonstrated in HIV positive patients who are treatment-naive with low 
total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and high 
density lipoprotein cholesterol (HDL-C) and these effects are thought to be due 
to the virus itself, with factors such as low CD4 counts, high viral loads, age 
and race playing a part (Riddler et al. 2003; El-Sadr et at. 2005). Upon starting 
ART, HIV infected patients have been observed to have increases in TC and 
LDL-C with little change in HDL-C (Riddler et al. 2003; El-Sadr et al. 2005). 
Additionally, compared to their HIV uninfected counterparts, patients on ART 
have been shown to have higher triglycerides and lower HDL-C as well as to 
have an atherogenic lipid profile similar to that found in obese and type 2 
diabetic patients (Riddler et al. 2008). HAART has also been associated with 
the development of dyslipidaemia. Pis have mostly been shown to have this 
effect, with the development of triglyceridaemia and hypercholesterolaemia 
over time (Carr et al. 1998; Jones et al. 2005a). NRTIs have also been shown 
to cause dyslipidaemia. This depends on the type of NRTI, with thymidines 
especially D4T being most implicated. TDF and ABC are associated with a 
more lipid friendly profile and indeed switching from a thymidine NRTI to TDF 
and ABC based regimens results in improvement in lipid levels (Gallant et al. 
2004; Jones et al. 2005a; Vigano et al. 2005; Moyle et al. 2006; Pozniak et al. 
2006). The NNRTl NVP shows little effect on lipids while EFV has been shown 
to have a lipid profile comparable to RTV boosted LPV (Behrens et al. 1999; 
Heath et al. 2001; Jones et al. 2005a; Pirmohamed 2009). The mechanisms of
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dyslipidaemia caused by ART are many and include mitochondrial toxicity, 
increase in lipolysis and adipocyte apoptosis as well as reduction in lipid 
accumulation in adipocytes as described above. Other mechanisms thought to 
underlie this effect are adipose gene expression derangements and 
proteasome defects leading to increased serum lipids:
Adipose gene expression derangements
Whole genome expression analysis using microarrays have provided 
interesting insights into the derangements that occur in the genes involved in 
adipocyte differentiation and lipid metabolism on exposure to antiretrovirals 
(Pacenti et al. 2006). An in vitro study with 3T3-L1 cells showed that Pis (IDV, 
SQV and LPV) induced or up-regulated genes that inhibit adipocyte 
differentiation, and down-regulated the expression of master adipogenic 
transcription factors as well as several genes mainly involved in lipid 
metabolism (Fukuhara et ai. 2005). These are summarized in Table 1.2. The 
same study showed that NRTIs (AZT, 3TC, D4T and DDC) showed a milder 
effect on these genes though they were found to induce a gene, Aebp-1 
(adipocyte enhancer-binding protein-1), the over-expression of which could 
inhibit adipogenesis (Fukuhara et ai. 2005). The PI suppression of 
adipogenesis and lipogenesis genes has been replicated in vivo in the 
subcutaneous adipose tissue (SAT) from lipodystrophic HIV-infected- patients 
(Bastard et al. 2002; Kannisto et al. 2003; Gougeon et al. 2004; Jan et al. 
2004).
Proteasome dysfunction
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Dysfunction of proteasome activity in cells has been implicated in the 
pathogenesis of HIV LD. Proteasomes are multi-subunit protease complexes 
engaged in the turnover of short-lived proteins that regulate a variety of cellular 
processes including signal transduction, stress response, transcription control, 
chromosomal segregation, DMA repair and cell cycle progression (Kruger et al. 
2001). Proteasome activity coordinates protein handling in the endoplasmic 
reticulum (ER) by removing misfolded proteins; disruption of this process leads 
to an ER stress response (Travers et al. 2000; Parker et al. 2005). An in vitro 
study by Parker et al. [working with a human hepatoma cell line (HepG2) and 
3T3-L1 mouse cells] found that Pis inhibited proteasome chemotryptic, and to 
a lesser extent tryptic, activity (Parker et al. 2005). The ER stress response 
induced by the Pis differed between the hepatocytes and the adipocytes as 
outlined in Table 1.3.
Table 1-2: Protease inhibitor effects on adipose tissue genes
Genes inhibiting adipocyte 
differentiation
Master adipogenic transcription 
factors
Genes involved in lipid 
metabolism
f wingless related MMTV 
integration site 10a (WntlOa)
| sterol regulatory element-
jinding protein 1c (SREBP-1c)
[ fat specific gene 27
(Fsp27)
| A-6 fatty acid desaturase 
(Fad2)a
1 CAAT enhancer-binding protein-
a (C/EBP-a)
| leptin (Lep)
l peroxisome proliferator 
activated receptor-y (PPAR-y)
[ adipsin (Adn)
| adiponectin (Adipoq)
J, inducible 6-
phosphofructose-2-kinase
(Pfkfb3)
1 CD36/FAT + S100AEP
]:induced or up-regulated; inhibited or down-regulated
aFad2 has also been associated with insulin resistance.
bCD36/FAT and S100A8 interact to facilitate cellular uptake of fatty acids.
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Table 1-3: Protease inhibitor-induced endoplasmic reticulum (ER) stress 
responses
Cell type/ER stress response Effect
Hepatocytes (HepG2)
tadipogenic and lipogenic transcription factors (C/EBP, 
PPAR-y, SREBP-lc), tmRNA of enzymes of fatty 
acid/cholesterol biosynthesis (e.g. acetyl CoA 
carboxylase, fatty acyl CoA ligase, fatty acid synthase, 
HMGCoA reductase)
Increased production of triglycerides 
and to a lesser extent, cholesterol; little 
effect on glucose transport via GLUT-43
Adipocytes (3T3-L1)
Inhibition of GLUT-4, J,adiponectin (an insulin
sensitizer) Inhibition of glucose uptake
y.up-regulation or increase in levels; i:down-regulation or decrease in levels.
aHepG2 cells express GLUT-3 and GLUT-1 (which are not sensitive to Pis), rather than GLUT-
4 (Parker et al. 2005).
1.2.2.5 Cytokines in HIV patients on ART
Derangements in proinflammatory cytokines and adipose tissue derived 
cytokines (adipocytokines) have been extensively studied and are thought to 
underlie most of the adverse effects of ART. The effects of some of the 
individual pro-inflammatory cytokines and adipocytokines can be summarized 
as follows:
1.2.2.5.1 Tumour necrosis factor-a
TNF-a is a pro-inflammatory cytokine. The level of TNF-a in adipocytes is 
increased in obesity, type II diabetes and HIV patients with LD (Lihn et al. 
2003; Ruan and Lodish 2003; Vigouroux et al. 2003; Jan et al. 2004). With 
regard to obesity, overexpression of TNF-a is higher in omental, compared 
with subcutaneous fat.(Cao et al. 2008) Visceral fat comprises omental and 
mesenteric fat and has been linked in epidemiological studies to the 
development of insulin resistance, dyslipidaemia, type 2 diabetes and 
cardiovascular disease (Haslam and James 2005; Cao et al. 2008). Visceral
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fat accumulation can be a feature of HIV ID (Chen et af. 2002). TNF-a may be 
the link between visceral obesity and development of these complications (Cao 
et at. 2008). TNF-a mediates insulin resistance via reduction of insulin receptor 
kinase activity. It induces lipolysis and down-regulates insulin receptor 
substrate (IRS)-I and the insulin-sensitive glucose transporter (GLUT)-4. It 
may act in an autocrine manner thereby profoundly altering adipose tissue 
biology (Fasshauer and Paschke 2003). It also induces apoptosis, which might 
underlie the lipoatrophy caused by nucleoside reverse transcriptase inhibitors 
(NRTIs) (Lagathu et af. 2004). The secretion of TNF-a is, at least partly, under 
genetic control. The TNF-a gene contains numerous polymorphisms and 
exhibits a complex haplotype structure. Many of these polymorphisms are 
thought to be functionally important, including the promoter region 
polymorphisms at positions -308 and -238, which have been the most widely 
studied. Maher et al. showed an increased frequency of the -238 G-A transition 
in HIV LD patients compared with those without LD. The patients were on both 
protease inhibitors (Pis) and NRTIs. This effect was thought to be attributable 
to the Pis, although the authors acknowledged that the NRTIs might also have 
contributed (Maher et al. 2002). This study, taken together with the replication 
of the findings in an Australian cohort (Nolan et al. 2003), suggests that TNF-a 
-238 promoter region gene polymorphism, which is functionally active, 
increases the risk of developing antiretroviral-related LD (Lindegaard et al. 
2004). The metabolic effects of HIV LD namely hyperlipidaemia, insulin 
resistance and hyperglycaemia are traditional risk factors of CVD.
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1.2.2.5.2 lnterleukin-6
IL-6 is a pro-inflammatory protein; systemic IL-6 is derived from adipose tissue 
(30%), macrophages and smooth muscle cells in vascular endothelium and 
mediates insulin resistance (Fasshauer and Paschke 2003). IL-6 levels are 
raised in obesity and insulin resistance states, and independently predict future 
development of type II diabetes and cardiovascular disease (Pickup et al. 
1997; Plutzky 2001; Pradhan et aL 2001; Cesari et al, 2003). IL-6 stimulates or 
induces hepatic gluconeogenesis with resultant hyperglycaemia and 
compensatory hyperinsulinaemia. It also induces hepatic triglyceride secretion. 
In murine adipocytes and hepatocytes, IL-6 directly impairs insulin signaling 
with decreased activation of IRS-1 and phosphatidylinositol 3-kinase 
(Fasshauer and Paschke 2003). Studies show that IL-6 levels are significantly 
higher in HIV infected patients on ART compared to healthy controls with HIV 
patients having levels that are twice those in HIV uninfected individuals (Jan et 
al. 2004; Ross et al. 2009). The virus itself contributes to raised levels of IL-6 
as demonstrated in the SMART study in those that interrupted therapy with 
resultant detectable viral loads (Kuller et al. 2008). The type of ART drugs the 
patient is on appears to have an effect on IL-6 levels with in vitro studies using 
both murine and human adipocytes showing increased expression and 
secretion of this cytokine in response to both Pis (such as LPV, NFV and RTV) 
and NRTIs (AZT and D4T) (Lagathu et al. 2004; Vernochet et al. 2005).
1.2.2.5.3 C-reactive protein (CRP)
CRP is an acute phase reactant produced in the liver which is marker of low
grade inflammation and has been implicated in the pathogenesis of
atherosclerosis in humans (Blake and Ridker 2002). Its secretion is
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predominantly stimulated by IL-6 (Pepys and Hirschfield 2003). High levels of 
this protein have been found be a predictor of coronary heart disease, 
congestive heart failure and ischaemic stroke in healthy subjects (Tracy et at. 
1997; Koenig et al. 1999; Ridker et at. 2002; Cesari et at. 2003; Pai et at. 
2004). In HIV patients, CRP levels are higher than in the general population. In 
a study by Noursadeghi et al (Noursadeghi and Miller 2005) the median CRP 
was 5.9mg/dL (range 0.5-108.6) in HIV positive patients. The CRP level is 
<3mg/dL in the general population (Pepys and Hirschfield 2003). This reflects 
the fact that there is a state of chronic inflammation in people with HIV; as such 
these patients will be expected to be at higher risk of cardiovascular disease.
1.2.2.5.4 Adiponectin
Adiponectin is a 30kDa cytokine synthesized and secreted exclusively by 
adipose tissue (Lindegaard et al. 2004). It is a potent insulin sensitizer acting in 
adipose tissue, muscle and liver. It has also been shown to have anti­
atherogenic, anti-inflammatory (Ouchi et at. 2003; Hara et al. 2005), 
antiangiogenic and anti-tumour functions (Brakenhielm et al. 2004). The level 
of adiponectin is reduced in obesity, particularly in visceral obesity, and in 
insulin resistant states (Weyer et al. 2001; Lindegaard et al. 2004). It has been 
shown from epidemiological studies that low levels of adiponectin are an 
independent predictor for developing type 2 diabetes (Daimon et al. 2003; 
Spranger et al. 2003), and myocardial infarction (Laughlin et al. 2007; 
Rathmann et al. 2007). Adiponectin profoundly influences endogenous insulin 
sensitivity: it reduces plasma glucose concentration (by reducing liver output of 
glucose), increases fatty acid oxidation in muscle and inhibits hepatic
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gluconeogenesis through its activation of S'-AMP-activated protein kinase 
(AMPK) (Fasshauer and Paschke 2003; Rajala and Scherer 2003; Tsuchida et 
al. 2005). Adiponectin knockout mice have impaired insulin sensitivity 
providing further evidence of its important role in the metabolic diseases that 
afflict a huge proportion of the global population (Kubota et al. 2002; Maeda et 
al. 2002). Adiponectin acts via the adiponectin receptor 1 (AdipoRI) in skeletal 
muscle and adiponectin receptor 2 (AdipoR2) in the liver (Kinlaw and Marsh 
2004). An additional receptor for hexameric and high molecular-weight 
adiponectin is T-cadherin (Kralisch et al. 2007). HIV-associated ID is 
associated with low plasma adiponectin levels and low expression of 
adiponectin in adipose tissue (Vigouroux et al. 2003; Leszczyszyn-Pynka et al. 
2005; Lihn et al. 2005) particularly after administration of Pis (via inhibition of 
adipogenesis), but has also been seen with D4T and AZT (Lindegaard et al. 
2004; Jones et al. 2005c). However, it is thought that the low levels seen with 
NRTIs may be due to a reduction in adipose tissue mass (seen in peripheral 
lipoatrophy) rather than a direct effect of the drugs (Lindegaard et al. 2004; 
Jones et al. 2005c). Consistent with this, in vitro studies have shown that 
adiponectin gene expression is down-regulated by Pis rather than by NRTIs 
(Parker et al. 2005; Pacenti et al. 2006). However, it is important to bear in 
mind that feedback loops operate with regard to cytokine expression and 
levels with in vitro studies in mouse and human adipocytes, showing that the 
levels of adiponectin can also be reduced by the pro-inflammatory cytokines 
TNF-a and IL-6 (Kappes and Loffier 2000; Maeda et al. 2001; Fasshauer et al. 
2002; Fasshauer and Paschke 2003).
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1.2.2.5.5 Resistin
There is conflicting evidence as to whether resistin plays a major role in 
obesity and insulin resistance (Kralisch et al. 2007). It has been suggested that 
resistin impairs glucose tolerance by inducing severe hepatic but not 
peripheral insulin resistance. However, conflicting data from other studies 
suggest that it may not have a major role in glucose homeostasis. For 
instance, while some studies have shown high levels of resistin in obesity, 
others have shown low levels (Fasshauer and Paschke 2003). Data on the 
effects of ARVs on resistin are scanty. A study in HIV patients showed that 
single nucleotide mutations in the resistin gene (C-T transition in the second 
intron of the gene) were associated with the development of adverse metabolic 
changes on HAART. This was further investigated by the same group where 
they showed that patients on HAART (in this study, patients were either on 
D4T and DDI or AZT and 3TC NRTI backbone) with this mutation developed 
significantly elevated lipids and insulin resistance and also experienced 
significant body composition changes, particularly limb fat loss, and all the 
patients were on a thymidine NRTI (Ranade et al. 2008). A study by Kamin et 
al found that levels of resistin were higher in HIV positive patients (both male 
and female) than those in HIV negative individuals (Kamin et al. 2005).
1.2.2.5.6 Leptin
Leptin is mostly expressed in adipose tissue and is found both in the
circulation and cerebrospinal fluid (Rajala and Scherer 2003). It acts centrally
to increase energy expenditure, inhibit appetite and weight gain by decreasing
appetite-enhancing and increasing appetite-inhibiting peptide expression in the
arcuate nucleus of the hypothalamus. It also has peripheral effects on skeletal
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muscle, liver, pancreas, adipose tissue and other cel! types where it acts via 5- 
AMP-activated protein kinase to decrease anabolic pathways (such as 
glucose, lipid and protein synthesis) and increase catabolic pathways (glucose 
and lipid utilization) (Rajala and Scherer 2003). Its levels are raised in obesity 
(Fasshauer and Paschke 2003). Obesity is a known risk factor for 
cardiovascular disease. Hubert et al and Lieb et al found that leptin levels were 
strongly correlated with body mass index (BMI) and high circulating levels were 
associated with a greater risk of congestive heart failure (CHF) and CVD, 
though this risk was attenuated upon adjustment for BMI (Hubert et al. 1983; 
Lieb et al. 2009). Leptin levels have also been found to positively correlate with 
BMI in HIV patients on HAART, although plasma levels of leptin did not differ 
between patients on or off treatment (Leszczyszyn-Pynka et al. 2005; Wunder 
et al. 2005). However, in vitro studies have demonstrated that leptin levels 
increase when human adipocyte stem cells are exposed to the Pis RTV, LPV 
and APV (Vernochet et al. 2005).
1.2.2.5.7 Visfatin
This is a visceral fat adipocytokine that was previously identified* as pre-B cell- 
colony-enhancing factor. It exerts insulin mimetic effects in cultured cells and in 
mice, leading to a lowering of plasma glucose levels, triglyceride accumulation 
in preadipocytes in fat depots and accelerated triglyceride synthesis from 
glucose. It binds to and activates the insulin receptor, at a site different from 
where insulin binds. Visfatin levels are high in obese people, particularly in 
those with increased visceral adiposity (Fukuhara et al. 2005; Haider et al. 
2006). A study found that visfatin levels increased by about 7-fold in HIV-
37
positive patients who were on HAART for 1 year compared with HIV-negative 
individuals, although other parameters of glucose metabolism and body fat 
mass were unchanged (Schindler et al. 2006).
1.2.2.6 Cardiovascular disease (CVD)
1.2.2.6.1 CVD in the general population
Atherosclerosis underlies CVD. The initial insult is vascular endothelial 
dysfunction which is caused by chronic exposure to various stressors such as 
oxidative stress (including the hyperglycaemic state of diabetes), modified low- 
density lipoprotein and stress from disturbed blood flow (such as in 
hypertension). These stresses result in impairment of nitric oxide (NO) 
production (a powerful vasodilator and inhibitor of platelet aggregation and 
thrombosis) and chronic inflammation (Antoniades et al. 2004; Hartge et al. 
2007). Raised levels of pro-inflammatory cytokines (e.g. IL-6, TNF-a and 
CRP), myeloperoxidase (a leucocyte enzyme), plasminogen-activator inhibitor- 
1 (PAI-1), adhesion molecules (e.g. soluble vascular cellular adhesion 
molecule-1 or sVCAM-1 and soluble intercellular adhesion molecule-1 or 
slCAM-1), monocyte chemoattractant protein (MCP-1) as well as increased 
carotid intima-media thickness (IMT) have been demonstrated, all of which 
contribute to atherogenesis. These markers are independent predictors of 
cardiovascular events (Ridker et al. 2000; Zhang et al. 2001; Brennan et al. 
2003; Cesari et al. 2003; Antoniades et al. 2004; Pai et al. 2004; Hartge et al. 
2007); (Bots et al. 1999; Espeland et al. 2005; Ogata et al. 2005).
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Large population studies have demonstrated certain conditions to be 
associated with increased risk of developing CVD. These include obesity, 
dyslipidaemia, insulin resistance and diabetes mellitus, hypertension, smoking, 
age and family history of myocardial infarction and angina pectoris (Hubert et 
al. 1983; Stamler et al. 1986; Hulley 1988; Neaton and Wentworth 1992; 
Austin et al. 1998; Wilson et al. 1998). CVD remains the most important cause 
of mortality and morbidity in the developed world, accounting for up to 57% of 
all cause mortality in Europe (Figure 1-10). Indeed many preventive and 
treatment programs in countries most affected by CVD have been instituted to 
counter these conditions which include life style modifications (smoking 
cessation, optimal diet, exercise and weight reduction) as well as drug 
treatments for dyslipidaemia, hypertension, diabetes and antiplatelet therapy 
for those at high risk of developing CVD as determined by the Framingham 
algorithms (NCEP 2002; JBS2 2005; Graham etal. 2007; NICE-TA94 2009).
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Figure 1-10: All cause mortality in WHO Europe region in 2004
EsOm«t*d Proportional Mortality (%), WHO EUROPEAN REGION, 2004
Rheumatic heart 0 2%
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Other NCOS 
10.2%
Respiratory
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Lymphomas 0 8% 
Leukemia 0 7% 
Cotorectal 2 S%
Hypertensive 1.4%
Ischemic heart.231%
Cerebrovascular 10 9%
Other CVDs 61% 
Lung:5 9%
Prostate 2 0%
Source QkOel Burden ol Disease dels sources methods and results WHO GJobel Infobaae (IBRef: 199998a2)
NCD: non-communicable disease; CVD: cardiovascular disease; adapted from 
httosJ/apos. who. int/infobase/Mortalitv. aspx
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1.2.2.6.2 CVD in HIV patients on ART
With the control of HIV infection and prolongation of life, patients will
experience diseases of aging including CVD. Apart from the known risk factors 
of CVD namely age, obesity, sex, smoking, family history of ischaemic heart 
disease or inherited dyslipidaemias, ART places patients at risk of developing 
modifiable risk factors such as dyslipidaemia, insulin resistance with glucose 
intolerance or frank diabetes and hypertension. Additionally, smoking rates 
tend to be higher in HIV patients than in the general population (Friis-Moller et 
al. 2003(a); Ross et al. 2009). As such CVD may occur at even younger age 
in this population. Indeed it has become apparent in recent years that patients 
with HIV and on treatment are at excess risk of myocardial infarctions, and that 
CVD now accounts for up to 10% of all deaths in these patients. Of particular 
concern is the fact that drugs such as ABC and DDI have been shown to be 
especially associated with this risk (Sabin et al. 2008).
HIV itself is associated with a chronic inflammatory state which predisposes to 
atherosclerosis with increased risk of CVD. Studies in HIV patients not on ART 
show increased pro-inflammatory markers (such as TNF-a, IL-6), markers of 
vascular endothelial activation, carotid intima-media thickness and platelet 
activation which are all markers of inflammation and predispose to 
atherosclerosis and CVD (Laughlin et al. 2007; Rathmann et al. 2007; Thant et 
al. 2007; Kaplan et al. 2008; Francisci et al. 2009; Ross et al. 2009). 
Additionally, ART interuption with attendant detectable viraemia has been 
associated with increased pro-inflammatory markers, implicating the virus in 
the pathogenesis of the chronic inflammatory state (Kuiler et al. 2008).
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1.3 MANAGEMENT OF COMPLICATIONS OF ART
Management of the long-term effects of ART is fraught with problems due to
interactions that can result between the individual drugs within HAART and the 
drugs being used to counter the adverse effects. This is because of 
overlapping toxicities or common metabolising pathways. Reversibility of some 
long-term effects may also be slow if not impossible.
1.3.1 Reconstructive therapy for facial LA
This involves injection into the face of either biodegradable fillers such as poly- 
L-lactic acid and hyaluronic acid (temporary measure, requiring re-treatment) 
or permanent fillers such as bio-alcamid (with the attendant risk of foreign body 
reaction or granuloma formation) (Moyle et al. 2004; Jones et al. 2005c; Moyle 
et al. 2006). This option is not possible for LA involving the limbs or buttocks. 
Figure 1-11 show the cosmetic results of facial injections with poly-L-lactic 
acid.
Figure 1-11: Before and After Poly-L-lactic acid injections
Before After
I UL 1 i j
1.3.2 Modifications of Antiretroviral Treatment
The main option has been to switch from drugs known to cause the LD 
syndrome, particularly switching from thymidine analogues (AZT and D4T) to
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TDF or ABC in LA (Martin et al. 2004; Moyle 2004; Moyle et al. 2006; BAGS 
2009), or switching from Pis associated with hyperlipidaemia to a Pl-sparing 
option or lipid friendly Pis. The morphological changes are not always 
completely reversible and can take a long time to resolve after switching 
regimens and alternative options might be restricted because of intolerance, 
co-morbidity, drug interactions, or viral resistance. Hence, a significant minority 
of patients may need to remain on potentially lipodystrophic regimens. 
Structured treatment interruption is no longer an option in light of new data on 
increase in opportunistic disease, non-AIDS illness and deaths in those that 
interrupted treatment (El-Sadr et al. 2006); there is also the risk that in the long 
term treatment interruption could result in virologica! rebound with risk of 
progression of the illness (Arjona et al. 2006). Current guidelines do not 
recommend treatment interruption as an option for treating LD (BAGS 2009).
1.3.3 Cytokines, adipocyte transcription factors and
nuclear receptors
Some of the studies looking at the use of cytokines such as leptin and PPAR-y 
agonists in HIV LD are summarized in Table 1-4.
1.3.3.1 Cytokines
Leptin therapy has been used successfully in cases of congenital and acquired 
non-HIV-related LD with resultant improvements in glycaemic control, 
hypertriglyceridaemia and a decrease in fatty infiltration of the liver (Oral et al. 
2002; Tsiodras and Mantzoros 2006). In HIV LD, leptin administration
improves lipid profiles, insulin resistance and fat accumulation and is well
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tolerated, but the studies were small (Brown et al. 2005; Lee et af. 2006; 
Mulligan 2007). More recent studies have confirmed most of these findings, 
except with respect to peripheral fat mass, which did not change (Brennan et 
al, 2009; Magkos et al. 2011). Adiponectin as well as its receptors AdipoRI 
and AdipoR2 are attractive future targets for drug development (Kralisch et al. 
2007). Studies with TNF-a antagonists designed to improve insulin sensitivity 
have not been promising in humans with obesity and type II diabetes (Ofei et 
al. 1996). Use of TNF-a antagonists such as infliximab in Crohn’s disease and 
rheumatoid arthritis does not improve insulin sensitivity (Kralisch et al. 2007). 
However, use of TNF-a antagonists has not been studied in HIV-treatment- 
associated LD since there is a risk of activation of opportunistic infections such 
as tuberculosis.
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Table 1-4: Study summaries of adipocytokine and PPAR ligand use in HIV LD
Research studies Patient
population
Treatments and duration Results
Leptin
(Brown et al. 2005) - in 
vitro study
ritonavir-treated
mice
leptin administration or 
polyunsaturated fatty acid 
(PUFA) diet
leptin use showed:
- reversal of raised TC
- ! in RTV-induced 
interscapular fat
- improved liver 
steatosis
(Lee et al. 2006) 
-randomized, placebo- 
controlled, double- 
blinded, crossover 
study
7 men with 
HAART-induced 
LA, low leptin and 
hypertriglyceridae 
mia
recombinant human leptin 0.04 
mg/kg daily or placebo for 2 
months
leptin improved insulin 
resistance, HDL, truncal 
fat mass
(Mulligan 2007) 
-open-label, proof-of- 
principle study
8 men with HIV- 
induced LA, low 
leptin, insulin 
resistance
recombinant methionyl human 
leptin for 6 months (0.01 mg/kg 
twice daily for 3 months, 
followed by 0.03 mg/kg twice 
daily for 3 months)
- 30%| in visceral fat (P 
= 0.001)
- J. in TC, LDL-C, non- 
HDL-C, TGs
- improved hepatic 
insulin sensitivity
-1 in lipolysis
(Brennan et al. 2009)
- randomized, 
placebo-controlled 
double-blinded, 
crossover study
7 men with 
HAART-induced 
LA, low leptin 
(<3ng/mL)
recombinant methionyl human 
leptin for 3 months (0.04 
mg/kg/day in 2 divided doses) 
or placebo
Leptin (> placebo): 
-jfasted serum insulin 
-No change in truncal 
or peripheral fat mass 
-jHOMA-IR 30%
-j. in visceral fat (P = 
0.001)
-attenuation of 
postprandial glycaemia
(Magkos et al. 2011)
- randomized, 
placebo-controlled 
double-blinded, proof- 
of-principle study
9 men with 
HAART-induced 
LA, low leptin 
(<4ng/mL)
Patients on pioglitazone 30mg 
daily received either 
recombinant methionyl human 
leptin for 3 months (0.04 mg/kg 
once daily) n=5 or placebo n=4
Leptin (> placebo): 
-|fasted serum insulin 
-No change in truncal 
or peripheral fat mass 
-jHOMA-IR 30%
-j in visceral fat (P = 
0.001)
-attenuation of 
postprandial glycaemia
increase; decrease/reduction; HAART: highly active antiretroviral therapy; RTV: ritonavir; 
bd: twice daily; od: once daily; TC: total cholesterol; TGs: triglycerides; LDL-C: low-density 
lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; d4T: stavudine; po: orally. 
TH: thiamidine
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Table 1-4: Study summaries of adipocytokine and PPAR ligand use in HIV LD 
(continued)
Research studies Patient
population
Treatments and duration Results
Thiazolidinediones
(Carr et al. 2004) 
-randomized, double­
blind, placebo- 
controlled study
108 patients with 
HIV LA
rosiglitazone 4 mg bd po or 
placebo for 48 weeks
rosiglitazone:
- improved insulin 
sensitivity
- no improvement of LA
- T in TC, TGs
(Slama et al. 2008) 
-randomized, double­
blind, placebo- 
controlled study
130 HIV patients 
with LA
pioglitazone 30 mg od or 
placebo for 48 weeks
pioglitazone group:
- | in limb fat (patients 
not on d4T)
- T in HDL-C
- no change in other 
lipid fractions
(Calmy et al. 2003) 
-open-label, 
Prospective study
11 HIV patients 
(all on d4T)
pioglitazone 30 mg od x 3 
months, then 45 mg od x 3 
months
- t in body fat mass 
(total and leg)
- no change to lipids
(Barb et al. 2005) 
-2><2 factorial, 
randomized, double- 
blinded, placebo- 
controlled study
14 HIV patients 
with HAART- 
induced metabolic 
side effects
pioglitazone 30—45 mg od po 
versus fenofibrate 200 mg od 
for 12 months
pioglitazone (but not 
finofibrate) 
improved insulin 
resistance, blood 
pressure and lipid 
profile
(Tungsiripat et al.
2010)
-randomized, double- 
blinded, placebo- 
controlled study
71 HIV patients 
with LA on TH 
sparing regimens 
>24weeks
Rosiglitazone (4mg od x
4weeks then bd) vs. placebo for 
48 weeks
Rosiglitazone (> 
Placebo):
- t in limb fat
- T in TC
- J.in insulin resistance
(Schindler et al. 2009) 
-randomized, double 
blind, placebo 
controlled parallel 
group study
40 HIV patients on 
HAART
Rosiglitazone (4mg od) vs. 
Dlacebo for 6 months
Rosiglitazone (> 
Placebo):
- no change in body fat 
distribution
- T in TC/LDL-C
- ! in peripheral insulin 
resistance
, ------------------------------------------------------- .......... uvscrvs nil \SVIIU 1^1 afjy, I \ I V . IIIVI lavil,
bd: twice daily; od: once daily; TC: total cholesterol; TGs: triglycerides; LDL-C: low-density 
lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; d4T: stavudine; po: orally. 
TH: thiamidine
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1.3.3.2 Thiazolidinediones
Thiazolidinediones or giitazones (such as rosiglitazone and pioglitazone) are 
ligands for the transcription factor PRAR-y and are used in type II diabetes to 
improve insulin sensitivity (Haider et ai 2007). Use of rosiglitazone in HIV ID 
appears not to be a viable option with its inability to improve peripheral 
lipoatrophy as well as its adverse effects on lipids (Carr et al. 2004) (Schindler 
et al. 2009), particularly in light of recent data on increased risk of 
cardiovascular events in type 2 diabetes patients with use of rosiglitazone 
(Lipscombe et al. 2007; Nissen and Wolski 2007). However, a recent study 
demonstrated increases in limb fat with rosiglitazone compared to placebo in 
patients that were on a non-thymidine regimen for more than Omonths 
(Tungsiripat et al. 2010). Since most ART naive patients will be starting on a 
non-thymidine regimen, ID will be minimised, the CVD risks with rosiglitazone 
would outweigh the benefits gained in terms of fat redistribution. Pioglitazone 
may have a place in the treatment of HIV LD in that it may increase limb fat 
though its effects on lipids are conflicting, with some studies showing no 
change and others showing improvement (Calmy et al. 2003; Barb et al. 2005; 
Siama et al. 2008).
1.3.4 Other drug options
Various drugs have been studied in the treatment of HIV LD. These include, 
among others, growth hormone (GH) and GH secretagogues, metformin, 
statins and uridine supplementation. Table 1-5 summarizes the results of 
studies looking at the use of these drugs in HIV LD patients.
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Table 1-5: Summary of studies of other drugs in HIV LD
Research studies Patient population Treatments and 
duration
Results
Recombinant GH
(Luzi et al. 2005) 
-randomized, placebo- 
controlled, double-blinded, 
crossover study
30 HIV patients with fat 
redistribution and 
metabolic 
derangement
rGH 0.2 lU/kg per week 
SC versus placebo *6 
months
rGH group:
- J, in truncal fat (P = 0.048)
- j in limb fat (P = 0.0248)
- J, in TC, TGs (non-significant)
(Moyle et al. 2001) -open- 
label study
8 men with HIV- 
associated fat 
accumulation
GH 3 mg/day SC * 6 
months
- | in total body fat (P = 0.05); 
primarily in the trunk region
- t in lean body mass (P =
0.03)
(Honda et al. 2007) 
-prospective, open-label 
study
25 HIV-1 patients with 
moderate to severe 
facial lipoatrophy
rGH 5 mg alternate days 
SC ^ 6 months: further 1 
month follow-up
- | soft tissue thickness at the 
level of zygomatics sustained at 
month 12 (P = 0.021)
GHRH analogues
(Falutz et al. 2007) 
-multicentre, randomized, 
placebo-controlled study
412 patients with HIV 
with abdominal fat 
accumulation
Tesamorelin 2 mg od SC 
(or placebo) *26 weeks
Tesamorelin group:
- i VAT by 15.2% in the 
Tesamorelin group (versus | by 
5.0% in the placebo group)
- | TC, TGs, TC:HDL-C ratio
- T HDL-C
(Koutkia et al. 2004a) 
-randomized, double-blind, 
placebo-controlled study
31 HIV-infected men 
with lipodystrophy
Geref or GHRH 1-29 1 
mg bd SC or placebo 
x12 weeks
Geref group:
- t lean body mass with GHRH 
(P= 0.04)
- trunk fat (P = 0.03)
- improved ratio of trunkdower 
extremity fat (P = 0.005)
- levels of glucose, insulin and 
lipids unchanged
Statins
(Mallon et al. 2006) 
-randomized, placebo- 
controlled study
33 HIV-positive men f 
TC (>6.5 mmol/L) on 
Pl-based HAART
pravastatin (40 mg each 
night) or placebo *12 
weeks
pravastatin group:
- tendency to j in TC
- no change in TGs
- | SAT (| limb fat, P < 0.04; f 
abdominal subcutaneous fat, P 
= 0.02)
Uridine
(Ross et al. 2009)
-pilot study (safety and 
effectiveness)
16 patients with 
lipoatrophy on 
stavudine-containing 
ART
NucleomaxX 36 g TDS 
every other day *16 
weeks
-improvement in LA scores 
-no changes in body mass 
index, lactate, lipids, insulin 
-no changes in fat and PBMC 
mtDNA levels
(Sutinen et al. 2007) 
-randomized, double- 
blinded, placebo-controlled 
study
20 patients with 
HAART-associated LA
dietary uridine 
supplement (36 g TDS 
for 10 consecutive 
days/month) or placebo, 
x 3 months
uridine group:
- t total limb fat (P < 0.001)
- | intra-abdominal fat (P <
0.05)
- t total body fat (P < 0.001)
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Table 1-5: Summary of studies of other drugs in HIV LD (Continued)
Research studies Patient population Treatments and 
duration
Results
Metformin
(Hadigan et al. 2000; 
Hadigan et al. 2002) 
-randomized, double- 
blinded, placebo- 
controlled, pilot study 
followed by a 6 month 
open-label continuation 
phase
26 HIV, non-diabetic 
patients with fat 
redistribution and 
abnormal OGTT, 
hyperinsulinaemia, or 
both
metformin 500 mg 
bd po or placebo 
*3 months
metformin group:
pilot phase
- i insulin resistance (| insulin area 
under curve by 20%) (P = 0.01)
- i weight (P = 0.005)
- i diastolic blood pressure (P = 0.009)
- VAT:SAT ratio unchanged 
continuation phase
- sustained l in insulin levels, weight 
circumference
- i t-PA and PAI-1
(Saint-Marc and Touraine 
1999)
-randomized, controlled 
study
29 HIV patients with 
central adiposity and 
hyperinsulinaemia on 
Pl-based HAART
metformin 850 mg 
TDS po or no 
treatment (control 
group) *2 months
metformin group:
- l basal plasma glucose, insulin, C- 
peptide
- 1 triglycerides by 30.1%
- 1 VAT, total adipose tissue and waist- 
to-hip ratio (increase of these in control 
group)
(Mulligan 2006) 
-randomized, controlled 
study
105 HIV patients with 
t waist-to-hip ratio 
and
hyperinsulinaemia
metformin (500- 
1000 mg bd) or 
rosiglitazone (4 mg 
od) or combined 
versus placebo
- no significant changes in VAT, SAT 
or total extremity fat among the groups 
(f in lower extremity fat with 
rosiglitazone)
(Kohli 2008)
-randomized, double- 
blinded, placebo- 
controlled study
48 HIV patients with
lipodystrophy (| 
abdominal girth and 
waist-hip ratio) and 
normal glucose 
tolerance
metformin 1500 
mg daily or 
placebo * 24 
weeks
metformin group:
- i appendicular fat mass compared 
with placebo (P = 0.03)
- no change in VAT and lipids
(Martinez et al. 2004) 
-randomized, blinded, 
placebo-controlled study
108 HIV patients on 
Pl-based HAART 
with abdominal 
obesity and | TGs
metformin 850 mg, 
gemfibrozil 600 mg 
or placebo bd ><1 
year
in both groups:
- loss of total and regional fat in all 
three groups (less with gemfibrozil)
- no significant change in waist-to-hip 
ratio
. vswuvsifvsrf, I I l \ I . I liy I 11 f a K,U V CM IIUI & U V VII d I U IGI Cl fj / f ILSsD. ff/ftW i/f#/C7d UCI///,
bd, twice daily; od: once daily; TC: total cholesterol; TGs: triglycerides; HDL-C: high-density lipoprotein 
cholesterol; GHRH: growth hormone releasing hormone; OGTT: oral glucose tolerance test; VAT: 
visceral adipose tissue; SAT: subcutaneous adipose tissue; mtDNA: mitochondrial DNA; PBMC: 
peripheral blood mononuclear cells; t-PA: tissue plasminogen activator; PAI-1: plasminogen activator 
inhibitor type 1; SC: subcutaneously; po, orally. 
aNucleomaxX (dietary supplement containing uridine).
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1.3.4.1 GH therapy
GH deficiency in HIV-negative patients is associated with increased 
cardiovascular mortality (Sesmilo et al. 2000). Effects of recombinant GH 
(rGH) therapy have been studied in patients with adult GH deficiency, obesity 
and HIV wasting. In these patients, GH replacement increases lean body 
mass; reduces fat mass with reductions in abdominal subcutaneous adipose 
tissue (SAT) and visceral adipose tissue (VAT); and increases energy 
expenditure, exercise performance and cardiac function. There may be a 
tendency for lipids to decrease (Johannsson et al. 1997; Schambelan et al. 
2002; Tai et al. 2002; Yin and Glesby 2005). GH therapy has, however, been 
thought to increase the risk of cancers, though extensive studies of the 
outcome of GH replacement in childhood cancer survivors showed no 
evidence of an excess of de novo cancers (Jenkins et al. 2005).
In HIV LD, patients have markedly reduced GH levels in association with 
excess visceral adiposity (Rietschel etal. 2001; Koutkia etal. 2004b). Impaired 
GH secretary patterns in these patients are influenced by gender, race and fat 
redistribution (increased waist-hip ratio) (Koutkia et al. 2006). GH therapy in 
HIV LD increases lean body mass; decreases trunk or visceral fat and limb fat; 
and improves facial lipoatrophy with little or no effects on lipid profiles. The 
most common adverse effects of GH therapy are fluid retention, arthralgia, 
muscle pains, carpal tunnel syndrome and a decrease in insulin sensitivity. 
These effects return to baseline levels after treatment with GH stops (Moyle et 
al. 2001; Luzi et al. 2005; Honda et al. 2007). The long-term effects of GH 
therapy on visceral fat, limb fat, insulin sensitivity, lipid profiles and the risk of
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carcinogenesis are not known. The possible worsening of insulin resistance 
may expose patients to an increased risk of cardiovascular disease, and the 
risk of further limb fat loss may be intolerable to patients.
Other studies have looked at use of GH secretagogues such as GHRH (growth 
hormone releasing hormone) analogues to induce a more physiological 
release of GH to avoid the side effects associated with treatment with GH 
(Koutkia et al. 2004a; Falutz et al. 2005). Compared with placebo, GHRH 
analogues (Geref or GHRH 1-29 and Tesamorelin or TH9507) significantly 
increase levels of IGF-1, increase lean body mass, decrease visceral and trunk 
fat and improve the ratio of visceral to lower extremity fat. There are no 
significant changes in levels of glucose and insulin. Adverse effects associated 
with GH excess are not seen (Koutkia et al. 2004a; Falutz et al. 2005; Falutz et 
al. 2007). The effects on lipids vary, with some studies finding no significant 
changes (Koutkia et al. 2004a) and others (Falutz et al. 2007) finding 
significant reductions in triglyceride and cholesterol to HDL ratio. Use of GHRH 
analogues appears to require long-term treatment for continued benefit, as 
patients who stop treatment regain their VAT (Falutz et al. 2007).
Both GH and GHRH analogues have to be given by injection, which might not 
be acceptable to some patients and, additionally, the cost of both drugs is 
prohibitive.
1.3.4.2 Metformin therapy
Metformin is a biguanide oral anti-diabetic agent, which is widely used in type
2 diabetes, particularly in patients with obesity. It acts by reducing endogenous
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glucose production by the liver and by sensitizing the liver and peripheral 
tissues to insulin by acting partly through the activation of AMPK (Hundal and 
Inzucchi 2003; Zou et al. 2004; Natali and Ferrannini 2006). Metformin has 
been shown to reduce cardiovascular risk in patients with type 2 diabetes 
through its reduction of lipids and markers of lipid peroxidation and platelet 
activation (isoprostanes and thromboxanes), and increases tissue antioxidants 
{vitamins A and E), which leads to a reduction in atherosclerosis (UKPDS34 
(1998; Formoso et al. 2008). Metformin therefore represents an interesting 
therapeutic option in HIV LD, in which fat redistribution and insulin resistance 
are prominent features (Hadigan et al. 2000). Indeed, studies do show that 
metformin may have a place in the management of HIV LD with reductions in 
VAT, total adipose fat and waist-to-hip ratio (Saint-Marc and Touraine 1999; 
Hadigan et al. 2002). However, some studies show no change in waist-to-hip 
ratio and, rather worryingly, further loss in limb fat (Martinez et al. 2004; 
Mulligan 2006; Kohli 2008).
1.3.4.3 Statins
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are used 
in the treatment of hyperlipidaemia and established cardiovascular disease in 
the general population. They have anti-inflammatory, anti-thrombotic, as well 
as inhibitory effects on T-cell proliferation and endothelial effects that 
contribute to their overall beneficial effects on reducing mortality from 
cardiovascular disease in both healthy people and diabetics (Egashira et al. 
1994; Rosenson and Tangney 1998; Rosenson et al. 1999; Sommeijer et al. 
2004; Brugaletta et al. 2006). The effects of statins on insulin resistance are 
contradictory with some studies showing beneficial, neutral or worsening
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effects (Sonmez et al. 2003; Gannage-Yared et al. 2005). The use of statins to 
treat the hyperlipidaemia associated with HAART has been extensively 
studied, showing efficacy in lowering total and LDL cholesterol and 
triglycerides (Calza ef al. 2003; Benesic et al. 2004). However, few studies 
exist that have looked at whether statins have beneficial effects on the physical 
aspects of HIV LD. A study by Mallon (Mallon et al. 2006) showed that apart 
from lowering lipids, pravastatin also increased subcutaneous fat and limb fat 
in patients when compared with placebo. There was no significant effect on 
visceral fat, trunk fat and body mass index.
The anti-inflammatory, anti-thrombotic and endothelial effects of statins make 
them an interesting therapy in untreated HIV patients to counteract the chronic 
inflammatory state induced by uncontrolled viraemia which would reduce risk 
of CVD. In vitro studies have also shown that statins may have anti-HIV effects 
(Maziere et al. 1994, Giguere and Tremblay 2004). A combination of these 
reasons would possibly mean that ART naive patients treated with statins 
could delay the start of ART, thereby avoiding the metabolic and physical 
effects of ART. In vivo studies in HIV patients do show that statins have anti­
inflammatory effects but unfortunately show no effect on HIV-1 RNA levels 
(Negredo et al. 2006; Ganesan et al. 2011). Obviously studies into the use of 
statins to counter chronic inflammation induced by HIV need to continue.
1.3.4.4 Uridine
In vitro studies show that the pyrimidine precursor uridine reverses the 
mitochondrial toxicity induced by pyrimidines such as DDC and D4T with 
restoration of cell proliferation. Uridine also reverses the cell depletion and
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lactic acidosis seen with AZT and 3TC combination. It, however, does not 
reverse similar effects caused by DD1 (a purine analogue) (Walker 2003). Use 
of uridine in HIV patients shows that it may be of benefit, with the improvement 
of lipoatrophy, and is well tolerated (Sutinen et al. 2007; Ross et al. 2009).
1.3.5 Management of frank diabetes, dyslipidaemia, 
hypertension and CVD
The management of patients that develop diabetes, dyslipidaemia, 
hypertension, coronary heart disease and cerebrovascular accidents follow the 
guidelines established for the HIV negative general population (NCEP 2002; 
Schambelan et al. 2002; JBS2 2005; Gazzard 2008; EACS 2009; NICE-TA94 
2009).
1.4 AIMS OF THE THESIS
1. To explore the markers of cardiovascular disease and HIV lipodystrophy 
in HIV patients on ART, comparing changes over 12 months of these 
markers in patients:
-continuing on a thymidine regimen
-continuing on a non-thymidine regimen
-switching from a thymidine to a non-thymidine regimen.
Markers explored include lipid profiles; glucose and insulin sensitivity; 
pro-inflammatory markers (IL-6 and TNF-a); adipocytokines 
(adiponectin, leptin, resistin and visfatine); plasma viscosity and 
markers of disease control (CD4 count and HIV viral load).
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2. To explore the levels of traditional risk factors of CVD in HIV patients 
conning from a background population at high risk of CVD and to 
evaluate the attending physicians’ ability to assess and manage 
appropriately conditions known to increase risk of CVD according to 
available guidelines.
3. To summarise interactions between drugs used to treat HAART induced 
dyslipidaemia and ART drugs, as an example of difficulties and 
complexicities faced by attending physicians treating a population of 
patients required to be on polypharmacy to achieve disease control.
1.5 Hypothesis
LD, lipid, glucose and insulin levels and markers of inflammation will be 
adversely affected over time in patients continuing on a thymidine 
regimen; with favourable profiles in those on a non-thymidine regimen 
while improvement should occur in the profiles in those switching from a 
thymidine to a non-thymidine regimen. Derangements in these 
measurements would place patients at risk of CVD.
55
CHAPTER TWO
CARDIOVASCULAR RISK, LIPID 
AND INSULIN SENSITIVITY 
PROFILES WITH TYPE OF 
ANTIRETROVIRAL DRUG IN HIV 
POSITIVE PATIENTS
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2.1 INTRODUCTION
Morbidity and mortality from cardiovascular disease (CVD) are becoming an 
increasing problem in HIV positive patients taking antiretroviral therapy (ART) 
and the incidence of myocardial infarction increases with increasing exposure 
to combination ART. (Law et al 2003; Friis-Moller et al. 2003(a); Friis-Moller et 
al. 2003(b); Triant et al. 2007; Sabin et al. 2008) This is because ART causes 
or accelerates derangements in levels of lipids, glucose and insulin resistance 
(Carr et al. 1998; Chen et al. 2002) which are traditional risk factors for CVD. 
Studies have shown an increased risk of myocardial infarction (Ml) with the 
use of specific ART drugs. The protease inhibitors class has been most 
associated with increased CVD risk (Henry et al. 1998; Holmberg et al. 2002; 
Klein et al. 2002; Mary-Krause et al. 2003). Additionally, Durand et al showed 
that any exposure to abacavir (ABC), didanosine (DDI), stavudine (D4T), 
zalcitabine (DDC), lopinavir (LPV) and ritonavir (RTV) is associated with 
increase in Ml risk and that recent exposure to ABC, D4T, LPV, RTV are also 
associated with increased risk (Durand M 2009) (Durand et al. 2011). The 
D:A;D study demonstrated that recent, but not cumulative, use of ABC or DDI 
was associated with an increased rate of Ml, but found no association between 
the rate of Ml and cumulative or recent use of zidovudine (AZT), D4T, or 
lamivudine (3TC) (Sabin et al. 2008). A lot of controversy surrounds ABC with 
regard to its association with risk of CVD, with some studies demonstrating 
excess risk while others showing no such association (summarised in Table 2- 
1). It is postulated that ABC increases risk of CVD events by adversely 
affecting markers known to increase the risk of CVD such as raising lipids (LDL 
and total cholesterol) (Martinez et al. 2010), reducing endothelial function 
(Hsue et al. 2009b) increasing markers of chronic inflammation such as high
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sensitivity C-reactive protein and interleukin-6 (SMART/INSIGH/D:A:D 2008) 
and increasing platelet activation induced by the abacavir metabolite carbovir 
triphosphate (Baum et al. 2011). However, others studies have shown no 
adverse change in such markers (Martinez et al. 2010) (McComsey 2009; 
Palella et al. 2010). The controversy around ABC will probably continue.
Despite these contradictions, CVD disease is becoming important in an aging 
HIV population and is now believed to account for 10% of deaths among HIV- 
infected individuals (Lewden et al. 2007; Sabin et al. 2008). Apart from the side 
effects of ART, HIV infection per se regardless of virological or immunological 
control is associated with a state of chronic inflammatory and endothelial 
activation which predispose to atherosclerosis (as measured by an increase in 
carotid intima-media thickness (IMT) compared to HIV negative controls) and 
therefore an increased risk of CVD (Hsue et al. 2009a; Ross et al. 2009).
Identification and management of risk factors for CVD in HIV patients is 
therefore a major concern for HIV physicians, and issues of which drugs to 
start or maintain patients on to minimise risk have become all important. 
Indeed, organisations focusing on HIV care have issued guidelines on the 
management of CVD in HIV positive patients. These include European AIDS 
Clinical Society (EACS) and the International AIDS Society-USA Panel (IAS) 
(Schambelan et al. 2002; Lundgren et al. 2008b). The EACS 2008 guidelines 
have recommended that all HIV-infected persons should be screened for 
history of metabolic disease, dyslipidaemia, diabetes mellitus, hypertension 
and alteration of body composition at regular intervals and that the composite
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Table 2-1: Summary of Clinical Trial and Cohort Analyses of Abacavir Use 
and increased CVD Risk
Study Design CV Events Effect of 
ABC?
(Lundgren 2009) 
D:A:D Study 
(N = 33347)
Observational
cohort Prospective, predefined Yes
(Lang et al. 2010)
(N =1173)
Case control 
study
Ml retrospectively 
validated
Yes
1 st yr of 
exposure
(SMART/INSIGH/D:A:D
2008)
(N = 2752)
RCT,
observational
analyses
Prospective, predefined Yes
(Martin et al. 2009) 
(STEAL study)
(N = 357)
RCT Prospective Yes
(Durand et al. 2011) 
(N=7053)
Observational 
cohort, nested 
case-control
Retrospective database 
search for AMI Yes
(Cutrell et al. 2008) 
(GSK analysis)
(N =14174)
54 RCTs Retrospective database search No
(Ribaudo et al. 2011) 
(ALLRT ACTG A5001)
(N = 3205)
5 RCTs
Retrospective by
2 independent 
reviewers
No
(Bedimo et al. 2011) 
(N=19424)
Observational
cohort
Retrospective database 
search for AMI and CVA No
CVD: cardiovascular disease; CVA: cardiovascular accident; AMI: acute myocardial 
infarction; RCT: randomised controlled trial; FHDH, French Hospital Database on HIV; 
Ml, myocardial infarction; RCT, randomized controlled trial.
of cardiovascular risk factors for individual patients should be summarized by 
the calculation of the 10-year absolute risk of contracting ischaemic heart 
disease (IHD) using the Framingham equations. This approach allows 
stratification into three risk categories: low risk (<10% 10-year risk of IHD), 
medium risk (10-20% 10-year risk of IHD) and high risk (>20% 10-year risk of 
IHD). As a matter of course all such individuals should be encouraged to 
initiate lifestyle changes namely; a healthy diet, increase physical activity and 
stop smoking. The guidelines also recommend drug treatment for LDL
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cholesterol, hypertension and blood sugar in individuals at high risk of CVD. 
The IAS guidelines pre-date the body of evidence that examines risk factors 
for CVD in HIV patients but essentially the guidelines were addressing the lipid 
abnormalities that ART induces. Additionally, guidelines on starting and 
switching ART are published which emphasize the need to look for evidence 
of CVD before starting or switching such ART as well as annual reviews of 
CVD status. Drugs that are less likely to increase the CVD risk are 
recommended for use (Gazzard 2008; Lundgren et ai 2008b). This 
emphasizes the importance of CVD in the HIV positive population.
In the UK in general, CVD is an important health problem. In England, death 
rates from all circulatory diseases stood at 125 per 100,000 of population in 
1999. This was higher than most European Union countries whose 
membership predates 2004. For example, the CVD death rate for France in 
1999 was 50 per 100,000. This is because there are highly modifiable risk 
factors in England; for instance, there are 10 million smokers (22% of the 
population) while 22% of men and 23% of women are obese. Twenty percent 
of coronary heart disease (CHD) deaths are linked to smoking in men and 
17% in women. Deaths from CVD in the UK have since been reduced by 40% 
(to 83.8 deaths per 100,000 population) by the year 2006 through government 
initiatives to reduce deaths from CHD, but even with this impressive 
achievement, CHD kills more than 110,000 people in England every year, 
making it the biggest killer (DOH-UK 1999; DOH-UK 2004; DOH-UK 2007).
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HIV patients in the UK will have the same non-modifiable traditional risk 
factors for CVD namely age, sex, race, family history of premature coronary 
heart disease and familial dyslipidaemia as the general public. However, HIV 
patients may be at higher risk of developing CVD than HIV non-infected 
people due to the adverse effects of ART drugs, having higher rates of 
modifiable risk factors such as smoking (Friis-Moller et al. 2003(a); Ross et al. 
2009), hypertension, diabetes, dyslipidemia (Triant et al. 2007) and having the 
virus itself which has been shown to be an independent risk for atherosclerosis 
that is similar in magnitude to traditional CVD risk factors such as smoking and 
advancing age (per decade of life) (Grunfeld et al. 2009; Palella and Phair 
2011). Indeed it has been shown that HIV infected patients whether on ART or 
not have a higher risk of developing ischaemic heart disease than HIV non- 
infected individuals (Obel et al. 2007; Triant et al. 2007); (Durand et al. 2011). 
As such the vulnerability to development of CVD in HIV patients on ART 
needs further investigation. This study addressed the issue of the prevalence 
and type of risk factors for CVD in HIV patients attending the North 
Manchester General Hospital Infectious Diseases unit.
2.2 METHODOLOGY 
2.2.1 The Research Site
Recruitment and follow-up of patients were done at the North Manchester 
General Hospital Infectious Diseases unit. This is a tertiary infectious diseases 
unit with 3 wards with a total of 41 beds. The unit has a large number of HIV 
positive patients totalling ~1500 who attend dedicated daily HIV outpatient 
clinics. The unit has a large research unit, which is involved in multi-centre
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research trials. The hospital is within Crumpsall, an area located to the north of 
the city of Manchester in the Northwest of England. It has a population of 
approximately 15,000 people which is very diverse comprising 73% white and 
27% non-white which are mostly Asian (MCC 2009).
2.2.2 The Studies
Patients were recruited into two studies:
STUDY 1: Effect of antiretroviral therapy containing the Nucleoside and 
Nucleotide reverse transcriptase inhibitors Zidovudine, Stavudine, Didanosine, 
or Tenofovir on lipid profiles, adipocytokine levels and insulin resistance in 
HIV-positive patients;
STUDY 2: Effects of switching a thymidine nucleoside reverse transcriptase 
inhibitor (zidovudine or stavudine), or didanosine), on lipid profiles, 
adipocytokines and insulin resistance in HIV positive patients.
Some challenges were encountered during recruitment into the two studies. 
Recruitment into some arms of the studies was slow, particularly patients 
maintained on D4T or DDI as most of the patients were being switched to non­
thymidine, non-DDI regimens in accordance to guidelines at that time (BHIVA 
2006). For the same reasons, only small numbers could be swiched from DDI 
regimens. Amendments were done accordingly so that the drugs studied were 
AZT, D4T, TDF and ABC within HAART. A total of 64 participants were 
recruited into the following groups:
Group 1: A total of 20 patients remaining on a thymidine (18 on AZT
and 2 on D4T)
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Group 2: A total of 27 patients remaining on a non-thymidine regimen 
(17 on TDF/FTC, 7 on ABC/3TC and 3 on TDF/ABC).
Group 3: A total of 17 patients switching from a thymidine to a non­
thymidine regimen (ABC/3TC, TDF/FTC or TDF/ABC). 14 switched 
from AZT and 3 switched from D4T.
A post-hoc power calculation was done using total cholesterol (TC) based on 
the number of patients in groups 1 and 2 based on total cholesterol (TC). This 
is based on the larger Study 934 which reported at 48 weeks an increase in 
total cholesterol that was greater in patients continuing on AZT containing 
regimen than those continuing on a TDF based regimen (mean change 
0.91mmol/L vs. 0.54mmol/L respectively, P<0.001; mean difference 
0.37mmol/L) (Gallant et al. 2006). Our study had 24% power to detect the 
same mean difference. We would have needed a sample size of 115 
participants in each group to detect this mean difference (0.37mmol/L) in TC 
between group 1 and 2, using an estimate of standard deviation of 1, at the 
5% significance level to give the study an 80% power. TC was chosen as it 
has been shown in large population studies to be a marker of CVD (Unknown 
1984; Stamler et al. 1986; Assmann et al. 1998; Austin et al. 1998; Wilson et 
al. 1998).
2.2.2.1 Objectives
To investigate the effects of remaining on a thymidine (AZT or D4T) regimen, 
non-thymidine regimen (containing TDF and/or ABC) or switching from a 
thyimidine to a non-thymidine regimen as part of HAART on lipid profiles (total 
cholesterol, low density lipoprotein cholesterol, high density lipoprotein 
cholesterol and triglycerides), proinflammatory cytokines (TNF-a and IL-6),
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adipocytokines (adiponectin, leptin, resistin and Visfatin) and insulin resistance 
in HIV positive patients.
2.2.2.2 Eligibility Criteria
The level of CD4 count or viral load did not form part of the eligibility criteria. 
While most research inclusion criteria are very narrow, all adults regardless of 
age were included, with the exclusions mainly being diabetes, occurrence of 
an opportunistic infection within the preceding 3 months and serious illicit drug 
use or existing poor adherence, the latter two because such patients would be 
unlikely to complete follow-up in the study. This was done to give an idea as to 
the level of CVD in a typical large HIV unit in order to inform HIV clinicians on 
the management of patients, taking into consideration published guidelines. 
The participants were recruited if they were HIV infected, above 18 years of 
age, able to give written consent to join the study, on their treatment 
consistently for at least 12 months, there was no anticipated change in ARV 
treatment for 3 months and they were able to commit to one year of follow-up 
in the study.
2.2.2.3 Study Conduct
The study protocols, patient information sheets and consent forms were 
approved by Oldham Local Research Ethics Committee.
2.2.2.3.1 Patient Selection
Patients due to attend consultant clinics for routine follow-up, had their notes 
pre-screened for inclusion and exclusion criteria. An invitation to participate 
was entered in the patients’ notes asking the physician to discuss their 
potential inclusion in the study. If the patient agreed, the study chief
investigator was then informed. The patient was given the study patient
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information sheet and consent form to take and read at home for at least 24 
hours to conform to good clinical practice requirements for human based 
research projects. A convenient date and time was agreed with the patient for 
them to attend for baseline investigations.
2.2.2.3.2 Study Procedures
On the day the patients enrolled into the study, written signed informed 
consent was obtained. In Study 2, patients due to switch their antiretroviral 
regimen were seen for study enrolment on the day they were due to change 
their regimen. Patients self-assessed for evidence of lipodystrophy (LD) using 
a validated questionnaire from the LD case definition study (Carr et al. 2003) 
(Appendix 1) and the investigator checked for antiretroviral drug adherence 
(Study 2) using a validated adherence questionnaire (Appendix 2) from the 
GEEMA study (Knobe! et al. 2002). Anthropometric assessment namely 
weights and heights were done. Blood pressure was determined using an 
automated sphygmomanometer. Forty (40) millilitres (mis) of blood (following 
an overnight fasting of at least 9 hours) were obtained from each participant at 
base-line:
1. 30mls of the blood was used to determine fasted total cholesterol (TC), 
high density lipoprotein cholesterol (HDL-C), low density lipoprotein 
cholesterol (LDL-C), triglycerides (TGs), glucose, haemoglobin (Hb), 
liver and renal function, plasma viscosity and C-reactive protein (CRP) 
and these were performed at the North Manchester General Hospital 
(NMGH) laboratory as part of the routine blood tests that patients on 
HAART undergo during their routine 3-monthly clinic visits. The NMGH 
laboratory uses the Benson Automated Plasma Viscometer BV 200 to
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measure plasma viscosity, which is determined by the concentration of 
plasma proteins present.The major influence on plasma viscosity is 
exerted by fibrinogen and immunoglobulins. Plasma viscosity changes 
when protein fractions are altered, such as in general illness, infection, 
inflammation and malignancy and all result in an increase in plasma 
viscosity. Samples are collected in EDTA blood bottles and are 
centrifuged to obtain plasma before they are analysed, and are 
therefore platelet-poor. The principle of the test is based on the time for 
an aliquot (50pL) of fluid to travel along a uniform capillary, in a fixed 
vacuum and temperature, relative to calibration fluid of a known 
viscosity.
2. 10 ml_s of blood were used to determine fasted insulin and cytokine 
levels. The insulin and cytokine analysis was performed by Millipore 
using Millipore's Cytokine Profiler™ according to their standard 
procedures (Millipore 2008). This service has been used previously by 
other investigators (de Jager et al. 2003; de Jager et al. 2005; Liu et al. 
2009). The detection limit for insulin was 50.9 pg/mL.
A description of the cytokines investigated is detailed in the next chapter 
(Chapters, Section 3.2, Methodology, page 101).
The body mass index (BMI) was calculated from weight and height using the 
BMI calculator (NHL-BMI 2008) which uses weight in kilograms divided by the 
square of height in meters. The cardiovascular (CV) risk over 10 year period 
was calculated using the CV risk calculator (Payne 2005) based on Joint 
British Societies and British National Formulary format with age, sex, systolic 
blood pressure, smoking status, total cholesterol and HDL cholesterol as
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variables. The Homeostasis Model Assessment (HOMA) was used to estimate 
[3-cell function (HOMA-%B) and insulin sensitivity (HOMA-%S) as a 
percentage of a normal reference population, and insulin resistance (HOMA- 
IR) using the HOMA Calculator v2.2.2 (DTD 2004) which is based on the 
formula: fasting glucose level (mg/dL) multiplied by the fasting insulin level 
(mll/mL) and divided by 22.5 (Matthews et al. 1985; Hadigan et al. 2000). 
Determination of insulin resistance using HOMA is an acceptable method 
because the estimate of insulin resistance obtained by HOMA correlates with 
estimates obtained by use of the euglycaemic hyperinsulinaemic clamp 
(Rs=0.88, P<0.0001) and the hyperglycaemic clamp (Rs=0.69, P< 0.01). 
Additionally, the estimate of deficient [3-cell function obtained by HOMA 
correlates with that derived using the hyperglycaemic clamp and with the 
estimate from the intravenous glucose tolerance test (Rs= 0.61, P< 0.01), as 
demonstrated by Matthews et al (Matthews et al. 1985; Hadigan et al. 2000).
All the blood tests, weight and blood pressure were repeated at three further 
visits at 3, 6 and 12 months (with a window period of plus or minus 1 week for 
each visit) as part of the longitudinal follow-up of the patients to see the trends 
in the levels of the lipids, glucose, CRP, plasma viscosity, liver and renal 
function. Cytokine and insulin levels were determined at baseline, visit 3 (6 
months) and visit 4 (12 months). When stable on treatment, patients are 
usually routinely seen every 3 months; therefore, the study visits were timed to 
coincide with these time points. Table 2-1 summarises the study visits and 
procedures.
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Table 2-2: Study Visit Schedule
Study visits and procedures
Procedure Visit 1 
(Enrolment)
Visit 2 
(3 months)
Visit 3 
(6 months)
Visit 4 
(12 months)
Consent X
Eligibility check X
Medical history X
LD questionnaire X X X X
Adherence questionnaire* X X X X
Physical examination X X X X
Blood draw (40mL) X X X X
LD: lipodystrophy; * Study 2
2.2.3 Statistical Analysis
The independent sample T-Test was used to compare the mean change 
between the three groups between 12 months and baseline for blood 
pressure, weights, body mass index, TC, HDL-C, LDL-C, TGs, TC-HDL-C 
ratio and plasma viscosity (SPSS v. 16, SPSS Inc. Chicago, USA). The 
independent sample T-Test was also used to compare the subjective 
lipodystrophy perception mean severity scores for various body regions 
between the groups between 6 months and baseline. The mean changes of all 
parameters were approximately normally distributed on testing using 
histograms. Descriptive analysis was used to compare CV risk over time 
between the groups. Fisher’s exact test was used to compare adherence 
levels between the three groups (STATA, Texas, USA, http://www.stata.com.).
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2.3 RESULTS
Results for cytokines, plasma viscosity, CRP and CD4 count are described in 
the next chapter.
2.3.1 Baseline Characteristics
Most patients were male (78.1%). The median age was 42.5 years (29-73). 
Forty six (71.9%) patients were white and 17 (26.6%) were black African. Forty 
two patients (65.6%) acquired HIV through men having sex with men; 15 
(23.4%) acquired HIV via heterosexual means; and 7 patients (10.9%) 
acquired HIV via other means (blood products, needle stick injury or source 
was unknown). Twenty five (39.1%) of the patients were current smokers with 
average smoking pack years of 22.2 (0.45-75.3) and 17 (26.6%) were ex­
smokers. Forty four (68.8%) of the patients took alcohol with an average 
alcohol intake of 10.7 units (range 1-60) per week. Three (15%) of the patients 
in Group 1, 5 (18.5%) in Group 2 and 3 (17.6%) in Group 3 had systolic BP > 
140mmHg. For Group 3 patients, 18/20 (90%) switched drugs because of 
toxicity and 2/20 (10%) switched due to virological rebound. More patients in 
Group 3 had a diagnosis of LD in their case notes (65%) compared to Group 1 
(25%) and Group 2 (48%). This was expected because Group 3 patients were 
switching treatment mostly because of toxicity which included LD. Table 2-3 
presents the baseline characteristics of the study population classified 
according to groups.
2.3.2 Antiretroviral Drugs Used
Figure 2-1 presents frequency data for the use of NNRTIs and Pis according
to group. Most patients were on a HAART regimen that included an NNRTl.
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EFV was the most frequently prescribed NNRTI, but in Group 2 the use of FIs 
such as FPV and ATV was higher.
Table 2-3: Baseline Characteristics for all patients
Group 1 
(n=20)
Group 2 
(n=27)
Group 3 
(n=17)
Age (years)-Median (range) 41.5(29-73) 41.0 (31-63) 41.0(34-56)
Duration of current ART (Months)-Median
(range)
35 (13-72) 13(3-89) 49 (7-86)
Duration all ART (years)- Median (range) 4.3 (1.2-12) 6.3 (0.8-16) 5.8 (0.7-11)
Previous stavudine exposure* 4 (20%) 13 (48%) 3(18%)
Previous protease inhibitor exposure* 7 (35%) 17(63%) 8 (47%)
Previous AIDS defining illness* 5 (25%) 8 (30%) 5 (29%)
Viral Load < 40 copies/ml* 17(85%) 26 (96%) 13(76%)
CVD Risk Factors*:
Smokers 7 (35%) 13(48%) 5 (29%)
hypertension/dyslipidaemia/CVA/CHD 0 4(15%) 1 (6%)
Family history of CVD and dyslipidaemia 5 (25%) 7 (26%) 1(6%)
Existing LA/LD diagnosis and/or on 
examination*
5 (25%) 13 (48%) 11 (65%)
Systolic BP-median (range) 121 (100-152) 121 (98-188) 116 (98-149)
Diastolic BP-median (range) 82 (58-105) 80 (65-105) 80 (66-107)
Weight ( kg)-median (range) 68 (48-88) 72 (58-118) 73 (57-89.1)
BMI-median (range) 23.7 (18.7- 
28.7)
23.5 (19- 
47.3)
24.0(19.9-
28.7)
CVD risk:
Median CV Risk % (range) 4.3 (0.3-25) 6.2 (0.2-22.5) 3.9 (0.5-17.5)
CV Risk>20%* 2 (10%) 2 (7%) 0
CV Risk 10-20%* 3(15%) 5(19%) 2(12%)
CV Risk <10%* 15(75%) 20 (74%) 15(88%)
» » J-------------------- ■ —  J w I I II Ijr 11 IIKJII Its I tsyil I Its I /,
Group 3: patients who switched from a thymidine to a non-thymidine regimen; LA: lipoatrophy; 
LD: lipodystrophy; BP: blood pressure; CVD: cardiovascular disease; CHD: coronary heart 
disease
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Figure 2-1: NNRTI and PI usage
Groupl Group2 GroupS1
□ NNRTI Use
□ PI Use
Groupl (NNRTIs: Nevirapine 5, Efavirenz 10; Pis: Kaletra 1, fosamprenavir 1, amprenavir 1); 
Group2 (NNRTIs: Nevirapine 9, Efavirenz 6; Pis: fosamprenavir 4, atazanavir 6, double PI 2); 
Group3 (NNRTIs: Nevirapine 5, Efavirenz 8; Pis: fosamprenavir 1, Kaletra 1); *2 patients were 
on Trizivir; All Pis were boosted with 100 mg ritonavir
Figure 2-2 presents the drugs Group 3 patients switched to. Panel (a) shows the 
NRTI backbones, the commonest being TDF/FTC (58.8%). Before the switch 
most patients in Group 3 were on an NNRTI as part of their regimen (13 of 17). 
After the switch, though most patients still remained on an NNRTI (11 of 17), a 
larger proportion had gone onto a PI (6 out of 17 vs. 2 out of 17 pre-switch), 2 
patients went on to trizivir (AZT/3TC/ABC). This is shown in Panel (b).
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Figure 2-2 (Panel a-b): Group 3 drug switches 
Panel (a)
Group 3 NRTI Switch Backbone Drugs (N=17)
□ TDF/FTC 
■ABC/3TC 
□TDF/ABC
□ TDF/ABC/3TC
Panel (b)
Groups NNRTI/PI Usage (N=17)
□
£ £ CL>
LU or. or Z
> >
CL CL
—1 LL
Pre-Switch
£
LU
gcr>
CL
Post-Switch
I >CL
TDF: tenofovir 
ABC: abacavir 
3TC: lamivudine
LPV/RTV: boosted lopinavir 
ATV/RTV: boosted atazanavir 
FPV/RTV: boosted fosamprenavir
NVP: Nevirapine 
EFV: Efavirenz
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2.3.3 Perception of Lipodystrophy
All patients filled out an LD questionnaire at each visit. However, enough data 
were available for the first 3 visits of the studies, that is, up to 6 months of 
follow-up. This was due to staffing problems towards the last part of the studies 
precluded getting data to 12 months; the analysis for the first 6 months was 
discussed and agreed upon by the study supervisors and the funder and 
sponsor (NMGH Research and Development Department). Table 2-4 (Panel a- 
b) summarises the patient perceptions of LD in various parts of the body at 
baseline, 3 and 6 months.
More patients in group 3 reported fat loss in various parts of the body at the 
start of the study before they switched their medication than in the other 
groups, though the differences were not statistically significant expect with 
respect to the buttocks which was worse in this group compared to group 1 
(mean severity scores 2.3 and 1.4 respectively, P=0.03). At 6 months, fewer 
patients in group 3 reported fat loss in the same areas. The proportion of 
patients reporting fat loss remained approximately similar between baseline 
and 6 months in groups 1 and 2. Few patients in all the groups reported fat 
gain in the face over the 6 month period. In group 3, patients reported more fat 
gain at the waist (64%) at baseline than in the other groups (33% in group 1 
and 42% in group 2), though again the differences between the groups were 
not statistically siginificant. At 6 months, fewer patients in group 3 reported fat 
gain at the waist (25%) while there was no change in patients reporting this in 
the other 2 groups.
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Prominence of veins was reported by most patients in all groups and the 
numbers increased over time, even in patients in group 3 who had switched 
from a thymidine to a non-thymidine based regimen (58% at baseline vs. 67% 
at 6 months) and those in Group 2 who had remained on a non-thymidine 
(42% at baseline vs. 46% at 6 months). However, the worsening in the 
prominence of veins was not statistically different between baseline and 6 
months within each of the groups.
More patients in group 2 reported lipomata at base line than the other 2 
groups, though the difference was not statistically significant. Interestingly, the 
numbers did not change at 6 months in the groups, indicating that no new 
lesions occurred in the rest of the patients.
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2.3.4 Adherence to Antiretroviral therapy
Patients in Study 2 filled out a treatment adherence questionnaire at each visit. 
Data available are up to the 6 months assessment point. The adherence data 
are summarised in Table 2-5. The majority of the patients were adherent with 
treatment. At baseline, however, more patients in the thymidine switch arm 
forgot to take their medication at some time (76.9%), had missed a dose or two 
in the preceding 1 week (23.1%) and had missed at least a day of treatment in 
the preceding 3 months (53.9%) compared to patients on a non-thymidine 
regimen (35%, 17.6% and 35.3% respectively). Fewer patients in the thymidine 
switch arm were 95-100% compliant in the week preceding their baseline visit 
compared to those that were on a non-thymidine regimen (76.9% vs. 82.4%). 
Additionally, fewer thymidine switch patients were assessed overall as being 
adherent with treatment (84.6%) compared to the non-thymidine patients 
(94.1%) at baseline. However, all these differences were not statistically 
significant.
Over the course of the study, adherence to treatment improved in both groups. 
In the thymidine switch group, 92% were 95-100% compliant with treatment in 
the week preceding their third visit compared to 77% at baseline, though this 
was not statistically significant (P=0.6). In the non-thymidine group 94% were 
95-100% compliant in the week preceding their third visit compared to 82% 
respectively at baseline, though again this change was not statistically 
significant.
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2.3.5 Lipids, glucose, insulin, HOMA, blood pressure, 
weights, BMI, haemoglobin (Hb), alanine aminotransferase 
(ALT), creatinine and calculated CVD risk percentage
Figure 2-3 (Panel A-D) shows the group means for each time point for TC, 
LDL-C, HDL-C, TGs, TC:HDL-C ratio, glucose, insulin, HOMA, blood pressure, 
weight, BMi, Hb, ALT and creatinine.
There was no change in the means for the three groups over the 12 month 
follow-up period for parameters such as TC, HDL-C, LDL-C, TGs, glucose, 
systolic blood pressure, ALT and creatinine. The TC:HDL-C ratio increased by 
1.2 from 6.6 to 7.8 in Group 1 and by 1.4 from 7.7 to 9.1 in Group 2. The Hb 
increased from 13.4 to 14.2g/dl in Group 3 and did not change in the other 2 
groups. The ratio did not change much in Group 3 (5.2 and 5.6). There was no 
change in the BMI within each group over 12 months. However, group 2 had a 
BMI which was 1.5Kg/M2 higher than the other groups throughout the study 
period though this was not statistically different.
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Figure 2-3: Panel (a-d): Trends in group means for Lipids, glucose, insulin, HOMA, 
blood pressure, weight, BMI, haemoglobin, ALT and creatinine over time
Panel (a): Lipids
Total Cholesterol
56
Group 1 
Group 2 
Group 3
(Months)
LDL Cholesterol
-J 2.5
Group 1 
Group 2 
Group 3
E 1.5
(Months)
Triglycerides
Group 1 
Group 2 
Group 3
(Months)
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Figure 2-3: continued
Panel (a): Lipids continued
HDL-cholesterol
Group 1 
Group 2 
Group 3
(Months)
TC:HDL-C Ratio
Group 1 
Group 2 
Group 3
(Months)
HDL: high density lipoprotein; TC: total cholesterol; C: cholesterol
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Figure 2-3: continued
Panel (b): Glucose and Insulin sensitivity
Insulin
12
(Months)
■Group 1 
■Group 2 
•Group 3
56 Glucose
(Months)
■Group 1 
•Group 2 
■Group 3
HOMA-IR
(Months)
■Groupl 
■Group 2 
■Group 3
IR: insulin resistance
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Figure 2-3: continued
Panel (b): Glucose and Insulin sensitivity continued
Group 1 
Group 2 
Group 3
0 6 12
(Months)
HOMA-%S
Group 1 
Group 2 
Group 3
0 6 12 
(Months)
HOMA-%B: percent /3-cell function; HOMA-%S: percent insulin sensitivity
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Figure 2-3: continued
Panel (c): Systolic Blood Pressure and Anthropometries
Systolic Blood Pressure
(Months)
Weight
S’ 70
IMonths)
Body Mass Index
23 ----------------
22.5
3 6 12
(Months)
■Groupl 
■Group 2 
Group 3
^ Group 1 
k-Group 2 
'-Group 3
■Group 1 
■ Group 2
Group 3
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Figure 2-3: continued
Panel (d): Haemoglobin, Renal and Liver function
Alanine Transaminase
Groupl 
Group 2 
Group 3
(Months)
Haemoglobin
(Months)
Creatinine
92 ------------------------------------------------------------------------------
(Months)
Group 1 
Group 2 
Group 3
Group 1 
Group 2 
Group 3
85
The mean insulin levels, p-cell function (HOMA-%(3), insulin sensitivity 
(HOMA-%S) and insulin resistance (HOMA-IR) did not change much in Group 
2 between baseline and 12 months. In Group 1, the mean insulin level was 
highest at baseline compared to levels at 6 and 12 months. The HOMA-IR was 
similarly highest at baseline while the HOMA-%S was lowest at at the same 
timepoint. The HOMA-%p remained the same throughout the 12 month period. 
In Group 3, the mean insulin level was highest at 6 months. Similarly, the 
HOMA-IR and HOMA-%(3 were highest while the HOMA-%S was lowest at the 
same time point. It is important to note that 2 patients each in Group 1 (at the 
baseline visit) and Group 3 (at the 6 month visit) had isolated high mean levels 
of insulin compared to the rest of their visits. Probably these patients had not 
fasted before blood samples were taken, which could explain the findings in 
these two groups.
In this cohort, most patients had mean insulin levels <15pU/ml, with only a 
small proportion having levels >15pU/ml (4 patients in Group 1 (20%); 1 in 
Group 2 (3.7%) and 2 in Group 3 (11.8%)).
The systolic and diastolic BP remained relatively normal in all the groups, 
though there was a reduction of 8mmHg in the diastolic blood pressure from 
baseline in Group 1 (86 at baseline vs. 78 at 12 months).
The calculated CV risk remained the same at 12 months compared to baseline 
in Group 3 patients with most patients having a CV risk of <10% (87% at 12 
months vs. 88% at baseline) with no patients having a risk of >20%. In Group
86
1 and 2, the majority of the patients had a CV risk of <10% (75% and 74% 
respectively) at baseline. However, at 12 months, fewer patients remained in 
this low risk category, particularly in Group 2 (67% in Group 1 and 52% in 
Group 2), with more patients having a moderate CV risk of 10-20% than at 
baseline (25% vs, 15% in Group 1 and 33% vs. 19% in Group 2). At 
12months, the number of patients with a CV risk of >20% did not change much 
compared to baseline (8% vs. 10% in Group 1 and 10% vs. 7% in Group 2),
Table 2-6 (Panel a-c) shows the mean change over the 12 months follow-up 
period, and the mean differences between the groups for TC, LDL-C, HDL-C, 
TGs, TC:HDL-C ratio, glucose, insulin, HOMA, blood pressure, weight, BMI, 
Hb, ALT and creatinine. There were no significant differences in the mean 
change between the groups in all the parameters except for Hb which had 
significantly increased in Group 3 compared to both Group 2 (P=0.02) and 
Group 1 (P=0.049).
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Table 2-6 (Panel a-c): Mean Change in parameters and Pairwise comparisons 
of change between groups 
Panel (a): Lipids
Variable Group
Mean Difference 
Between 12 Months 
and baseline (SD)
Pairwise comparisons
P valueGroups Meandifference
Total
Cholesterol
(mmol/L)
1 0.28 (0.7) 1 vs. 2 0.07 0.81
2 0.21 (1.1) 1 vs. 3 0.07 0.72
3 0.21 (0.6) 2 vs. 3 0.002 0.99
HDL cholesterol 
(mmol/L)
1 -0.71 (0.2) 1 vs. 2 -0.01 0.99
2 -0.70 (0.3) 1 vs. 3 -0.11 0.39
3 0.04 (0.5) 2 vs. 3 -0.11 0.36
Low Density 
Lipoprotein 
(mmol/L)
1 0.22 (0.60) 1 vs. 2 0.11 0.63
2 0.11 (0.71) 1 vs. 3 -0.01 0.97
3 0.2 (0.7) 2 vs. 3 0.12 0.59
Triglycerides
(mmol/L)
1 0.42 (0.99) 1 vs. 2 0.04 0.93
2 0.38(1.61) 1 vs. 3 0.59 0.07
3 -0.2 (0.8) 2 vs. 3 0.55 0.21
TC:HDL 
cholesterol ratio
1 0.60 (0.8) 1 vs. 2 0.37 0.23
2 0.23(1.1) 1 vs. 3 0.59 0.11
3 0.01 (1.3) 2 vs. 3 -0.21 0.55
Group 1: patients on a thymidine regimen; group 2: patients on a non-thymidine regimen; 
group 3: patients that switched from a thymidine to a non-thymidine regimen; SD: standard 
deviation
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Table 2-6: Mean Change in parameters and Pairwise comparisons of change 
between groups continued
Panel (b): Glucose and Insulin sensitivity ______________________ |___
Variable Group
Mean Difference 
Between 12 Months 
and baseline (SD)
Pairwise comparisons
P value
Groups Meandifference
Glucose
(mmol/L)
1 0.05(1.59) 1 vs. 2 -0.05 0.88
2 0.10(0.62) 1 vs. 3 -0.3 0.45
3 0.4 (0.7) 2 vs. 3 -0.3 0.19
Insulin
(pmol/L)*
1 -57.3(187.4) 1 vs. 2 -67.6 0.11
2 10.2 (40.5) 1 vs. 3 -64.6 0.20
3 7.3 (38.6) 2 vs. 3 2.9 0.83
HOMA-%B
1 -28.4 (95.2) 1 vs. 2 -38.7 0.15
2 10.3 (56.7) 1 vs. 3 -21.6 0.43
3 -6.8 (38.2) 2 vs. 3 17.1 0.31
HOMA-%S
1 23.1 (61.0) 1 vs. 2 54.3 0.23
2 -31.2(139.1) 1 vs. 3 17.8 0.71
3 5.2 (146.1) 2 vs. 3 -36.5 0.45
HOMA-IR
1 -1.0 (3.4) 1 vs. 2 -1.2 0.11
2 0.2 (3.4) 1 vs. 3 -1.2 0.20
3 0.2 (0.7) 2 vs. 3 0.0 0.99
* Insulin levels in brackets are converted levels in ijilnits/ml; Group 1: patients on a thymidine regimen; 
group 2: patients on a non-thymidine regimen; group 3: patients that switched from a thymidine to a 
non-thymidine regimen; SD: standard deviation
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Table 2-6 continued: Mean Change in parameters and Pairwise comparisons 
of change between groups continued
Panel (c): Systolic blood pressure, anthropometries, routine blood tests and 
CD4 count
Variable Group
Mean Difference 
Between 12 Months 
and baseline (SD)
Pairwise comparisons
P value
Groups Meandifference
Systolic BP 
(mmHg)
1 -1.5(13.3) 1 vs. 2 -9.2 0.09
2 7.7(16.4) 1 vs. 3 -9.7 0.08
3 8.3(14.7) 2 vs. 3 -0.6 0.92
Weight (kg)
1 2.4 (7.1) 1 vs. 2 1.0 0.57
2 1.4 (2.7) 1 vs. 3 5.6 0.27
3 -3.2(14.4) 2 vs. 3 4.6 0.16
Body Mass Index
1 0.2 (1.5) 1 vs. 2 -0.3 0.43
2 0.5 (1.0) 1 vs. 3 0.1 0.84
3 0.04 (1.1) 2 vs. 3 -0.4 0.22
ALT
1 2.9 (8.5) 1 vs. 2 7.3 0.19
2 -4.4 (21.2) 1 vs. 3 -42.1 0.25
3 44.9(147.5) 2 vs. 3 -49.4 0.09
Haemoglobin
1 -0.04 (0.8) 1 vs. 2 0.1 0.71
2 -0.1 (0.9) 1 vs. 3 -0.9 0.049
3 0.8 (1.6) 2 vs. 3 -0.9 0.02
Creatinine
1 -0.5 (9.6) 1 vs. 2 4.2 0.38
2 -4.7(17.4) 1 vs. 3 -6.0 0.15
3 5.5(13.5) 2 vs. 3 -10.2 0.05
HOMA: homeostatic model assessment (-%B=(3-cell function, -%S= insulin sensitivity, -IR= 
insulin resistance); ALT: alanine aminotransferase; TC: total cholesterol; HDL: high density 
lipoprotein; Group 1: patients on a thymidine regimen; group 2: patients on a non-thymidine 
regimen; group 3: patients that switched from a thymidine to a non-thymidine regimen; SD: 
standard deviation
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2.4 DISCUSSION
Thymidine analogues (AZT and D4T) and DDl have been associated with the 
development of lipoatrophy and dyslipidaemia through a combination of 
mitochondrial toxicity, induction of insulin resistance and altered lipogenesis. 
TDF and ABC have been shown not to cause these effects to a great extent 
(Jones et al. 2005a). It was anticipated that patients who remained on a 
thymidine based regimen for 12 months would develop or experience 
worsening of lipoatrophy, dyslipidaemia, insulin resistance and an adverse 
calculated CV risk. In comparison, those that were and continued on a non- 
thymidine/non-DDI regimen would have better profiles at baseline and 
demonstrate continuing improvements in these parameters. Additionally, those 
patients that were switched from a thymidine to a non-thymidine/non-DDl 
regimen would demonstrate improvements in these profiles at 12 months 
compared to baseline levels. This was the rationale for chosing the 3 groups 
reported in these studies.
The baseline characteristics were similar between the groups as has been 
found in similar studies (Moyle et al 2006, Gallant et al 2004). Smoking rates 
were higher in this HIV population than in the general population in England 
(39.1% vs. 25%). High smoking rates have been seen in other studies of HIV 
positive patients (Friis-Moller et al. 2003(a); Ross et al. 2009). The patients 
were generally virologicaliy well controlled though less so in Group 3, which 
was expected, as part of the inclusion criteria in this group was that the 
patients were switching regimens due to virological rebound.
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Overall for all the groups, patients were at low risk (<10%) of cardiovascular 
disease over 10 years, but 10% and 7% of patients in Group 1 and 2 
respectively had a CV risk of >20%. Patients in Group 2 had apparent 
worsening of their CV risk, having more patients move from a low risk of <10% 
at baseline to a moderate risk of 10-20% at 12 months. It is important to note 
that more patients in Group 2 had previous exposure to D4T and Pis than the 
other groups. Some studies have shown an increased risk of CVD with 
exposure to D4T and that PI use is associated with thicker carotid IMT (a 
marker of atherosclerosis (Stein et al. 2008; Hsue et al. 2009a). Group 2 also 
had more patients who had the traditional CVD risk factors namely smoking, 
pre-existing history of hypertension, dyslipidaemia, cardiovascular disease, 
ischaemic heart disease, family history of premature heart disease and familial 
dyslipidaemia. This could therefore explain the worsening of the calculated CV 
risk in Group 2 patients over one year follow up period.
LD changes were subjectively reported by the patients. The changes of fat 
loss, fat gain and prominence of veins were mostly being reported as mild or 
moderate in severity, with only a few patients reporting severe changes. At 6 
months, fewer patients who switched from a thymidine to a non-thymidine 
based regimen reported obvious fat loss than at baseline though they did not 
see obvious fat gain in various parts of the body. The fat gain which may not 
be discernible to the patient could have been demonstrated by DEXA or CT 
scan. Others have demonstrated fat gain by DEXA scanning in patients who 
switched from a thymidine NRTI to either tenofovir or abacavir at 48 weeks
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(Moyle et al. 2006). Patients remaining on a thymidine based regimen mostly 
reported fat loss which has been replicated in other studies (Heath et al. 2001; 
Gallant et al. 2004; Shlay et al. 2005; Shlay et al. 2008; Shiay et al. 2009). 
Patients who remained on a non-thymidine regimen variably reported fat loss 
and fat gain with no consistent pattern over the 6 month period. We expected 
this group to mostly report peripheral fat gain as has been shown by other 
researchers such as Gallant or Moyle et al (Moyle et al. 2006). There are 
limitations to the assessment of LD in this study. We reported LD results up to 
6 months (24 weeks) of follow up which may have been an insufficient period 
of time for LD changes to have become overt. We could have seen similar 
changes if we had reported LD changes at 48 weeks as was the case in the 
other studies. The subjective nature of the LD reporting by questionnaire 
without clinician verification may have over or underreported LD changes, 
however, this method of assessment has been shown to have a reported 98% 
concordance between patient self-assessment and clinical examination 
findings (Carr etal. 1998).
Most patients in this cohort were adherent to treatment. However, poor 
adherence was mostly at baseline in patients that were on a thymidine based 
regimen who were about to switch ART drugs compared to those that were 
continuing on a non-thymidine based regimen. Adherence did improve 
markedly by 6 months of follow-up. These differences at baseline could be due 
to adverse effects (particularly lipoatrophy) of the thymidine-based regimens 
influencing patient adherence before they switched drugs, with improvement of
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adherence on being on non-thymidine drug regimen. The phenomenon of poor 
adherence because of fear of side effects of ART is well documented (Lenert 
et at. 2002; Nachega et at. 2009). Indeed, the thymidine switch patients 
reported less lipoatrophy at 6 months, showing possible improvement in 
perception of their body image and therefore willingness to adhere to 
treatment. However, adherence levels could also have improved because 
patients knew they would be filling out an adherence questionnaire at each 
visit.
With regards to lipids, large population studies have shown a link between the 
development of new-onset and recurrent CHD events in men and women and 
high TC, LDL-C, TG levels and low levels of HDL-C (Unknown 1984; Stamler 
etal. 1986; Assmann etal. 1998; Austin et al. 1998; Wilson et al. 1998). In HIV 
patients, raised TC and TGs have also been shown to be associated with an 
increased risk of myocardial infarction (Friis-Moller et al. 2003(b)). The lipids 
(TC, LDL-C, HDL-C and TGs) in this cohort did not change over time in each 
group and there was no significant difference in these parameters over the 12 
month period between the groups. The mean TC in all the groups was 
<6.5mmol/L (The US National Cholesterol Education Program III 2002 
guidelines define as high TC s 6.5mmol/L). However, the mean TC:HDL-C 
ratio was high in Group 1 (7.4) and Group 2 (8.1) and did increase in these two 
groups over the 12 month period while it remained stable in Group 3 (TC:HDL- 
C ratio greater than 6.5 mmol/L is defined as high by the US National 
Cholesterol Education Program III guidelines). Most studies in HIV patients on 
ART show a favourable lipid profile in patients on a non-thymidine containing
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regimen than those on a thymidine containing regimen. Pozniac et al showed a 
rise in TC and LDL-C at 96 weeks which was significantly lower in patients on 
TDF/3TC/EFV combination compared to those on AZT/3TC/EFV (25 mg/dl vs. 
38 mg/dl respectively, P=0.001), however, the change in fasting TGs was not 
significantly different between the two groups (Pozniak et al. 2006). Gallant et 
al also demonstrated increases in TC, LDL-C, HDL-C and TGs which were 
significantly attenuated in patients using a TDF containing regimen compared 
to those on a D4T regimen over 144 weeks (Gallant et al. 2004). Jones et al 
showed that patients on a TDF regimen did not develop hypercholesterolaemia 
(defined as >6.5 mmoi/L [254 mg/dL]), while those on a D4T or PI containing 
regimen (particularly neifinavir) developed hypercholesterolaemia in a shorter 
period of time. They also showed that NNRTI containing regimens had a 
favourable lipid profile (Jones et al. 2005a). Additionally, studies show 
improvement of lipid levels in patients who switch from a thymidine to a non­
thymidine based regimen. Vigano-Alessandra et al demonstrated in a 
paediatric population switching from D4T to a TDF based regimen 
improvements in TC, TC:FIDL-C ratio and TG levels in the TDF group over 48 
weeks (Vigano et al. 2005). In addition, Moyle et al reported in a UK based 
population that switching from either AZT or D4T to either TDF or ABC showed 
modest improvements in TC, LDL-C and TGs in the TDF group but were 
unchanged with ABC over a 48 week follow up period (Moyle et al. 2006).
In the present study, it was expected that patients in Group 1 who remained on 
a thymidine based regimen would demonstrate worsening in lipid profiles over
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time. It was also expected that the components of the lipid profile would 
improve in patients in Group 2 who remained on a non-thymidine regimen; and 
for those in Group 3 who switched to a non-thymidine regimen. An adverse 
lipid profile at start of the study when the patients were adherent to a thymidine 
regimen was not observed, and the expected improvement in lipid profile over 
time after the patients switched to a TDF or ABC based regimen was absent. 
Failure to detect such changes may be due to several factors. Firstly, use of 
lipid lowering drugs such as statins obviously lowers lipid levels and we did not 
exclude patients on lipid lowering drugs. However, very few patients (2) were 
co-prescribed such drugs. Secondly, most of the patients in all the groups 
were on an NNRTI particularly EFV rather than Pis (particularly older ones 
such as nelfinavir and indinavir which could contribute to unfavourable lipid 
profiles). Thirdly, 44% of patients in Group 2 were on a PI; however, usage of 
kaletra was low, with most patients being on atazanavir (known to be lipid 
friendly) (Sax and Kumar 2004) which could explain the lack of adverse lipid 
profile changes. Fourthly, use of D4T was low (20%) in Group 1, this drug 
being the most implicated in dyslipidaemia as detailed above. Fifthly, most 
patients (48%) in Group 2 had previous D4T exposure while 63% in the same 
group and 47% in Group 3 had previous PI exposure, probably the older Pis. 
The long-term effects of these may not have adequately reversed for us to 
observe favourable lipid profiles, as previous exposure to Pis has been 
associated with elevated TC and TGs (Heath et al. 2001).
Group 2 had a higher BMI than the other two groups which was expected as 
they were on regimens not expected to cause fat loss. It was expected that the
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BMI in group 3 would improve after switching from a thymidine, compared to 
those that remained on a thymidine regimen, because these patients would be 
expected to regain some of the fat lost while they were on a thymidine as has 
been shown in other studies (Carr et al. 2002; Moyle et al. 2006). This could 
be because the duration of follow-up was too short for improvements to occur 
or the patients may have been on the thymidine drug for too long so that fat 
loss was possibly irreversible. In this study, the median time on a thymidine 
before the switch was 48 months (range 7-86) (4 years, range 0.6-7.3) (Carr et 
al. 2002; Moyle etal. 2006).
NRTIs and Pis have been implicated both in in vitro and in vivo studies to 
cause the development of glucose intolerance and insulin resistance via 
adverse effects on adipose tissue differentiation, insulin-stimulated glucose 
uptake and induction of lipolysis, the worst offending drugs being the thymidine 
NRTIs (D4T and AZT) and some Pis (lopinavir, ritonavir, saquinavir, indinavir 
and nelfinavir) but not others such as atazanavir (Janneh et al. 2003; Jones et 
al. 2005b; Lagathu et al. 2005; Kim et al. 2006; Noor et al. 2006; Pacenti et al. 
2006). Indeed many studies have investigated glucose intolerance and insulin 
resistance in HIV patients on HAART with patients developing hyperglycaemia, 
hyperinsulinaemia and insulin resistance with cumulative exposure to NRTIs 
and Pis but not NNRTIs (Hadigan etal. 1999; Hadigan etal. 2000; Brown etal. 
2005; Tien et al. 2008). Glucose homeostasis remained normal throughout the 
study period. This did not worsen in the group that remained on a thymidine 
nor improve in the group that switched from a thymidine to a nonthymidine 
based regimen. The mean glucose level for all the groups was below 6.0
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mmol/L; p-cell function was comparable to that of a normal population (being 
98-110%) in all the groups; and group mean insulin levels were below 15pU/ml 
(levels >15pU/ml have been considered to signify hyperinsulinaemia in 
studies) (Brown et al, 2005). In my studies, use of the more offending drugs 
such as D4T was low (2/20 patients in Group 1 remained on D4T, 3/27 
patients in Group 3 switched from D4T) and none of the patients were on the 
older Pis such as IDV, SQV and NFV as such a favourable glucose profile 
could be expected. Additionally, even though previous use of D4T and older 
Pis was prevalent, their effects on glucose homeostasis may have reversed by 
the time this study was conducted.
Renal toxicities have been reported with adherence to TDF, present data 
would indicate maintenance of normal renal function in all groups despite high 
level of TDF use in treatment groups 2 and 3. This is in keeping with renal 
function results reported by others (Moyle et al. 2006; Pozniak et al. 2006). 
ALT as a surrogate marker of liver function showed the liver function was not 
different between the groups. Haemoglobin significantly improved in Group 3 
at 12 months compared to the other groups. This is likely because most 
patients in this group switched from AZT-based regimen, a drug known to 
cause anaemia which is reversible on stopping the drug (GSK 2010).
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2.5 CONCLUSIONS
In this study, lipid levels, insulin sensitivity and weights remained normal over a 
one year period and did not differ between patients that remained on a 
thymidine or non-thymidine or those that switched from a thymidine to a non­
thymidine based regimen. This cohort had high levels of pre-existing traditional 
risk factors of CVD, though most patients had a low or moderate risk of 
developing CVD over 10 years.
The study population was diverse and the exclusion criteria were minimal. The 
results were meant to reflect the situation in real clinic settings. The patients 
were generally adherent to their treatment. The results show that pre-existing 
risk factors for CVD are prevalent in HIV patients on HAART. We have also 
shown that the relationship between the development of dyslipidaemia, 
deranged glucose homeostasis, abnormalities of blood pressure or changes in 
body habitus and the level of cardiovascular risk is not straight forward. Use of 
newer NRTIs (e.g. TDF and ABC) is affecting patient perception on body 
habitus changes particularly in those that switch from a thymidine to 
nonthymidine NRTI noting subjective improvements in lipodystrophy over time. 
Caution must be exercised in that these are subjective rather than objective 
assessments, since the present data do not statistically support this view. 
Additionally, use of the newer NRTIs and FIs (atazanavir) may be having a 
favourable effect on lipid profiles and glucose metabolism. Several limitations 
exist with the current work; the numbers of patients enrolled in each study was
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small as such we cannot draw firm conclusions on the effects of individual 
drugs on lipid profiles, glucose homeostasis and CV risk.
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CHAPTER THREE
ANTIRETROVIRAL DRUGS AND 
BIOMARKERS OF 
CARDIOVASCULAR DISEASE AND 
INFLAMMATION IN HIV PATIENTS
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3.1 INTRODUCTION
In the general population, inflammation has been shown to play a role in 
development of cardiovascular disease (CVD) (Ross 1999; Hansson 2005). 
Inflammatory cytokines such as interleukin 6 (IL-6), tumour necrosis-a (TNF-a), 
C-reactive protein (CRP), myeloperoxidase, markers of vascular endothelial 
activation and carotid intimal-media thickness (IMT) have all been shown to 
predict the development of myocardial infarction, stroke and diabetes mellitus 
(Bots et al. 1999; Ridker et al. 2000; Zhang et al. 2001; Brennan et al. 2003; 
Cesari et ai 2003; Pai et al. 2004; Espeland et al. 2005; Ogata et al. 2005).
Apart from the inflammatory markers, adipose tissue derived cytokines 
(adipocytokines) such as leptin, adiponectin, resistin and visfatin are involved 
in energy homeostasis (lipid, glucose and insulin metabolism) and have also 
been implicated in the pathogenesis of the metabolic derangements found in 
obesity, diabetes mellitus and cardiovascular disease (Hubert et al. 1983; 
Fasshauer and Paschke 2003; Rajala and Scherer 2003; Lieb et al. 2009).
HIV infection is a chronic inflammatory disease in which derangements of 
inflammatory cytokines, adipocytokines as well increased carotid IMT have 
been demonstrated, showing that HIV infected patients are at risk of 
accelerated atherosclerosis and therefore increased risk of myocardial 
infarctions (Laughlin etal. 2007; Rathmann etal. 2007; Thant et al. 2007; Ross 
et al. 2009). Indeed, HIV patients have been shown to be at higher risk of
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developing ischaemic heart disease by virtue of having the virus or being on 
antiretroviral therapy compared to HIV negative people (Obel et al. 2007; 
Triant et al. 2007). With this in mind, we investigated the serum levels of 
adipocytokines namely adiponectin, leptin, resistin and visfatin; the 
proinflammatory cytokines TNF-a and IL-6; and CRP over a one year follow-up 
period in patients on antiretroviral therapy, specifically to look at any trends in 
cytokine levels depending on the type of drugs the patients were on. We also 
looked at disease control by looking at the trends in CD4 count and HIV viral 
load. Additionally, we also looked at plasma viscosity, particularly as there 
have been case reports in the literature of the hyperviscosity syndrome 
occurring in HIV infected patients which predisposes to a thrombotic state 
(Garderet et al. 2004).
3.2 METHODOLOGY
The research site, the study protocols, ethics approvals, study conduct and 
procedures are described in the foregoing Chapter 2 (Methodology, Section 
2.2, pages 61-65). To summarize, 2 studies were conducted from which the 
following comparison groups were derived:
1. Group 1: A total of 20 patients remaining on a Thymidine based highly 
active antiretroviral therapy (HAART) regimen (18 on AZT and 2 on 
D4T)
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2. Group 2: A total of 27 patients remaining on a non-thymidine regimen 
(17 on tenofovir and emtricitabine (TDF/FTC), 7 on abacavir and 
lamivudine (ABC/3TC) and 3 on TDF/ABC).
3. Group 3: A total of 17 patients switching from a thymidine to a non­
thymidine non-DDI (ABC/3TC, TDF/FTC or TDF/ABC) regimen. 14 
switched from AZT and 3 switched from D4T.
Blood for cytokine level determination was taken after an overnight fast at 
baseline (day 0), 6 months and 12 months. After venesection, the blood was 
immediately placed on ice and allowed to stand for 20 minutes. It was then 
centrifuged to obtain serum. The serum was aliquoted and stored in a -80°C 
freezer. The cytokine levels (TNF-a, IL-6, adiponectin, leptin and resistin) were 
determined using Millipore CytokineProfiler™ service (Millipore 2008). The 
detection limits were: adiponectin 145.4pg/mL, resistin 6.7pg/mL, IL-6 
1.6pg/mL, Leptin 85.4 pg/mL and TNF-a 0.14pg/mL. Visfatin levels were 
determined by ELISA (human Visfatin, AdipoGen, Axxora UK LTD) and the 
detection limit was 30pg/mL. Blood for determination of CD4 cell count, CRP 
and plasma viscosity was analyzed at the North Manchester General Hospital 
laboratory as part of the routine blood tests that patients on HAART undergo 
during their routine 3-monthly clinic visits (see Chapter 2, Section 2.2.2.3.2, 
Study Procedures, page 64).
3.2.1 Statistical analysis
The independent sample T-Test was used to compare the mean change 
between the three groups between 12 months and baseline for the variables 
TNF-a, IL-6, leptin, adiponectin, resistin, plasma viscosity and CD4 cell count
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(SPSS v. 16, SPSS Inc. Chicago, USA). The mean changes of all parameters 
were approximately normally distributed on testing using histograms. Median 
CRP levels were determined for the groups and the Mann-Whitney U test was 
used to test for significance in the difference in the medians between the 
groups. The Fisher exact test (STATA, Texas, USA, http://www.stata.com.) 
was used to assess the significance of any difference in virological control 
between baseline and 12 months for each group.
3.3 RESULTS
Baseline characteristics were as described in the foregoing chapter 2 (Section 
2.3.1, page 68 and Table 2-3, page 69). Table 3-1 shows the mean change 
over the 12 months follow-up period in the parameters TNF-a, IL-6, leptin, 
adiponectin, resistin, plasma viscosity and CD4 cell count. Figure 3-1 (Panel 
A-C) shows the trends in group means over 12 months for the same 
parameters.
3.3.1 Proinflammatory Cytokines and CRP
TNF-a level did not change between baseline and 12 month in groups 1 and 3. 
There was an increase of 0.6 pg/mL in the TNF-a level in group 2 by 12 
months. There was no statistically significant difference in the group mean 
change at 12 months from baseline between the groups. At 12 months, IL-6 
level increased by 0.3 pg/mL in group 1 and by 2.6 pg/mL in group 3. The level 
did not change in group 2. There was no statistically significant difference in 
the group mean change at 12 months from baseline between the groups.
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Table 3-1: Mean Change in parameters and Pairwise comparisons of change 
between groups _________________  ___________________________ ____
Mean of Delta Pairwise comparisons
Variable Group valueFor 12 Months - 
baseline (SD)
Groups Meandifference
P value
Tumour 1 0.3(1.9) 1 vs. 2 -0.18 0.81
necrosis
factor-a
(pg/ml)
2 0.4(2.1) 1 vs. 3 -0.01 0.98
3 0.3(2.9) 2 vs. 3 0.2 0.84
Interleukin 6 1 0.3(0.9) 1 vs. 2 0.3 0.62
(pg/ml) 2 0.002(2.0) 1 vs. 3 -2.3 0.60
3 2.6(14.3) 2 vs. 3 -2.6 0.40
Leptin 1 -4.8(23.2) 1 vs. 2 -4.4 0.40
(ng/ml) 2 -0.3(6.0) 1 vs. 3 -5.4 0.39
3 -0.6(4.6) 2 vs. 3 -0.9 0.60
Adiponectin 1 -3.5 (6.2) 1 vs. 2 -3.5 0.26
(pg/ml) 2 -0.01(9.3) 1 vs. 3 0.18 0.97
3 -3.7(13.1) 2 vs. 3 3.7 0.32
Resistin 1 7.9(34.9) 1 vs. 2 8.1 0.32
(ng/ml) 2 -0.2(12.2) 1 vs. 3 15 0.89
3 6.4(21.3) 2 vs. 3 -6.6 0.24
CD4 count 1 79(107) 1 vs. 2 52 0.27
(cells/mm3) 2 27(173) 1 vs. 3 -51 0.45
3 130(253) 2 vs. 3 -103 0.15
CD4 % 1 -10(7.7) 1 vs. 2 0.3 0.91
2 -13(7.2) 1 vs. 3 -2.1 0.51
3 11(9.8) 2 vs. 3 -2.3 0.41
Plasma 1 4.4(13.4) 1 vs. 2 -4.2 0.51
viscosity (mPa) 2 8.6(25.7) 1 vs. 3 6.2 0.14
3 -18(11.0) 2 vs. 3 10.4 0.12
Group 1: patients on a thymidine regimen; group 2: patients on a non-thymidine regimen; 
group 3: patients that switched from a thymidine to a non-thymidine regimen; *overall group 
mean over the 12 month period; SD: standard deviation
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Figure 3-1 Panel (a-c): Group means for Tumour necrosis factor-a, Interleukin 
6, Leptin, Adiponectin, Leptin, resistin, CD4 cell count, CD4 cell percentage 
and Plasma viscosity at each time point.
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Figure 3-1: Panel (c): CD4 cell count and Plasma viscosity (continued)
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The median CRP in group 1 was 2.9 (1.0-37.8), in group 2 was 2.6 (1.0-27.0) 
and in group 3 was 1.8 (1.0-13.0). There was no significant difference between 
the 3 groups. Patients with a CRP>3 were 13 (72%) in group 1,11 (44%) in 
group 2 and 7 (44%) in group 3, with P=0.11 for group 1 vs. group 2 and 
P=0.16 for group 1 vs. group 3. In group 1, 4 (22%) patients had CRP>5.9 
while this was 7 (28%) and 4 (25%) patients in group 2 and 3 respectively.
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3.3.2 Adipocytokines
Levels of leptin decreased by 4.8 ng/mL at 12 months in group 1; there was 
little change in group 2 and 3. There was no statistically significant difference 
in the group mean change at 12 months from baseline between the groups. 
Adiponectin levels decreased by 3.5 pg/mL in group 1 and by 3.7 pg/mL in 
group 3 by 12 months. In group 2, the level of adiponectin increased by 4.3 
pg/mL by 6 months but returned to baseline levels by 12 months. There was 
no statistically significant difference in the group mean change at 12 months 
from baseline between groups. Resistin levels increased by 7.9 ng/ml in group 
1 and by 6.4 ng/mL in group 3 by 12 months. The level dropped by 0.2 ng/mL 
in group 2. There was no statistically significant difference in the group mean 
change at 12 months from baseline between the groups. Visfatin levels are not 
reported as all samples had levels below the detection limit of the assay used, 
despite our attempts to optimize the assay which included reducing the 
number of wash cycles.
3.3.3 Immune status, virological control and plasma 
viscosity
At baseline, the median CD4 count was 425cells/mm3 (229-816) in group 1; 
496cells/mm3 (176-1302) in group 2 and 512cells/mm3 (99-1128) in group 3. 
The median CD4 percentage of the total lymphocyte count was 27% (17-53) in 
group 1; 27% (9-48) in group 2 and 28.5 (12-48) in group 3. None of the 
patients in Group 1 had a CD4 count <200 cells/mL3. However, 4 (14.8%) 
patients in Group 2 and 3 (17.6%) patients in Group 3 had a CD4 count < 200 
cells/mL3. The group median CD4 ceil levels remained above 400 cells/mm3 in
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all the groups between baseline and 12 months. The CD4 cell percentage 
remained reasonably good as well, being between 25-29% throughout the 
study period. The CD4 count increased by 79 cells/mm3 in Group 1, 130 
cells/mm3 in Group 3 and 27 in Group 2 over 12 months. There was no 
statistically significant difference in the group mean change at 12 months from 
baseline between the groups.
The majority of the patients had an undetectable viral load of ^ 40 copies/ml of 
blood (87.5%, 88% and 82% in Group 1, 2 and 3 respectively) at 12 months. 
This is comparable to base line levels (85%, 96% and 76% for Group 1, 2 and 
3 respectively) with P=0.7, 0.7 and 0.4 for group 1, 2 and 3 respectively. Most 
patients who had detectable viral load could have been due to minor viral 
bleeps. Two patients each in Group 2 and 3 had clear-cut virological failure 
with levels between 500 and 509887 copies/ml. One of these patients had 
adherence level of 85-94% with some missed doses over the preceding week 
and 3 months. Although the other 3 patients’ overran adherence was 95-100%, 
they all had missed one or more doses over the preceding 3 months. While the 
patients would have had a resistance test done, this data was not recorded in 
this study.
There was not much change in the plasma viscosity over time within each 
group and there was no statistically significant difference in the group mean 
change at 12 months from baseline between the three groups. With regard to 
patients on a non-ABC/non-DDI regimen, there was a median increase at 12 
months from baseline of 5mPAs in the plasma viscosity while this was
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1.5mPAs for those on an ABC regimen and this difference was not statistically 
significance (P=0.06).
3.4 DISCUSSION
This longitudinal study was designed to investigate the levels of 
proinftammatory cytokines TNF-a and IL-6; adipocytokines namely 
adiponectin, leptin, resistin and visfatin; the nonspecific marker of inflammation 
CRP; immune status specifically looking at the CD4 count and viral load as 
well as to explore plasma viscosity and to relate these parameters to the NRTI 
backbone the patients were taking.
The patients were immunologically and virologically well controlled throughout 
the study period. There were increases in the CD4 counts in groups 1 and 3. 
The increase in CD4 cells was greater in patients that switched from a 
thymidine to a nonthymidine regimen (group 3) compared to those remaining 
on a thymidine (group 1) (130 vs. 79 cells/mm3) which is in agreement with 
other studies such as Pozniak et al who demonstrated a significantly greater 
increase in CD4 count (270 vs. 237 cells/mm3; P= 0.036) in patients on a TDF 
regimen compared to those on an AZT regimen (Pozniak et al. 2006). With 
respect to virological control, there was no difference between the 3 groups as 
demonstrated by others who have studied patients on AZT or D4T based 
regimens compared to TDF or ABC containing regimens (Gallant et al. 2004). 
However, virological and immunological control do not appear to have an 
effect on overall risk of development of atherosclerosis and hence CVD (Hsue 
et al. 2009a; Ross et al. 2009).
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The plasma viscosity did not increase markedly in all the groups, though those 
patients on a non-ABC/non-DDI regimen had a higher increase in the plasma 
viscosity than those on an ABC regimen but this was not statistically 
significant. The lack of major changes in plasma viscosity with the use of the 
various drugs in this study could be a reflection of the fact that the 
hyperviscosity syndrome in HIV infection was described in those with untreated 
disease with end-stage AIDS and is believed to be due to dysregulation and 
polyclonal activation of B-lymphocytes (Jin et al. 2000), and therefore these 
derangements could be brought under control with virological control due to 
treatment of the disease.
Although the median CRP was <3 in all the groups, which is the level quoted 
for the general population (Pepys and Hirschfield 2003), a quarter of patients 
in each group had a CRP>5.9, the median level found in HIV patients in 
another study (Noursadeghi and Miller 2005). These patients could potentially 
be at risk of CVD (Tracy et al. 1997; Koenig et al. 1999; Ridker et al. 2002; 
Cesari et al. 2003; Pai et al. 2004).
High levels of TNF-a and IL-6 have been shown to predict the development of
CVD in the general population. High levels of these cytokines have been
demonstrated in HIV infected people (Ross et al. 2009) which would mean that
these patients would be at high risk of CVD. Indeed studies have shown
increased risk of CVD in HIV patients by virtue of having the virus and being
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on ART (Friis-Moller et al. 2003(b); Obel et at. 2007; Triant et al. 2007). Both in 
vitro and in vivo studies have demonstrated high levels of these cytokines in 
association with type or class of drugs within ART. In these studies, incubating 
differentiating adipocytes with Pis particularly indinavir, nelfinavir, ritonavir and 
lopinavir as well as AZT and d4T resulted in increased expression of the 
pro inflammatory cytokines (Lagathu et al. 2004; Jones et al. 2005b). High 
circulating levels and increased mRNA expression in adipose tissue of TNF-a 
and IL-6 have been demonstrated in HIV patients with lipodystrophy (LD) 
compared with those that did not have LD (Lihn et al. 2003), showing that 
patients with LD are at increased risk of CVD.
The mean serum levels for the three groups for TNF-a levels in this study were 
similar to those found by Ross et al (2009) in HIV infected people (4.6- 
6.3pg/ml in this study vs. 4.0pg/mL in Ross’s study). This is higher than the 
levels found in HIV negative people (1.8pg/mL in the study by Ross et al). This 
study confirms that the levels of this cytokine are raised in HIV infected people, 
which would put them at increased risk of developing CVD. There was no 
statistically significant difference between patients that remained on a 
thymidine or a non-thymidine and those switching from a thymidine to a non­
thymidine regimen and the levels of TNF-a did not rise over the one year 
follow-up period.
With regard to IL-6, the highest levels were in the switch group (group 3, mean: 
6.6 pg/mL) which is similar to the findings by Ross et al (6 pg/mL) and the
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levels increased over the one year follow-up in this group. Patients continuing 
on a thymidine (group 1) or a non-thymidine (group 2) had levels that were 
similar to those in HIV uninfected people in the study by Ross et al (i.e. 
2.8pg/mL vs. 3.0pg/mL in group 1 and 2.2pg/mL in group 2 in this study). 
However, there was no statistically significant difference in the group mean 
change at 12 months from baseline between the groups. It was expected that 
IL-6 levels would be higher in patients on a thymidine compared to those on a 
non-thymidine regimen and that levels would improve in patients that switched 
from a thymidine to a non-thymidine (group 3), the thymidine drugs having 
been shown to cause increased expression of this cytokine by others (Lagathu 
et al. 2004; Jones et al. 2005b; Lagathu et al. 2007). The unexpected high 
level of IL-6 in group 3 could be explained by the fact that 3 patients had very 
high levels of this cytokine. In 2 patients, IL-6 levels were high at baseline and 
at 6 months which improved at 12 months (for patient 1: 18.9, 23.7 and 
3.6pg/mL respectively; for patient 2: 24.25, 33.75 and 12.5pg/mL respectively), 
both had switched to TDF, however, one of the patients had been on ABC with 
AZT and 3TC for 51 months before they switched. Both patients had TNF-a 
levels that were similar to the other patients within the group. The third patient 
(with levels of 2.27, 8.76 and 52.08pg/mL at baseline, 6 and 12 months 
respectively), had switched to ABC, and had TNF-a levels above 4pg/ml at all 
the visits (7.59, 13.7 and 12.1pg/mL respectively). One patient switched drugs 
for virologicai failure and the other two for LD. Neither of these 3 patients had 
intercurrent illness at any of the visits to explain the high levels of IL-6. Within 
group 3, 7 patients switched to ABC and they had median change of 
0.17pg/mL at 12 months from baseline; 10 patients switched to TDF and these
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had a median change of 0.9pg/mL, the difference between the two was not 
statistically significant (P=0.96). It is possible that the increase in IL-6 in group 
3 may be driven by ABC use, as has been shown in the SMART study 
(Lundgren 2008) but the numbers in this study are low for firm conclusions to 
be drawn.
Both in vitro and in vivo studies have shown reduced circulating levels and 
expression of mRNA in the adipose tissue of adiponectin and leptin in HIV 
patients on ART particularly in lipodystrophic patients (Lihn et ai. 2003; Jan et 
ai. 2004; Lagathu et ai. 2007). Reduced levels of adiponectin and leptin could 
be explained by the reduction in adipose tissue mass in these patients 
(Sweeney et al. 2007). As is the case with the proinflammatory cytokines, Pis 
and NRTIs have been shown to reduce the levels of these adipocykines. In the 
study by Lagathu et ai, thymidines NRTIs (AZT and D4T) (ABC) and Pis 
(lopinavir, nelfinavir and indinavir) reduced the release of adiponectin and 
leptin from differentiated human adipocytes; ABC and some Pis (ATV and 
APV) had no effect (Lagathu et ai. 2007). Eighty percent of patients were on 
D4T in addition to other NRTIs and Pis in the study by Jan et al in which fat 
from HIV patients had reduced adiponectin and leptin mRNA, further showing 
the adverse effects of thymidines (Jan et al. 2004). High resistin levels have 
been demonstrated in HIV positive patients compared to HIV negative 
individuals (Kamin et al. 2005). Additionally, patients with a single nucleotide 
polymorphism in the resistin gene on thymidine NRTIs, DDI and 3TC have 
been shown to develop physical changes of LD as well as dyslipidaemia and 
insulin resistance (Ranade et al. 2008).
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In this study, adiponectin levels declined at 12 months from baseline levels in 
patients remaining on a thymidine (by 3.5pg/mL) which is in agreement with 
the studies described. After an initial rise in adiponectin levels at 6 months, 
levels returned to baseline values in patients that remained on a non-thymidine 
regimen, it was expected that this group would have a favourable adiponectin 
profile. Adiponectin levels declined in those switching from a thymidine to a 
nonthymidine regimen (by 3.7pg/mL); the expectation here was that there 
would be an adverse adiponectin profile which would improve upon switching 
to a nonthymidine. With regard to leptin, although the mean change from 
baseline were not different between the three groups, the levels declined in 
those patients remaining on a thymidine regimen (by 4.8ng/mL) in agreement 
with other studies and remained the same over the 12 month period in the 
other 2 groups. Similarly with resistin, although there were no statistically 
significant differences in the mean change between the three groups in the 
level of this cytokine at 12 months, levels did increase in those continuing on a 
thymidine regimen (by 7.9ng/mL), which is in agreement with previous studies 
described showing that this group of drugs has an adverse effect on adipose 
tissue derived cytokines. The increase (by 6.4ng/ml_) in resistin in the group 
that switched from a thymidine to a nonthymidine regimen was unexpected, as 
the nonthymidine drugs should have more friendly effects on adipose tissue 
function. This probably shows that even the nonthymidines (TDF or ABC) may 
have a negative effect on adipose tissue or the effects of the preceding 
thymidine NRTIs had not completely reversed. Additionally, for those 
unexpected cytokine levels at different time points (e.g. in the case of
117
adiponectin), this may indicate that biomarker changes are dynamic as such 
the trend in levels may be demonstrated better with longer follow up.
Schindler et al clearly demonstrated high levels of visfatin in HIV patients on 
HAART compared to HIV negative controls (Schindler et al. 2006). This study 
was unable to demonstrate detectable levels of visfatin in all the patients. This 
could have been due to sample handling or problems with the assay used. To 
characterize the effects of various HIV drugs on this relatively new cytokine 
and its effects on CVD is still of great interest and as such merits further work.
There has been a lot of new data showing increased risk of CVD with current 
or recent use of ABC (Sabin et al. 2008). However, Martinez et al have 
recently shown that ABC does not affect cardiovascular biomarkers of 
inflammation, endothelial dysfunction, insulin resistance, or hypercoagulability 
in virologically suppressed HIV-infected patients. There was no difference at 
48 weeks between patients on ABC and TDF based regimens in the serum 
levels of high-sensitivity CRP, monocyte chemoattractant protein-1 (MCP-1), 
osteoprotegerin, IL-6, IL-10, TNF-a, ICAM-1, VCAM-1, selectin E and P, 
adiponectin, insulin, and D-dimer (Martinez et al. 2010). This is in agreement 
with the in vitro study by Lagathu et al (2007) which found that ABC did not 
increase the release from human adipocytes of IL-6 and TNF-a or decrease 
the release of adiponectin and leptin. In our study, 41% of patients who 
switched ART went on to an ABC based regimen and 37% patients in Group 2 
were on an ABC regimen, which shows that there was substantial use of this
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drug. In this study, all the mean levels of markers under study (with the 
exception of resistin and adiponectin which showed adverse change in those 
that switched from a thymidine to a non-thymidine regimen) did not differ 
between the various drug regimens, including those that switched drugs, which 
shows that ABC did not add adversely to CVD biomarkers. This is in 
agreement with the findings of the study by Martinez et al. The adverse 
change in resistin and adiponectin cannot directly be attributed to use of ABC, 
particularly as the findings with regard to the other biomarkers in this study do 
not clearly support that ABC had an adverse effect on CVD biomarkers.
3.5 CONCLUSIONS
We set out to investigate cytokine levels in a typical large HIV unit. Cytokine 
derangements have been implicated in the pathogenesis of the metabolic 
syndrome, diabetes and cardiovascular disease. HIV positive patients are 
living longer and therefore the prevalence of cardiovascular disease and 
morbidity and mortality from this disease will increase. Investigating underlying 
cytokine derangements will provide a platform for investigating treatments to 
ameliorate these problems. This study has shown that thymidine NRTIs cause 
derangements in cytokines that have been shown to predict the development 
of CVD. ABC use did not clearly cause adverse changes in these cytokines. 
However, the numbers of patients in this study are small and we did not have a 
control group therefore firm conclusions cannot be drawn. Differences in 
findings within this study from other studies can be due to differences in 
methodology and populations. However, the accumulated data on the adverse
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effects of thymidines has lead to the World Health Organization recently 
recommending that the thymidine D4T be removed from national ART 
programs (WHO 2009).
Clearly, research into risk factors of CVD posed by HIV drugs needs to 
continue, and treatments explored so that the success of treating HIV and 
turning it into a chronic manageable disease is not marred by development of 
disabling or fatal CVD.
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CHAPTER FOUR
AUDITS OF CARDIOVASCULAR 
DISEASE MANAGEMENT IN HIV 
CLINICS IN MANCHESTER
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4.1 INTRODUCTION
The HIV population is living longer with the aid of antiretroviral therapy (ART) 
and as such will experience diseases of aging such as CVD since they also will 
have the same risk factors as the general population (Friis-Moller et al. 
2003(b)). These include smoking, dyslipidaemia, increased age, male sex, 
obesity, diabetes, hypertension and a family history of premature heart disease 
which increase the risk of CVD (Stamler et al. 1986; Wilson et al. 1998). 
Indeed HIV patients may have enhanced risks. Studies have shown increased 
rates of smoking of up to 51% in HIV patients (Friis-Moller et al. 2003(a); Ross 
et al. 2009) compared for example with a smoking rate of 25% in England 
amongst adults (NHS 2006). Usage of ART drugs particularly nucleoside 
reverse transcriptase inhibitors (NRTIs) and protease inhibitors (Pis) cause 
increases in total cholesterol (TC), LDL cholesterol (LDL-C), triglycerides 
(TGs), glucose intolerance and insulin resistance (Carr et al. 1998; Behrens et 
al. 1999; Jones et al. 2005a). There has been a lot of controversy on risk 
associated with particular ART drugs, especially abacavir (ABC). The D:A:D 
study (Sabin et al. 2008; Worm et al.) and Durand et al showed an increased 
risk of myocardial infarction (Ml) with recent use or any exposure to ABC and 
didanosine (DDI) while Bedimo et al did not demonstrate this effect (Bedimo R 
2009; Durand M 2009). Regardless of this conflicting information, combination 
ART has been shown to be independently associated with a 26 percent 
relative increase in the rate of myocardial infarction per year of exposure 
during the first four to six years of use and that cardiovascular disease now 
contributes to more than 10% of deaths in HIV-infected patients (Law et al. 
2003; Friis-Moller et al. 2003(a); Friis-Moller et al. 2003(b); Sabin et al. 2008).
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HIV physicians therefore face the challenge of monitoring, identifying, treating 
and or referring patients who develop risk factors of CVD on ARVs.
In the North West of England, there were 6363 cases of HIV infection by the 
end of 2007. Of these, 5212 accessed treatment and care from statutory 
treatment centres. An audit represents a valuable tool to assess the way HIV 
physicians identify and manage patients who develop metabolic complications 
of ARVs that would put them at risk of CVD. The Joint British Societies (JBS2) 
Guidelines on Prevention of Cardiovascular Disease in Clinical Practice can 
be used as a standard for such an audit (JBS2 2005). The Joint British 
Societies comprise the British Cardiac Society, the British Hypertension 
Society, Diabetes UK, HEART UK, the Primary Care Cardiovascular Society 
and the Stroke Association. The JBS2 guidelines are aimed at improving the 
management of individuals with risk factors for the development of CVD in the 
general population. The target population for management of these risk factors 
have been defined as:
• Patients with any form of established atherosclerotic CVD;
• Patients with diabetes (type 1 or 2);
• Asymptomatic individuals without established CVD who have >20% 
estimated risk of developing atherosclerotic CVD over 10 years;
• People with elevated single risk factors
o Blood pressure >160mmHg systolic or >100mmHg diastolic, or 
lesser degrees of blood pressure elevation with target organ
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damage, including left ventricular hypertrophy, grade 3 or 4 
hypertensive retinopathy, raised creatinine, micro/macro­
albuminuria or proteinuria;
o Ratio of total to high density lipoprotein cholesterol (TC:HDL-C) 
>6 mmol/I;
o Familial dyslipidaemias, such as familial hypercholesterolaemia 
or familial combined hyperlipidaemia.
• Patients with a family history of premature CVD (CVD event in a male 
first degree relative before age 55 or a female first degree relative 
before age 65 years) should have their CVD risk assessed and treated 
accordingly.
The guidelines suggest that patients require professional lifestyle and risk 
factor management to achieve the defined targets in the following categories:
• Lifestyle changes:
o Smoking cessation; 
o Healthier food choices; 
o Increase aerobic physical activity; and 
o Achieve optimal weight and weight distribution
• Optimal Blood Pressure (BP):
o Systolic BP <140 mmHg and diastolic BP <85 mmHg in high risk 
people (<130 mm Hg systolic and <80 mmHg diastolic in patients
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with established atherosclerotic disease, diabetes or chronic
renal failure)
• Optimal Lipids:
o TC <4.0 mmol/l or a 25% reduction;
o LDL-C <2.0 mmol/l or a 30% reduction in LDL-C
• Blood Glucose
o Optimal fasting glucose <6.0mmol/l (patients with levels between 
6.1-6.9 on 2 occasions would require an oral glucose tolerance 
test, while those with levels >7mmol/l on 2 occasions are 
considered diabetic)
• Cardioprotective drugs in selected people:
o Antithrombotic therapy (aspirin or clopidogrel)
o All people over the age of 50 years who have a total CVD risk > 
20%
o All people with established coronary, peripheral or 
cerebrovascular atherosclerotic disease
• Blood pressure lowering therapy (such as (3-blockers, angiotensin 
converting enzyme inhibitors, calcium channel blockers and diuretics 
alone or in combination)
o In patients with established atherosclerotic disease whose blood 
pressures are not below the optimum or patients with severe high 
blood pressure as a single risk factor.
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• Lipid lowering therapy (Statins plus other lipid lowering drugs (LLAs)) 
o People with established atherosclerotic disease 
o People with high total risk of developing CVD >20% 
o Diabetics aged 40years or more
o Diabetics aged less than 40years with microvascular disease, 
poorly controlled diabetes, TC >6mmol/l, on treatment for 
hypertension, the metabolic syndrome and a family history of 
premature CVD in a first-degree relative.
Use of statins is also recommended in these groups of patients by the National 
Institute of Health and Clinical Excellence (NICE-TA94 2009).
Other than the optimal standards of care which should be achieved for high 
risk people, the JBS has less stringent audit standards which are considered to 
be the minimum standard of care for high-risk people though it is 
recommended that wherever possible, the optimal treatment targets should be 
achieved. The audit standards include achieving a blood pressure of < 150 mm 
Hg systolic and <90 mmHg diastolic; TC of <5.0 mmol/l (or a 25% reduction in 
total cholesterol) and LDL-C of <3.0 mmol/l (or a 30% reduction in LDL-C).
Two audits were undertaken in HIV positive patients in the North West. The 
first audit was conducted at North Manchester General Hospital (NMGH) -
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Audit 1, and the second at 5 clinics in the Greater Manchester area (namely 
NMGH, Bolton, Oldham, Manchester Royal Infirmary [MRI] and 
Rochdale/Bury) - Audit 2. In these audits, we compared our patient 
management with the JBS2 audit standards rather than optimal standards of 
care. The JBS2 optimal standards are more strigent and require lower levels to 
be achieved for the CVD risk factors while the audit standards are less 
stringent, requiring levels that are higher than the optimal standards to be 
achieved. Since we were carrying out these audits for the first time, it was felt 
that we should compare our practice against the audit standards, with a view 
to comparing against the optimal standards upon re-auditing in the future.
4.2 Aims and Objectives
To determine if the HIV treatment clinics in the Greater Manchester area 
(Figure 4-1) appropriately identify CVD risk factors in HIV patients on HAART 
and institute corrective measures or treatments according to JBS2 guidelines.
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Figure 4-1: Greater Manchester HIV treatment clinics
Rochdale
/Bury
MRI: Manchester Royal Infirmary; NMGH: North Manchester General Hospital
4.3 Methodology
The audits were retrospective HIV patient case note reviews looking at record 
keeping, identification and institution of corrective measures for cardiovascular 
risk factors. Case notes reviewed were those retrieved by medical records in 
readiness for consultant clinics.
4.3.1 Data collection
In Audit 1, patients were those attending clinic from January 2006 to January 
2007 at the NMGH, which has 1500 HIV patients registered for care. One
hundred and one (101, 7%) case notes were reviewed for this audit.
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Consecutive casenotes were selected from lists of patients attending each of 
the consultants’ clinics. Up to five lipid (for TC, LDL, HDL-C, TGs and TC:HDL 
ratio) and glucose results documented in the case notes or on the hospital 
computer chemistry results system over the one year period were recorded. All 
patients had at least 1 reading. The medians for each lipid fraction and glucose 
over the year were calculated per patient.
In audit 2, the case notes of 78 patients under the care of 16 HIV consultants 
working within 5 clinics in Manchester (as listed above) were reviewed, each 
consultant reviewing approximately 5 case notes. The clinics involved were 
either Infectious Diseases or Genito-Urinary Medicine, and in total they had 
just over 2500 HIV patients registered for care. Data from April 2005 - April 
2006 were recorded. The highest recorded TC level and any HDL-C level or 
the highest recorded TC:HDL-C ratio in the year of interest were used in the 
audit. The glucose was recorded as either euglycaemic or raised.
In both audits, the highest blood pressure measurement recorded when the 
patient was noted to be well was used. The lipid and glucose levels were 
mostly random, rather than fasted. Data were recorded on predesigned data 
collection forms, each of the 2 audits having their own form. Data collection 
forms were designed in line with the wishes of the participating consultant 
physicians, agreed and used across all sites. The medians for each lipid 
fraction, glucose, blood pressure (systolic and diastolic) and duration of 
treatment were calculated; the Mann-Whitney U test was used to check for
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statistical significance of the differences in the above parameters for the 
different drug regimens (SPSS v. 16, SPSS Inc. Chicago, USA). Appendix 3 
and 4 show the data collection forms for Audit 1 and 2 respectively.
CVD risk calculation was done using the University of Edinburgh 
cardiovascular risk calculator and chart v2.0 (Payne 2006). Variables entered 
were age, systolic blood pressure, smoking status, TC and HDL-C. A 
percentage risk over 10 years was obtained for all patients except those with 
established diabetes and ischaemic heart disease, who should be considered 
high risk and treated accordingly.
4.3.2 Lifestyle advice recorded
For life style advice and risk factor management, the following documentation 
was sought in the case notes:
Smoking cessation - if the physician documented having counselled the 
patient to stop smoking; if the patient was advised to access general 
practitioner (GP)-led smoking cessation clinics; or the patient was prescribed 
nicotine patches or gum.
Diet - if the physician documented having informed the patient to change their 
diet or any documentation of nutritional advice or a referral to a dietician.
Weight reduction and exercise - if the physician documented having informed 
the patient to reduce weight either via diet or increase in exercise, or referral to 
a fitness unit.
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Alcohol moderation - if the physician documented having informed the patient 
to reduce their alcohol intake, or if the patient was advised to seek community 
based alcohol misuse treatment centres or if the patient was referred to a 
hospital based alcohol misuse team.
4.3.3 Additional analysis
\With the new controversy over increased risk of myocardial infarction with 
ABC and DDI, analyses have been undertaken to look at CV risks for patients 
on combination ART that includes these 2 drugs.
4.4 RESULTS
The results of the two audits are presented separately because the audits 
were undertaken at different times, the design was different and separate 
databases were set up. This was because more complete lipid and glucose 
profiles were collected in audit 1 (5 for each lipid fraction and glucose) while 
the highest TC and TC:HDL-C ratio in the year were recorded and, 
additionally, glucose levels were recorded as “eugiycaemic”, “raised" or 
“borderline” in audit 2.
4.4.1 Audit 1
4.4.1.1 Demographics
Eighty-three patients out of 101 were male and the median age was 41 years 
(range: 21-71 years). Sixty eight percent of patients were Caucasian, 13% 
were Black African, 1% were Asian and in 12%, the ethnicity was not recorded 
or was unknown.
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4.4.1.2 Antiretroviral drug usage:
Table 4-1 shows the antiretroviral therapy (ART) drugs used at the time of the 
audit. Zidovudine with lamivudine (AZT/3TC) was the most commonly used 
nucleoside reverse transcriptase inhibitor (NRTI) backbone (27/101, 26.7%), 
tenofovir (TDF) with 3TC or emtricitabine (FTC) being the second commonest 
NRTI backbone (24/101, 23.8%). There was increasing use of lipid friendly 
protease inhibitors (Pis) such as atazanavir (ATV) rather than boosted 
iopinavir (LPV/RTV) (15% vs. 10% respectively). Most patients were on a non- 
NRTI (NNRTI) rather than on a PI in keeping with guidance at the time 
(Gazzard et al. 2006). A third of the patients were on ABC based regimen 
while only a small proportion (11%) were on a DDI based regimen.
Patients on a non-thymidine (NTH) based regimen had been on their current 
regimen for shorter duration of time than those on a thymidine (TH) based 
regimen (P=0.04) though the total duration on ARVs was not significantly 
different. Additionally, the NTH group had more frequently been exposed to 
Pis (P=0.009) as well as being triple-class experienced than those on a TH 
based regimen (see Table 4-4). Nearly three quarters of the patients on ABC 
and DDI regimens had previous PI exposure (72 and 73% respectively) while a 
smaller proportion (39%) of those on a non-ABC/non-DDI regimen had 
previous PI exposure (ABC vs. non-ABC/non-DDI: P=0.003; DDI vs. non- 
ABC/non-DDI P=0.04). Additionally, nearly 50% of the patients in the ABC and 
DDI group were triple class experienced while this was only 19% in the non- 
ABC/non-DDI group (ABC vs. non-ABC/non-DDI: P=0.005; DDI vs. non-
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ABC/non-DDI P=0.06). However, the duration of the current regimen or total 
duration on all ART was similar between the 3 groups (see table 4-5).
Table 4-1: Antiretroviral drugs used (Audit 1)
Group Drug No. of Patients %of total (101)
Thymidine (45,
44.5%)
AZT based double or triple
NRTI backbone
37 38.4
D4T based double or triple
NRTI backbone
8 8.1
Non-thymidine (56, 
55.4%)
TDF/FTC or 3TC 24 10.1
ABC/3TC or FTC 9 8.1
DDI combinations0 10 10.1
TDF/ABC 11 10.1
Other NRTI combinations 2 2.0
ABC (non-DDI) 
based (29, 28.7%)
ABC/3TC or FTC 9 8.9
ABC/TDF 11 10.1
ABC/D4T +/- other NRTI 4 4.0
Other NRTI combination 5 4.9
DDI (non-ABC) 
based (11, 10.9%)
Various double/triple NRTI 
combinations
11 10.9
Protease Inhibitors 
(38, 37.6%)
Ritonavir boosted Lopinavir 10 10.1
Atazanavir 15 15.2
Fosamprenavir 11 11.1
Double-boosted Pis 2 2.0
NNRTIs (60, 59.4%) Efavirenz 30 30.3
Nevirapine 30 30.3
a In combination with TDF, 3TC or ABC; NNRTI: non- nucleoside reverse transcriptase 
inhibitor
4.4.1.3 Cardiovascular Risk FactorsPre-existing Risk Factors for
CVD
Table 4-2 shows the risk factors that were documented in the case notes for 
the time period of the audit for all the patients. There were high levels of 
smoking and family history of premature ischaemic heart disease (IHD). There 
were low levels of pre-existing diabetes, hypertension or IHD, though it should 
be noted that frequently, case notes did not have a record of whether a patient 
did or did not have a risk factor for CVD (99.1% of case notes for pre-existing 
IHD, 45.5% for family history of CVD, 16.8% for smoking status, and 9.9% for
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hypertension). It was not possible to ascertain from the case notes whether the 
patients did not have these risk factors or that the clinicians omitted to ask 
about them or failed to document appropriately. Table 4-3 presents risk factors 
according to NRTI backbone. The highest rates of smoking were in patients 
taking DDI (63.6%) and ABC (58.6%) compared to those on a non-ABC/non- 
DDI regimen (47.4%) or those on a TH (48.9%) and NTH regimen (53.6%). 
More patients on DDI also had a family history of premature CVD compared to 
patients on the other regimens. Diabetes and hypertension were uncommon in 
all the drug groups.
Table 4-2: Recorded cardiovascular disease risk factors (Audit 1)
Risk Factor Yes (%) No (%)
Smoker 52 (51.5) 36 (31.7)
FH of CVD 21 (20.8) 34 (33.7)
Diabetes 7(7) 88 (87.1)
Hypertension 7(7) 84 (83.1)
Pre-existing IHD 1 (0.9)
FH of CVD: family history of premature cardiovascular disease; 
IHD: ischaemic heart disease
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Table 4-3: Cardiovascular disease risk factors and NRTI backbone (Audit 1)
Thymidine
regimen
n=45
Non-
Thymidine
regimen
n=56
ABC (non-DDI) 
regimen 
n=29
DDI (non-ABC) 
regimen; non- 
ABC 
n=11
Non-ABC,
non-DDI
regimen
n=57
CV Risk:
>20 % 3 (6.7%) 4(7.1%) 2 (6.9%) 1 (9%) 4 (7%)
10-20% 9 (20%) 12(21.4%) 9(31%) 2 (18%) 9 (15.8%)
<10% 27 (60%) 32 (57.1%) 16(55.2%) 6 (54.5%) 34 (59.6%)
Smokers:
Current 22 (48.9%) 30 (53.6%) 17(58.6%) 7 (63.6%) 27 (47.4%)
Exsmokers 9 (20%) 8(14.3%) 4(13.8%) 1 (9%) 11 (19.3%)
Diabetes 2 (4.4%) 5 (8.9%) 2 (6.9%) 1 (9%) 4 (7%)
FHx of CVD 8(17.8%) 13 (23.2%) 5 (17.2%) 5 (45.4%) 10 (17.5%)
Hypertension 2 (4.4%) 5 (8.9%) 1 (3.4%) 1 (9%) 4 (7%)
4.4.1.3.2 Lipids
The median TC was 4.8mmol/l (3.0-7.9) and median LDL-C was 2.6 mmol/I 
(1.3-5.2), both of which were below the JBS2 audit standards. Forty five 
(44.5%) patients had a median TC >5.0mmol/l, 27(60%) of these patients also 
had an LDL-C >3.0mmol/l. Twenty nine (28.7%) patients had LDL-C 
>3.0mmol/l alone. The total number of patients identified with raised lipids 
(either TC or TGs or both) at some point in the 1 year period of the case note 
review was 58 (57.4%). Twenty (34.5%) patients out of 58 had raised TC 
alone, 9 (15.5%) patients had raised TGs alone and 29 (50%) patients had 
raised TC and TGs. Twenty seven (45.5%) had raised LDL-C. The median 
(and range) of lipid fractions over a 1 year period, as well as the duration of 
treatment and previous PI use with type of NRTI backbone and PI or NNRTI 
use, are shown in Tables 4-4 to 4-6. There were no differences in the lipid
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fractions between TH vs. NTH, ABC or DDI vs. nonABC/nonDDI regimen. 
Patients on a Pl-based ARV regimen had lower levels of TC and LDL-C than 
those on an NNRTI (P=0.03 and 0.007 respectively); however, there was no 
significant difference between the two groups with respect to TGs.
4.4.1.3.3 Blood Pressure and Blood glucose
Median systolic blood pressure for the 101 patients was 124mmHg (range 96- 
170) which was below the JBS2 audit standard. Of the 101 patients, 95 had 
BP recorded while 6 case notes (6.3%) did not. Of the 95 patients with a BP 
record, 6 (6.3%) had a systolic blood pressure greater than 150mmHg. 
Notably, 7 patients (7%) had pre-existing hypertension and 5 of these were 
already on treatment, however, only 2 of these 7 patients had a recorded 
systolic BP <150mmHg. There was no difference in the systolic blood pressure 
between TH vs. NTH, ABC or DDI vs. nonABC/nonDDI regimens and PI vs. 
NNRTI users.
Of the 101 patients, 99 (98%) had blood glucose results in the case notes 
while 2 (2%) had no record over the whole year of interest. The median blood 
glucose for the 99 patients was 4.9mmol/l (3.9-10.2). Thirteen patients (13.1%) 
had a blood glucose level >6.1mmol/L; of these, 7 (7%) were already diabetic. 
There were no differences in the blood glucose levels between TH vs. NTH, 
ABC or DDI vs. nonABC/nonDDI regimens and PI vs. NNRTI users (Tables 4-4 
to 4-6).
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Table 4-4: Lipids, Blood pressure (BP), glucose levels and CV risk- thymidine and 
non-thymidine NRTI backbone (Audit 1)
Thymidine NRTI 
use; n=45
Non-thymidine 
NRTI use; n=56
2-tailed P value 
(Mann-Whitney U 
test)
Age (median, range) 41 (29-71) 41 (21-69) 0.80
Previous PI exposure (n, %)* 18(40%) 37 (66.1%) 0.009
Triple-Class drug exposure (n, %)* 10(22%) 22 (39%) 0.07
Duration current drugs (months)- 
(median, range)
10 (4-159) 13 (1-89) 0.04
Duration all ART (months)- (median, 
range)
60 (6-192) 70.5 (11-214) 0.28
TC(mmol/l) - (median, range) 4.9 (2.0-7.0) 4.7 (3.1-7.9) 0.61
LDL(mmol/l) - (median, range) 2.5(1.4-5.2) 2.6 (1.3-5.1) 0.56
TG(mmol/l) - (median, range) 2.0 (0.7-6.3) 1.6 (0.6-5.2) 0.12
HDL-C(mmol/l) - (median, range) 1.2 (0.5-4.2) 1.2 (0.4-2.8) 0.51
TC:HDL-C - (median, range) 4.5 (2.0-8.0) 4.0(2.0-13.5) 0.47
BP systolic (mmHg) - (median, range) 129 (105-160) 123 (96-170) 0.12
Blood Glucose (mmol/l) - (median, 
range)
4.9 (3.9-8.7) 4.9 (4.0-10.2) 0.62
CV risk (%) - (median, range) 6.8 (0.2-20.3) 6.0 (0.2-28.3) 0.58
*Pearson’s Chi Square test used for these variables
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Table 4-6: Lipid and blood pressure levels with PI or NNRTI use (Audit 1)
Current PI use; 
n=38
Current NNRTI 
use; n=62
2-tailed P value (Mann- 
Whitney U test)
TC - (median, range) 4.5 (3.0-7.9) 4.8 (3.1-7.8) 0.03
LDL(mmol/l) - (median, 
range)
2.2(1.3-5.2) 2.6 (1.5-5.1) 0.007
TG(mmol/l) - (median, 
range)
1.8 (0.6-5.7) 1.6 (0.6-6.3) 0.41
TC:HDL-C ratio - 
(median, range)
4.0(2.0-13.5) 4.3 (2.0-7.0) 0.71
BP systolic (mmHg) - 
(median, range)
123 (96-149) 125 (96-170) 0.29
Blood Glucose (mmol/l) -
(median, range)
4.8 (4.0-6.6) 4.9(3.9-10.2) 0.07
CV risk (%) -
(median, range)
6.5 (0.2-24.4) 6.5 (0.2-29.3 0.99
4.4.1.3.4 Cardiovascular risk calculation
The CV risk was not calculated in 8 (7.9%) patients due to pre-existing CVD (7 
with diabetes, 1 with I HD). Six (5.9%) did not have enough data to calculate 
the CV risk %. Eighty seven (86%) patients had enough data to calculate the 
CV risk. The median CV risk was 6.5% (0.2-29.3%). Overall, most patients (80, 
79.2%) were at low to moderate risk of CVD with a calculated CV risk of <20%. 
These patients however did have some isolated CVD risk factors, as shown in 
Table 4-7, and frequently, they had 2 or more of these risk factors namely: 
raised lipids, smoking, family history of CVD, hypertension, high recorded BP 
or blood glucose. Seven (8%) patients had a high calculated CV risk of >20%.
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Table 4-7: Cardiovascular Risk < 20% and associated Risk factors, n=80 
(Audit 1)
Risk Factor Number of patients (%)
Smoking 43 (54)
High Lipids 41 (51)
Having > 2 risks (raised lipids, smoking, FH of CVD, 
hypertension, high recorded BP or blood glucose)
22 (27)
Fifteen out of the 101 patients (14.8%) were identified to be at high risk of CVD 
in the following categories:
• Calculated CV risk >20% over 10 years 7 (7.4%)
• Diabetes 7 (7.4%)
• Established ischaemic heart disease 1(0.9%)
Other associated risks identified in the 15 high-risk patients are shown in table 
4-8 below which shows high prevalence of risk factors particularly smoking 
(67%) and high lipids (80%). All 7 patients with a high calculated CV risk had 2 
or more risk factors for CVD (namely raised lipids, smoking, family history of 
CVD, hypertension, high recorded BP or blood glucose).
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Table 4-8: Associated Risks in High Risk Patients (Audit 1)
Risk Factor Number (%)
Smoking 10(67%)
Raised Lipids 12 (80%)
Hypertension 3 (20%)
FH of CVD 5 (33%)
FH of CVD: family history of cardiovascular disease
4.4.1.4 Management of cardiovascular risks:
Table 4-9 shows the management aspects that were documented in the case 
notes of patients identified to be at low to moderate risk of CVD (<20%). 
Interventions in the form of life style advice such as smoking cessation or 
dietary advice were offered to about a third of patients with high lipids (31.8%) 
or those who smoked (36.6%). A small proportion (4, 9.1%) were started on 
lipid lowering therapy namely statins (such as pravastatin or atorvastatin) or a 
fibrate (most commonly fenofibrate).There were only small numbers of patients 
with hypertension (2.5%) and raised glucose levels (8.8%) in this group, 2 
patients who had hyperglycaemia received smoking cessation advice, and no 
action was taken to address hypertension.
Table 4-10 shows the management aspects that were documented in the case
notes of patients identified to be at high risk of CVD (>20%). Most patients
were likely to have received some advice regarding life style such as dietary or
smoking cessation, though this was not done in all patients. Importantly, some
patients did receive multiple interventions. Most of the patients with diabetes
and those with dyslipidaemia were on lipid lowering therapy. Antiplatelet drugs
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as such aspirin were not uniformly used in this high-risk group, with 3 of the 15 
being on aspirin.
Table 4-9: Management of risk factors in patients with cardiovascular risk <20% 
(n=80) (Audit 1)
Total
Action taken 
(In patients 
with risk)
Type of action taken
Life style advice Drug treatment or Referral
Smokers 41 (51%) 15(36.6%) Smoking cessation (15) 0
tGlucose 7 (8.8%) 2 (28.6%) Smoking cessation (2) 0
T Lipids 44 (55%) 14(31.8%) Dietary advice (9) 
Smoking cessation (7) 
Alcohol moderation (1)
Statins (3)
Statin and fibrate (1)
Tsystolic
BP(>150
mmHg)
2 (2.5%) 0
T (Increased or raised); BP: blood pressure
4.4.2 Audit 2
4.4.2.1 Demographics
Three out of the 5 units self-reported that they followed the JBS guidelines, the 
other 2 following clinical judgement. The median age of patients was 39.5 
years (range 24-70). Males comprised 69%; 58% were Caucasian and 33% 
were Black African. Ethnicity was not recorded in 6%.
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Table 4-10: Management of risk factors in patients with calculated cardiovascular 
risk >20% or pre-existing cardiovascular disease (n=15) (Audit 1)
Total (%) Action taken (in patients with risk)
Type of action taken
Life style advice Drug treatment or Referral
Smokers 10(67) 5 (50%) Smoking cessation 
(5)
0
t Glucose
(including
Diabetics)
8(53) 7 (88%) Dietary advice (3) Statins (4) 
Statins+fibrate(2)
Fish oil (1)
Antidiabetics (4)
Aspirin (1)
Anti-hypertensives (2)
T Lipids 
(No Diabetes)
7(47) 5 (71%) Dietary advice (4) Statins (2)
Statin+fibrate (1)
Aspirin (2)
T BP 2(13) 1 (50%) Antihypertensives (1)
T:(lncreased or raised; BP: blood pressure
4.4.2.2 Antiretroviral drug usage
Most patients were treatment experienced. Median duration on treatment was 
4.5 years (range 1-16). Table 4-11 shows the type of NRTI backbone and the 
concomitant PI or NNRTI patients were on. Most patients were on NTH NRTIs 
TDF or ABC in combination with each other or with FTC or 3TC (59%), with 
fewer being on TH NRTIs (17 were on AZT and 3 on D4T as part of a 2 or 
more nucleoside backbone). Thirty (38%) patients were on an ABC based 
regimen, while 6 (8%) patients were on a combination that included DDL Nine 
(12%) patients were on a triple or more nucleoside backbone. Most patients 
(57.7%) were on an NNRTI, particularly EFV, compared to protease inhibitors 
(37.2%). Boosted LPV was the most commonly used PI in this population. As 
was the case in audit 1, patients in this audit who were on a NTH based 
regimen had been on their current regimen for shorter duration, they had been 
on ART for a longer duration and had been more frequently exposed to Pis as
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well as being triple-class experienced than those on a TH based regimen 
(Table 4-12), however, most of these differences were not statistically 
significant.
Table 4-11: Antiretroviral Drugs Used (Audit 2)
Drug No. of Patients %of total (78)
NRTIs Zidovudine/lamivudine 14 17.9
Tenofovir/emtricitabine or 
lamivudine
22 28.2
Abacavir/lamivudine 16 20.5
T enofovir/Abacavir 8 10.3
Other combinations 7 9
Triple nucleoside combinations 9 11.5
Protease
Inhibitors0
Lopinavir* 14 17.9
Atazanavir* 5 6.4
Fosamprenavir* 6 7.7
Saquinavir* 2 2.6
Double-boosted Pis 2 2.6
NNRTIs Efavirenz 32 41
Nevirapine 13 16.7
*ritonavir boosted, aone patient was on unboosted atazanavir.
4.4.2.3 Cardiovascular disease Risk FactorsPre-existing Risk 
Factors for CVD
Forty six (59%) patients were smokers. Fifteen (19%) of the patients had a 
history of pre-existing CVD (hypertension, ischaemic heart disease, 
cerebrovascular accident, diabetes or dyslipidaemia). Nineteen percent had a 
family history of premature CVD. Eight percent were hyperglycaemic and 8% 
had impaired glucose tolerance. CVD risk factors were not documented in a
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proportion of case notes as follows: smoking status (19%), family history of 
CVD (40%) and previous CVD (17%).
4.4.2.3.2 Blood Pressure, lipids and Blood sugar
Tables 4-12 to 4-14 present the lipid and blood pressure levels with drug 
regimens. The median systolic BP for the whole sample was 126mmHg (91- 
210). Most patients had normal blood pressure. Nine patients (11.5%) had a 
systolic BP of > 150mmHg. Of these, 5 were on a TH based regimen (25% of 
this group) and 4 were on a NTH (7.1%). Twenty one patients out of 30 on 
ABC had recorded BPs and of these 3 (14%) had a systolic BP>150mmHg. 
One of 6 (17%) patients on DDI and 5 of 57 (9%) patients on non-ABC/non- 
DDI regimen had a systolic BP>150mmHg. Four (20%) patients on Pis and 5 
(15%) on NNRTI had systolic BP>150mmHg. The systolic blood pressure level 
was not significantly different between the TH vs. NTH groups, PI vs. NNRTI 
groups, ABC vs. Non-ABC/non-DDI groups and DDI vs. Non-ABC/non-DDI 
groups.
Median TC was 5.2mmol/l (2.3-87), which is above the JBS2 audit standard 
(<5.0mmol/l). The median TC:HDL-C ratio was 4.3 (1.5-7.1). Seventy one 
patients had a recorded TC level and 43(61%) had TC >5.0mmol/l. Of the 20 
patients who were on a TH based regimen, 19 had cholesterol levels recorded, 
of these 14 (74%) had high total cholesterol levels (> 5.0mmol/l). Fifty six 
patients were on a NTH regimen and of these, 51 had TC levels recorded with 
22 patients (48%) having high total cholesterol levels of > 5.0mmoi/l. The TC 
was > 5.0mmo]/l in 14 (67%) of patients on ABC, 1 (17%) on DDI, 26 (46%) on 
non-ABC/non-DDl, 13(52%) on Pis and 29(67%) on NNRTIs. However, there
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was no statistically significant difference in the TC levels between the TH vs. 
NTH groups, PI vs. NNRTI groups, ABC vs. Non-ABC/non-DDI groups and 
DDI vs. Non-ABC/non-DDI groups.
Most patients (>75%) were recorded as euglycaemic on all the drug regimens. 
However, patients on an ABC or DDI regimen were more likely to be 
euglycaemic than those on a non-ABC/non-DDI regimen (P=0.005 and 0.03 
respectively).
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Table 4-12: Lipid, blood pressure (BP), glucose levels and CV risk - thymidine 
and non-thymidine NRTI backbone (Audit 2) ______________ ____________
NRTI backbone Thymidine NRTI use;n=20
Non-thymidine 
NRTI use; n=56
2-tailed P value 
(Mann-Whitney U test)
Age (median, range) 40.5 (24-54) 39.0 (24-70) 0.41
Previous PI exposure* 3(15%) 19 (33.9%) 0.11
Triple-class drug exposure* 2 (10%) 13 (23%) 0.20
Duration current drugs 
(months) - median (range)
36 (4-72) 11.5 (1-68) 0.04
Duration all ART (years) - 
median (range)
4 (1-12) 4.7(1-16) 0.97
TC (mmol/l) 5.3 (2.8-7.8) 5.1 (2.3-8.7) 0.67
TC:HDL-C ratio-median 
(range)
4.1 (2.0-7.0) 4.4 (2.4-7.0) 0.84
BP systolic (mmHg)-median 
(range)
131 (91-210) 122 (97-170) 0.24
CV Risk (%)-median, range 8.3 (0.4-22.8) 5.5(0.1-37.7) 0.26
Blood Glucose - n(%)*:
Euglycaemic 16 (80) 46 (82) 0.83
Raised glucose 4(20) 10(18) 0.83
*Pearson’s Chi Square test used for these variables
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Table 4-14: Lipid and blood pressure levels with Protease inhibitor or Non- 
nucleoside reverse transcriptase inhibitor use (Audit 2)___________ _ ___
Current PI use; 
n=29
Current NNRTI use; 
n=44
2-tailed P value (Mann- 
Whitney U test)
Age - median, range 39 (24-59) 40.5 (24-70) 0.72
TC(mmol/l) - median, range 5.1 (2.3-8.7) 5.2 (2.8-7.7) 0.67
TC:HDL-C ratio - median, 
range
4.9 (1.0-7.1) 4.1 (2.0-7.0) 0.41
BP systolic(mmHg) - 
median, range
125 (106-170) 126 (91-210) 0.66
CV Risk (%)- median, range 5.4 (0.1-37.7) 6.5 (0.4-22.8) 0.10
Blood glucose - n(%)*:
Euglycaemia 26 (90) 34 (77) 0.18
Raised glucose 3(10) 10 (23) 0.18
*Pearson’s Chi Square test used for these variables
4.4.2.3.3 Cardiovascular risk calculation
A CV risk percent was not calculated in 16(21%) patients due to incomplete 
data and 11 patients (14%) due to age being less than 30 (the cut-off for the 
CV calculator v2.0) and considered at low risk. Fifteen patients (19%) were 
already classified as having pre-existing CVD. Therefore 36 of 78 (46%) 
patients had CV risk calculated. The median CV risk for the whole sample was 
6.5% (0.1-37.7). Thirty three patients (42%) had a low to medium calculated 
CV risk of <20% and 3 patients (4%) had a high CV risk of >20%. All patients 
with a high calculated CV risk had 1 or more other factors such as high 
recorded lipids or blood glucose, smoking or family history of premature CVD. 
Fifteen patients (45%) with a low to medium CV risk had one or more isolated 
risk factor (smoking, family history of premature CVD or high recorded TC). Of
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the 3 patients with a high calculated CV risk, 1 was on ABC and 2 were on an 
NTH regimen.
For patients on a TH (n=14), 7(50%), 6(43%) and 1(7%) had a CV risk of 
<10%, 10-20% and >20% respectively. This was 24(70%), 6(18%) and 4(12%) 
for patients on an NTH regimen; 8(53%), 5(33%) and 2(13%) for patients on 
ABC regimen; 18(60%), 7(20%) and 3(6.7%) for patients on a Non-ABC, non- 
DDI regimen.
4.4.2.3.4 Management of cardiovascular Risks
Units not following the JBS2 guidance (total number of patients 26) instituted 
corrective measures in nearly all patients with identified risk factors (5/5 
smokers, 4/4 hypertensive, 5/6 dyslipidaemic and 4/4 overweight patients). 
Measures included counselling, referral to other specialties, medication, advice 
or change of HAART.
Tables 2-15 and 2-16 show the management of patients in units that followed 
JBS2 guidelines (total number of patients 52). In general, for patients at low 
risk of CVD (<20% over 10 years, n=19), some intervention was instituted for 
patients with identified risk. For patients with multiple risk factors, several 
interventions were instituted in the same patient, or for a single risk such as 
high lipids, the patient received dietary advice, drugs or was referred. The 
interventions were however not across the board for patients with identified risk 
factors.
In high risk patients (n=14: calculated CV risk n=3 and pre-existing CVD n=11), 
interventions were also instituted but not uniformly across all the patients and
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crucially, only one patient in this category was started on aspirin. As was the 
case in low/moderate risk, patients with multiple or single risk factors received 
several interventions for each risk factor including being commenced on 
drugs/drug switches or being referred.
Table 4-15: Management of cardiovascular risk factors in patients with 
cardiovascular risk <20% (n=19) (Audit 2)
Total
Action taken 
(In patients 
with risk)
Type of action
Life style advice Drug treatment or Referral
Smokers 6 (43%) 4 (67%) Smoking cessation (4)
tGlucose 5 (23%) 4 (80%) Dietary advice (2)
Weight reduction (1)
Exercise (2)
Alcohol moderation (3)
Referred to GP (2)
HAART changed and 
statins started (2)
T Lipids 12 (63%) 8 (67%) Dietary advice (5)
Exercise (3)
Alcohol moderation (4)
Smoking cessation (2)
HAART changed and 
statins started (2)
Referred to a GP (3)
T BP 3 (16%) 1 (33%) Diet(1)
Weight reduction/exercise (1)
Referred to GP (1)
BP: blood pressure; *statins included pravastatin and simvastatin
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Table 4-16: Management of risk factors in patients with calculated cardiovascular 
risk >20% or Pre-existing cardiovascular disease (n=14*) (Audit 2)
Total Action taken Type of action
risk) Life style advice Drug treatment or
Referral
Smokers 8 (57%) 3 (38%) Smoking cessation (3) Stop smoking clinic 
referral (1)
TGIucose 6 (43%) 3 (50%) Dietary advice (3)
Weight reduction (3)
Alcohol reduction (2)
Referred to GP (3)/lipid 
specialist (1)
Statins started (3)
Aspirin and ACEI started 
(1)
t Lipids 9 (64%) 5 (56%) Dietary advice (2)
Smoking cessation
Exercise (2)
Weight reduction (2)
Alcohol reduction (2)
Statin started (4)
HAART changed (1) 
Referred to GP 
(2)/dietician(1)
tBP 3(21%) 3(100)% Diet/weight
reduction/exercise/alcohol 
moderation (1)
Statin started(1)
Referred to GP (1)
calculated CV risk n-3, pre-existing CVD, n=11, T(Increased or raised); BP: blood pressure
4.5 Discussion
ART and HIV infection place patients at particular risk of CVD. Large cohort 
studies have demonstrated increased rates of CVD in HIV patients (Friis-Moller 
et al. 2003(b)). Apart from the traditional CVD risk factors of sex, age, obesity 
and family history of premature heart disease which apply in this population 
just like in the general population, HIV patients have been shown to have 
higher rates of some modifiable risk factors. Smoking rates are higher in HIV 
patients than in the general population. The study by Ross et al showed a 
smoking rate of 38% in HIV patients compared to 10% in their non-infected 
counterparts (Ross et al. 2009). Smoking rates as high as 51-59% have been 
documented in the HIV infected population (Friis-Moller et al. 2003(b); Pere et
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al. 2008). Hyperlipidaemia as an adverse effect of ART has been extensively 
reported. Development of hyperlipidaemia in patients on ART is worse in 
patients on thymidine NRTls (particularly D4T) and is less pronounced in 
patients on non-thymidine NRTls. Pis, particularly the older generation ones 
such as lopinavir (LPV), RTV, SQV, NFV and IDV as well as the newer PI 
fosamprenavir (FPV) have been shown to cause increase in TC and TGs, 
while the new Pis ATV and DRV showed smaller increases in these 
parameters. Additionally, EFV has an adverse lipid profile comparable to that 
caused by Pis such as RTV boosted LPV and FPV (Behrens et al. 1999; 
Heath et al. 2001; Jones et al. 2005a; Pirmohamed 2009). Development of 
insulin resistance leading to glucose intolerance or frank diabetes has also 
been seen in HIV patients on ART. Older generation Pis and thymidine NRTls 
have been implicated, with the newer PI ATV and newer NRTls TDF and ABC 
having little or no effect (Shlay et al. 2007; Tien et al. 2008).
We assessed via audits if the HIV physicians within clinics in the Greater 
Manchester area evaluated patients for risk factors of CVD and whether 
corrective measures were instituted for identified risk factors, the JBS2 
guidelines being used as the standard of care. Whether clinics followed the 
JBS2 guidelines or used clinical judgement, on the whole most patients did 
have some clinical assessment (e.g. smoking history, BP check and medical 
history) or had biochemical evaluation of lipids and glucose which were 
documented in the case notes. However, the documentation was incomplete in 
some notes with no record found regarding some risk factors (For Auditl:
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previous CVD 99.1%; family history of CVD 45.5%; smoking status16.8%; and 
for Audit 2: previous CVD: 17%; family history of CVD 40%; smoking status 
19%). As such, a higher proportion of patients may be at unidentified higher 
risk of CVD and would not be appropriately treated.
Our cohort of patients had high smoking rates (up to 60%) comparable to 
those found by Pere et al and Friis-Moller et al. This was also higher than the 
smoking rates of 2004 in England (25%) and in the Northwest of England 
(28%), which was the second highest smoking rate by region in England as 
reported by the NHS National Statistics (NHS 2006).
High lipids were also fairly common (seen in 44.5% of patients in audit 1 and 
61% in audit 2) but it is important to note that patients did not always fast 
overnight before having their blood taken for lipid levels though a large study 
found a less than 5% difference in lipid fraction concentrations between the 
fasted and nonfasted state (Mora et al. 2008). The TC was higher in patients 
from audit 2 compared to those in audit 1 (5.2 vs. 4.8mmol/l respectively). 
However, the TC level which was used in audit 2 was the highest that was 
recorded in the case notes during the year of interest. This could have resulted 
in more patients being classified as having high TC though they may have had 
normal levels during most of the year. The median TC, TGs and LDL-C in audit 
1 were more representative as they were derived from several readings over 
the one year period. Compared to other studies, we found no difference in the 
levels of the various lipid fractions between patients on a TH and NTH; an ABC
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and non-ABC/non-DDI or a DDI and non-ABC/non-DDi based regimens. We 
however demonstrated in audit 1 (but not in audit 2) significantly higher TC and 
LDL-C in patients on an NNRTI compared to patients on a PI (/^O.OS and 
0.007 respectively). This might have been due to the fact that the NNRTI EFV 
was commonly used (30.3% of all the patients) and this has been shown to 
have an adverse lipid profile (Behrens et al. 1999; Heath et al. 2001; Jones et 
al. 2005a; Pirmohamed 2009). Additionally, there was increasing use of the 
lipid friendly PI ATV. Our results could have been influenced by the duration of 
the current regimens, previous treatment experience and type of PI drugs 
used. It is important to note also that patients on an NTH regimen in audit 1 
were likely to have been on their current drugs for a longer duration (P=0.04), 
more triple class experienced (but this did not reach statistical significance at 
P=0.07), to have been exposed to Pis (P=0.009) and to have been on all ART 
for a longer duration than patients on a TH based regimen (but this was not 
statistically significant), reflecting the fact that patients on an NTH regimen may 
have undergone drug switches from less lipid or CVD friendly drugs, whose 
effects could have not reversed yet, thus explaining the lack of the expected 
favourable lipid profile in this group.
The majority of our patients were at low calculated risk of CVD over 10 years. 
However a large proportion of these had either single or multiple risk factors for 
CVD namely smoking, hypertension, and family history of CVD or 
dyslipidaemia (43.5% in Audit 1 and 36% in Audit 2). We did find quite a good 
proportion of patients who had either a high calculated risk of developing CVD
155
within 10 years or had pre-existing CVD (15% in Audit 1 and 23% in Audit 2) 
though it should be noted that patients with a history of hypertension and 
dyslipidaemia were included within the group classified as having pre-existing 
CVD in Audit 2 (due to the design of the data collection form). As such the 
rate of patients at high risk of CVD may have been overestimated in this audit. 
Any planned re-auditing should classify hypertension and dyslipidaemia as risk 
factors to allow appropriate calculation of CV risk (as was the case in Audit 1), 
which would in turn prevent the risk of overestimation of numbers of patient in 
the high risk category. TH drugs particularly D4T have been reported to cause 
hyperlipidaemia as reported, but large cohort studies have shown no excess 
risk to developing Mis with the use of AZT and D4T (Sabin et al. 2008). We 
found similar CV risk percent categories between patients on a TH compared 
to an NTH regimen.
There is conflicting information regarding ABC and its effect on myocardial 
infarction (Ml). Some studies show increase in risk of Ml (Sabin et al. 2008; 
Durand M 2009) while others show no increased risk (Bedimo R 2009). ABC 
has been thought to have a favourable effect on lipid profiles (Moyle et al. 
2006), though a recent study by Hill et al has shown ABC use (like AZT and 
D4T use) to cause elevations in TC, TGs and LDL-C compared to TDF (Hill et 
al. 2009). These reports were not available when the audits were done but a 
re-analysis of the data reveals no difference in the lipid fractions between 
patients on ABC and non-ABC regimens. Other parameters such as BP or 
blood glucose were similarly not different. However, in Audit 1, patients on
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ABC were twice as likely to have a moderate CV risk (10-20%) than those on a 
non-ABC/non-DDI regimen (31% vs. 15.8% respectively). This was also 
replicated in Audit 2, with 33% patients on ABC having a moderate risk while 
this was 20% in those on a non-ABC/non-DDI regimen. Additionally, twice as 
many patients in audit 2 on ABC (13%) had a high CV risk of >20% compared 
to those on a non-ABC/non-DDI regimen (6.7%). This would give the 
impression that patients on ABC in this cohort are at higher CV risk than those 
who are not on this drug which would be in agreement with studies described 
previously. However, it should be noted that patients on ABC in these audits 
had high smoking rates, were more likely to be heavily treatment experienced, 
have previous PI exposure and be on ART for longer duration than those not 
on the drug, which may have influenced the results. Additionally, the numbers 
are too small to make firm conclusions. GKS Trial ABC prescription biais
The number of patients on DDI regimens was too small for any meaningful 
conclusions regarding CVD risk to be made.
With respect to management of risk factors, the clinics instituted some 
corrective measures in most patients with specific risk factors. However, all 
patients at high risk of CVD require intensive risk factor management to correct 
identified risks through life style changes, drug treatment or referral for 
specialist care. The clinics did not institute these measures in all the patients 
identified to be at high risk, for instance, not all patients received life style 
advice and the use of antiplatelet therapy (such as aspirin) was very
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inadequate with 3 of 15 patients in audit 1 and none of the 11 patients in audit 
2 being on these drugs. Referrals for specialist treatment were at best patchy, 
which means patients would not be managed appropriately. A national British 
HIV Association (BHIVA) audit on CVD management in HIV patients involving 
137 clinical centres in the UK which was carried out in 2006 had similar results 
with clinics mostly able to carry out routine lab tests for lipids and glucose and 
identifying CV risks appropriately but access to lipid specialists, smoking 
cessation services and exercise classes was poor (BHIVA 2006).
Obviously there are a number of limitations with these audits. The design of 
data collection forms were different in the two audits as such combining the 
data to get unified conclusions was difficult. Documentation by clinicians was 
not always complete as such missing data could have led to over or 
underestimation of the impact of a risk factor. The highest record in the case 
notes of some parameters such as BP or TC were recorded which may have 
led to overestimation of the CV risk percentage, taking an average of readings 
over the one year of interest could have given more accurate results. But on 
the whole, these audits were designed to provide an idea as to whether 
clinicians acted on abnormal results. The data collection forms were also 
meant to be easy to fill, which was a requirement by the participating 
consultants due to time constraints. As such the quality of the information 
collected may not have been the best to give an idea of the true level of CV 
risk in this population.
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The results of these audits were presented in the joint meetings of the involved 
HIV clinics. In order to improve care with regard to CVD and other conditions in 
HIV patients that rely on diligent documentation, I was tasked to design 
proformas: the first one to be completed at start of ART and the second one 
annually thereafter and at each drug regimen change (appendix 5 and 6). 
These proformas have recently been adopted for use by the NMGH HIV unit A 
re-audit of CVD risk management has been undertaken at the MRI to assess 
any change in managent practices following these audits.
4.6 Conclusion
Long-term survival of HIV patients on ARV drugs presents problems of 
diseases associated with an aging population such as cardiovascular disease. 
ART drugs and HIV infection are associated with risk factors of CVD. 
Identification and treatment of these risk factors is the modern day challenge of 
managing HIV patients. Units treating HIV patients could improve management 
of patients by:
1. Adopting a formal system to identify and manage CVD risk factors. Formal 
guidelines which are used in the general population and can equally apply to 
HIV patients include the JBS ones which we used as our standards in these 
audits: the World Health Organisation guidelines for Prevention of 
Cardiovascular Disease which take into account geographical diversity in the 
level of CVD risk (WHO 2007); and the National Cholesterol Education
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Program (NCEP) guidelines for management of high cholesterol and CVD 
(Adult Treatment Panel III) (NCEP 2002). It is uncertain whether these 
guidelines that apply to an HIV negative population can be directly applied to 
HIV patients on ART, particularly as this population may be at higher risk for 
CVD than the general population because of the adverse effects of ART drugs 
on lipid, glucose and insulin sensitivity profiles as well as the chronic 
inflammatory state due to the virus itself. The European AIDS Clinical Society 
(EACS) guidelines on the prevention and management of metabolic diseases 
in HIV infected patients have been developed to address the issue of 
management of CVD risks in this particular group of people. These guidelines 
use the same targets in terms of lipids, glucose and blood pressure as the 
guidelines for the general population but go further to tackle other metabolic 
complications such as lactic acidosis, renal and bone disease (Lundgren et a/. 
2008b). The D:A:D group has also developed risk equations specific to HIV 
infected people taking into account the ART drugs the patient takes such as 
indinavir, lopinar and abacavir in addition to the parameters used in the 
Framingham equations namely age, sex, systolic blood pressure, smoking 
status, family history of CVD, diabetes, total cholesterol and HDL cholesterol. 
This model has been shown to estimate more accurately the CVD outcomes in 
HIV patients than the Framingham score (Friis-Moller et at. 2010). A calculator 
based on the D:A:D risk equations has been developed and will be more 
appropriate to use in HIV patients for the estimation of 10 year CVD risk (CHIP 
2010).
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2. Developing proformas to aid recording of CVD risk factors and action taken. 
These could be used at the start of ART and revisited at regular intervals such 
as annually or at change of treatment regimen and filed in patient case notes.
3. Establishing clear referral routes (Dietician, lipid or cardiology clinics, 
General Practitioner, lipodystrophy clinic) for further specialist management.
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CHAPTER FIVE
MANAGEMENT OF DYSLIPIDAEMIA IN HIV 
PATIENTS: A SYSTEMATIC REVIEW OF DRUG- 
DRUG INTERACTIONS WITH CONCOMITANT 
USE OF PROTEASE INHIBITORS AND STATINS
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5.1 BACKGROUND
Dyslipidaemia is a common adverse effect of treatment of HIV infection with 
highly active antiretroviral therapy (HAART) and the virus itself (Behrens et al 
1999; Carr et al. 1999). The dyslipidaemia associated with HAART is 
characterised by hypertriglyceridaemia, hypercholesterolaemia and decreased 
high-density lipoprotein cholesterol (HDL-C) (Martinez et al. 2004). Protease 
inhibitors (Pis) have most strongly been shown to cause dyslipidaemia 
(Behrens et al. 1999; Periard et al. 1999; Manfredi and Chiodo 2001). 
However, nucleoside reverse transcriptase inhibitors (NRTIs) have also been 
implicated in the pathogenesis of dyslipidaemia, particularly stavudine (D4T) 
(Jones et al. 2005a). Additionally, the non-nucleoside reverse transcriptase 
inhibitor (NNRTI) efavirenz has also been shown to have an adverse lipid 
profile (Behrens et al. 1999; Heath et al. 2001; Jones et al. 2005a; 
Pirmohamed 2009).
In the general population, dyslipidaemia is a risk factor for cardiovascular 
disease (CVD) (Stamier et al. 1986; Assmann et al. 1998; Austin et al. 1998; 
Wilson et al. 1998). Many guidelines are in use for the management of the 
disorder, which include lifestyle changes (such as sensible diet, regular 
exercise) and lipid lowering drugs (NCEP 2002; JBS2 2005). It is now 
understood that HAART associated dyslipidaemia in HIV patients needs to be 
managed along the same lines as in the general population. Indeed, guidelines 
have been developed for the management of this problem in HIV patients 
(Lundgren et al. 2008b). Management includes lifestyle changes as above,
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drug switches to Pl-sparing regimens or to lipid-friendly antiretroviral (ARV) 
drugs and drug treatment with lipid lowering drugs.
Drug treatment of hypercholesterolaemia includes 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors (statins) and/or ezetimibe. Fibric 
acid derivatives (fibrates) with or without Omega 3 acid ester drugs or nicotinic 
acid derivatives are used to treat hypertriglyceridaemia. Statins and fibrates 
can be combined in the case of mixed dyslipidaemias. The recommended 
statins for use in the setting of HAART dyslipidaemia are pravastatin and 
fluvastatin with caution being emphasised with the use of atorvastatin and 
rosuvastatin (Schambelan et ai 2002; Gazzard 2008; Lundgren et al. 2008b).
Drug treatment of HAART associated dyslipidaemia can be complicated by 
serious interactions between statins and Pis due to the nature of the 
metabolism of these drugs. The interactions can be at the level of absorption, 
distribution, metabolism or excretion. These interactions mostly occur at the 
level of the intestine and liver (Dresser et al. 2000). Statins and Pis are either 
substrates, inhibitors, inducers or a combination of these of the Cytochrome 
P450 (CYP450) mixed function oxidases which are a family of enzymes 
responsible for the majority of oxidative biotransformation of xenobiotics and 
endogenous compounds. The most important CYPP450 isoform is CYP3A4, 
which is responsible for the metabolism of about 50-60% of all drugs in current 
use. Other isoforms that have been demonstrated to be important for drug 
metabolism include CYP2D6, 2C9, 2C19, 1A2, 2E1, 2B6 and 2A6 (Dresser et
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a/. 2000; Fichtenbaum and Gerber 2002; Khoo et al. 2005). Other than the 
CYP450 system, several cell membrane transporters are involved in the 
disposition of endogenous organic compounds (such as bile salts, steroid 
conjugates, thyroid hormones) and numerous drugs including statins and Pis. 
The organic anion transporting polypeptides (OATPs) are expressed in many 
tissues and are involved in the sodium-dependent transport of a diverse range 
of compounds. OATP1B1 (or OATP-C, OATP2) is expressed in the liver at the 
basolateral (sinusoidal) membrane of hepatocytes and is involved in the 
hepatic clearance of statins. Bioavailability of statins is also affected by efflux 
transporters located in the apical membrane of intestinal enterocytes, proximal 
tubules of kidneys and canalicular membrane of hepatocytes. These include 
multidrug resistance-protein 1 (MDR1 or P-giycoprotein), multidrug resistance- 
associated protein (MRP2), breast cancer resistance protein (BCRP) and bile 
salt export pump (BSEP). These efflux transporters decrease drug absorption 
into the portal circulation and increase drug elimination into bile and urine. 
Alterations in the function of all these transporters can decrease statin 
elimination. Variations in genes encoding these transporters (such as 
SLC01B1 gene encoding OATP1B1) can also result in alterations in function 
of the transporters (Dresser et al. 2000; Shitara and Sugiyama 2006; Ho et al. 
2007; Kivisto and Niemi 2007; Consortium 2008; Neuvonen et al. 2008). Pis 
have been shown to be substrates and inhibitors of these transporters as such 
interactions with statins could occur at this level (Williams and Feely 2002; Pal 
and Mitra 2006; Neuvonen et al. 2008).
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With regard to statins, simvastatin and lovastatin are lipophilic lactone 
prodrugs that undergo extensive first-pass metabolism by CYP3A4/5 and to a 
lesser extend CYP2C8 in the intestinal wall and liver to their active acid forms 
and several other active and inactive metabolites. Being lipophilic, they are 
also extensively protein bound (>95%). Their bioavailability is therefore low 
(<5%) (Fichtenbaum and Gerber 2002; Williams and Feely 2002; Neuvonen et 
di, 2008). Atorvastatin is also metabolised by CYP3A4 though less extensively 
than simvastatin and has a bioavailability of 12%. It is also extensively protein 
bound (>98%). Fluvastatin is metabolised by CYP2C9 and to a lesser extent 
by CYP3A4 and CYP2D6. It has a better bioavailability (30%) and is even 
more extensively protein bound (>99%) (Fichtenbaum and Gerber 2002; 
Williams and Feely 2002; Neuvonen et ai 2008). Pravastatin and rosuvastatin 
are excreted largely unchanged into urine and bile. About 10% of rosuvastatin 
is metabolized, mainly by CYP2C9 while pravastatin is partially degraded in 
the stomach and partially metabolized by non-CYP enzymes (mostly 
glucuronidation). Being hydrophilic, pravastatin is less protein bound (50%) 
and has a bioavailability of 18% (Yee and Fong 1998; Fichtenbaum and 
Gerber 2002; Williams and Feely 2002; Martin et ai 2003; Consortium 2008; 
Frishman and Horn 2008; Neuvonen et al. 2008).
HIV Pis (APV, DRV, FPV, IDV, NFV, RTV, LPV, SQV and tipranavir (TPV)) are 
both substrates and potent inhibitors of CYP3A4, with RTV being the most 
potent inhibitor followed by IDV, NFV, APV and SQV in decreasing order of 
potency (Inaba et ai 1997; Fichtenbaum and Gerber 2002; Granfors et ai
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2006; Vourvahis and Kashuba 2007; Back et al. 2008; Frishman and Horn 
2008). RTV and NFV also induce the CYP2C9, 2C19, 1A2 and 2E1 isoforms 
as well as some of the enzymes involved in conjugation (Fichtenbaum and 
Gerber 2002). Additionally, Pis may interact with efflux drug transporters in the 
intestine and liver. RTV and SQV have been shown to be substrates and 
inhibitors of P-glycoprotein and MRP2. Interactions with other substrates of 
these drug transporters, e.g. statins, would therefore be possible (Gutmann et 
al. 1999; Kis et al. 2009).
With increasing polypharmacy in HIV patients and the metabolic effects of 
HAART, drug interactions are inevitable. Concomitant use of statins for 
HAART-associated dyslipidaemia and boosted or unboosted PI regimens can 
result in increased oral bioavailability of the parent statin drug and/or its active 
metabolites leading to toxicity or can lead to reduced statin levels resulting in 
attenuation of the lipid lowering effect. Toxicity resulting from increased 
exposure to statins includes gastrointestinal symptoms such as nausea and 
vomiting, elevated liver function enzymes (LFTs) and benign myalgias which 
occur in 0.5-2.5% of patients (Williams and Feely 2002), although these are 
mostly mild (Baldini et al. 2000; Moyle et al. 2001; Doser et al. 2002; Palacios 
et al. 2002; Aberg et al. 2005). However, significant interactions leading to 
clinically significant conditions have been reported. These include myopathy 
(characterised by a 10-fold elevation in creatine kinase with muscle pain or 
weakness) in up to 0.3% of patients which can rarely progress to 
rhabdomyoiysis, a life-threatening condition which is characterised by massive
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muscle necrosis, hyperkalaemia and severe myoglobinuria, which may 
precipitate oliguric renal failure and can result in death (Williams and Feely 
2002). Most cases of these have involved the concomitant use of simvastatin 
and Pis (Aboulafia and Johnston 2000; Hare et al. 2002; Schmidt et al. 2007; 
Mikhail et al. 2009). Indeed this led to the withdrawal of cerivastatin from 
clinical use (Charatan 2001). Of the currently available statins, simvastatin and 
lovastatin pose the most concern in Pl-treated patients because of their 
extensive metabolism by the CYP3A4 isoform, and are therefore 
contraindicated in Pl-treated patients. Lower doses and caution are 
emphasized with use of atorvastatin. Pravastatin and fluvastatin do not utilise 
CYP3A4 for their metabolism and are therefore the statins of choice for the 
treatment of dyslipidaemia in Pl-treated patients. Starting at low doses is 
recommended for atorvastatin and rosuvastatin (Baldini et al. 2000; 
Fichtenbaum and Gerber 2002; Schambelan et al. 2002; Martinez et al. 2004; 
Gazzard 2008; Lundgren et al. 2008b)
5.2 OBJECTIVES
The aim of this systematic review was to look at the evidence in the literature 
of the pharmacokinetic interactions between statins and protease inhibitors. 
The clinical significance of such interactions was analysed. A previous 
systematic review undertaken in 2007 reviewed the available evidence 
concerning the treatment of dyslipidaemias in the setting of HIV infection and 
HAART, with regard particularly to the effects of interventions on lipid levels as 
well as on efficacy and safety (McGoldrick and Leen 2007). The current review
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summarises the interactions between the two groups of drugs and relates 
these to the nature, severity and frequency of adverse effects.
it was anticipated that there would be a scarcity of data on this topic. As such, 
randomised controlled studies, retrospective/prospective cohort and/or case- 
control studies were all included in the review.
The outcome measures included:
Drug levels of Pis and statins (when concomitantly used) in HIV positive 
and negative patients.
The nature, frequency and severity of the adverse effects encountered.
5.3 METHODS
The review included all studies that recruited HIV positive patients that were: a) 
established on a Pl-based regimen and started on statins, or b) established on 
the statins and then commenced on a Pl-based regimen. Studies in HIV 
negative people administered a statin and a PI to study the pharmacokinetics; 
safety and tolerability of concomitant use of these drugs were also included. 
Table 5-1 shows the inclusion and exclusion criteria used to identify relevant 
records.
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Table 5-1: Inclusion and Exclusion Criteria
Inclusion criteria:
a. Studies in the English language
b. Studies looking at pharmacokinetic interactions between statins and Pis
c. Results show or list pharmacokinetic effects and clinical side effects 
encountered
d. Studies that report adverse effects associated with combining statins and Pis
e. Studies published after 1996
Exclusion Criteria:
a. Studies that do not address the pharmacokinetic and/or adverse effects of 
concomitant use of statins and protease inhibitors.
b. Studies not relevant to purpose of systematic review
c. Studies published in a language other than English
5.3.1 Search Strategy
Several databases were searched and the search terms used were as follows:
• PubMed: (HIV OR AIDS) AND (HAART OR Antiretroviral* OR Protease 
inhibit*) AND (Statin* OR HMG-CoA Reductase Inhibit*);
• SCOPUS: ALL(“HIV” OR “AIDS”) AND (HAART OR Protease inhibitors) 
AND (Dyslipidemia OR Hyperlipidemia) AND (Statins OR HMG-CoA 
Reductase inhibitor) AND (Interaction OR Pharmacokinetics) AND 
(Adverse effects);
• ISI Web of Knowledge: (Statin*) AND (Protease inhibit*) AND (interact*) 
refined by (HIV);
• The Cochrane Central Register of Controlled Trials abstract databases: 
(HIV OR AIDS) AND (Dyslipid* OR Hypercholesterol* OR Hyperlipid* 
OR Hypertriglycerid*) AND (Protease inhibit* OR PI*) AND (Statin* OR
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HMG-CoA Reductase Inhibit*) AND (Interact* OR pharmacokinetic* OR 
PK) and
• The grey literature (S1GLE) database (www.opensiqle.inist.fr) for 
unpublished data: ((Dyslipid* OR Hyperlipid*) AND (Statin* OR HMG- 
CoA Reductase Inhibit*) AND (protease inhibit*) AND (interact* OR 
"adverse effect" OR pharmacokinetic*)).
Additionally, reference lists of all primary studies identified were also 
scrutinised for further papers of potential interest. The titles of studies and their 
corresponding abstracts were combined as well as the lists of references and 
any duplicates removed. The titles and abstracts were then reviewed and 
irrelevant reports removed. The full text of the remaining studies were then 
retrieved and reviewed to see if they fulfilled the inclusion criteria. Only those 
studies that reported pharmacokinetics, drug levels or listed adverse effects 
and their frequencies when statins and Pis were concomitantly used were 
included. For all the databases, the search was limited to studies published 
after 1996, when protease inhibitors came into clinical use.
5.3.2 Data Extraction
Data were extracted in accordance with the methods set out in the Cochrane 
Handbook for Systematic Reviews of Interventions. A data collection form was 
prepared and used to record data which included study design, objectives, 
study period, study duration, sample size, HIV status of subjects, mean or
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median age of subjects, the drugs being investigated, pharmacokinetic (PK) 
changes (maximum concentration, Cmax; minimum concentration, Cmin; and 
area under the concentration curve, AUC) or drug concentration changes 
(increase or decrease in plasma drug level), adverse effects and their 
frequencies. Outcome data was collected in the format that it was reported or 
transformed as necessary at a later stage.
5.3.3 Statistics
Descriptive analysis was used to summarise the nature of interactions between 
statins and protease inhibitors. The proportion of patients with adverse effects 
and the nature as well as the severity grading of those side effects was 
summarised.
5.4 RESULTS
Figure 5.1 summarises the systematic review process. Thirteen studies were 
included in the analysis. Ten of these studies reported PK percentage or fold 
changes of the drugs which included area under the concentration curve 
(AUC), maximum concentration (Cmax), minimum concentration (Cmin) or 
change in drug concentration. These studies also reported the adverse effects 
encountered as well as their frequency. Three studies reported only on the 
safety of concomitant use of statins and Pis, listing the nature and frequency of 
these adverse effects. The PK studies involved sequential administration of the 
study drugs. In some studies, the statin was initiated in patients already
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established on a Pl-based ART. PK studies were mostly conducted in HIV 
negative participants, the studies were of shorter duration and participants 
were younger. In contrast, safety and efficacy studies were mostly conducted 
in HIV positive participants who were older and the study durations were 
longer.
Tables 5-2 to 5-4 show the summaries of the studies included in this review. 
Table 5-2 shows the study details including the main author, study design and 
objectives, the year the study was conducted or the study period, the sample 
size, the subjects’ HIV status and their median or mean age. Table 5-3 shows 
the drug concentration changes encountered with combinations of the PI and 
statin drugs, specifically summarising the drug PK changes (AUC, Cmax, and 
Cmin) or plasma drug level change (the drug whose PK was under study is 
indicated in bold). Table 5-4 summarises the nature of the adverse effects 
encountered including their frequencies, total events in each study as well as 
any discontinuations and their nature.
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Figure 5-1: Systematic literature review process
Literature search:
Databases: PubMed (n=144), Scopus (n=169), ISI Web of Knowledge (n=60), Cochrane 
Central Register of Controlled Trials abstract databases (n=3), the grey literature (SIGLE) 
database(n=97)
Reference lists of primary studies and reviews: n=34 
Limits: English language, published between 1996-2010 
Total (n=507)
_______i___________
Records after duplicates removed 
(n=481)
_________ ±_________
Records screened and 
selected on the basis of title 
and abstracts
*
Pharmacokinetic/therapeutic drug monitoring with safety studies 
(n=10)
Safety and efficacy studies (n=3)
Full articles assessed for 
eligibility (n=38)
Full-text articles excluded:
Did not meet inclusion criteria (n=8) 
Reviews (n=12)
Case reports (n=4)
Full article not found (n=2)
Total records excluded (n=443)
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Three studies evaluated the PK of pravastatin, the AUC and Cmax were 
reduced significantly by 40-50% by RTV boosted SQV (Fichtenbaum et al. 
2002) or NFV (Aberg et al. 2006). The third study evaluated the Cmin of 
pravastatin, and this remained unchanged when used with ATV, APV or 
lopinavir (LPV) (Fichtenbaum et al. 2002; Aberg et al. 2006; Aslangul et al. 
2010). Five studies evaluated the PK of rosuvastatin 3 of these studies 
showed that there was more than 200% and nearly 600% increase in the AUC 
and Cmax, respectively, when co-administered with RTV-boosted LPV or ATV 
while RTV-boosted FPV did not affect these parameters (Floody 2007; Busti et 
al. 2008; Kiser et al. 2008). Similar findings have been demonstrated in a 
recent study co-administering rosuvastatin with darunavir (DRV) which resulted 
in increases in the Cmax and AUC of rosuvastatin of 140% and 48% 
respectively (Samineni et al. 2011). Two studies looked at Cmin of 
rosuvastatin. One of these studies demonstrated an increase of rosuvastatin 
Cmin of 1.6 times with co-administration with RTV-boosted LPV (van der Lee 
et al. 2007) while the other showed no significant change in this parameter 
with ATV, APV or LPV (Fichtenbaum et al. 2002; Aberg et al. 2006; Aslangul et 
al. 2010). Two studies that evaluated simvastatin PK levels demonstrated 
profound elevations in AUC and Cmax (500-3059% and greater than 500% 
increase, respectively) with co-administration with RTV/SQV or NFV. 
Atorvastatin levels were evaluated in the same 2 studies which showed a 
greater than 70% increase in AUC and 122% increase in Cmax with co­
administration of RTV/SQV or NFV (Hsyu et al. 2001; Fichtenbaum et al. 
2002). This is in agreement with data presented at a conference by Carr et al
182
who demonstrated moderate increases in the Cmax and AUC of atorvastatin
(4.7 and 5.9 fold, P<0.02) when coadministered with RTV boosted LPV 
(previously known as ABT138) (Carr 2000) and the study by Hoetelmans et al 
which showed increases in atorvastatin AUC, when atorvastatin 10mg was 
administered with RTV boosted DRV, to levels similar to atorvastatin 40mg 
dose (Hoetelmans 2004). No studies were found evaluating PK effects of co­
administration of lovastatin and Pis.
Seven of the 13 studies evaluated various PI drug levels (AUC, Cmax, Cmin, 
plasma drug levels) with co-administration with all the statins currently in 
clinical use and all found no significant change in the PI levels (Hsyu et al. 
2001; Fichtenbaum et al. 2002; Benesic et al. 2004; Hoody 2007; van der Lee 
etal. 2007; Kiser et al. 2008; Aslangul etal. 2010).
Of the adverse effects encountered in the 13 studies included in this review, 
gastrointestinal (GIT) adverse effects (AEs) were the commonest, being 
reported in 9 of the 12 studies and included mostly nausea, vomiting, 
diarrhoea and abdominal pain. Myalgia was reported in 2 studies and this was 
less frequent than the GIT symptoms, being graded as mild to moderate. No 
episodes of rhabdomyolysis were reported. Various other clinical adverse 
effects were reported but were less common and included rashes, headache 
and were mostly mild or moderate in severity. Kiser et al reported a case each 
of liver toxicity with nausea, vomiting, anorexia and jaundice in the LPV/RTV 
alone and rosuvastatin with LPV/RTV arms which were mild and did not
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necessitate withdrawal from the trial (Kiser et al. 2008). Two thirds of patients 
in the study by Busti et al developed mild jaundice, which is expected with ATV 
use (Busti et al. 2008). Laboratory adverse events were also commonly 
encountered, the commonest being raised creatinine phosphokinase (CPK), 
which was reported as mostly mild. However, 6 participants from 3 studies had 
CPK values that were high and described as life threatening in some cases but 
discontinuations did not mostly occur because of this. One participant had 
CPK levels of 17 times the upper limit of normal (ULN, 195u/l) (Kiser et al. 
2008); one had levels 4 times the ULN (ULN 120u/i) and 3 reported to have 
had levels of 363-676u/l (van der Lee et al. 2007); and one had 16.9 times 
ULN (ULN, 195u/l) (Hoody 2007). One study reported grade 2 or higher rise in 
CPK though the level was not defined (Fichtenbaum et al. 2002). However, 1 
patient in the study by Aberg et al discontinued from participation due to grade 
2 rise in CPK (levels not defined) and was not included in the PK analysis 
(Aberg et al. 2006). The next commonly encountered laboratory adverse effect 
was elevated liver enzymes which were mostly mild to moderate in severity 
and did not result in discontinuations. Rises in CPK and LFTs occurred with all 
statins and were not confined to simvastatin use only. Neutropaenia was 
reported in 2 participants in 2 studies and in both cases resulted in 
discontinuation from study participation (Hoody 2007; Kiser etal. 2008).
5.5 DISCUSSION
Concomitant use of Pis and statins in HIV positive patients with dyslipidaemia 
is common and will increase as an aging HIV population develops
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cardiovascular problems requiring pharmacotherapy. Interactions between the 
Pis and statins are to be expected. As previously stated, guidelines 
recommend that certain statins (such as pravastatin, rosuvastatin and 
fluvastatin) can be used relatively safely in PI induced dyslipidaemia. Caution 
is to be exercised with the use of others statins (atorvastatin) while others are 
to be avoided altogether (simvastatin and lovastatin). These recommendations 
are mostly based on the knowledge of the drugs’ metabolism by the CYP450 
enzyme system, with the aim of minimising the chances of adverse 
interactions.
The results of some of studies in this review clearly demonstrate that 
differences in interactions between the individual statins and Pis are a result of 
the differences in the metabolism pathways used by the drugs as well as the 
extent to which a drug is metabolised by a particular enzyme, such that the 
levels of a statin that is extensively metabolised by the main CYP isoforms 
(3A4) rise to dangerous proportions when combined with Pis, which are potent 
inhibitors of CYP3A4. This phenomenon is clearly demonstrated in the study 
by Hsyu et al (Hsyu et af. 2001), where nelfinavir use with atorvastatin resulted 
in an increase in the AUC and Cmax of atorvastatin by 74% and 122%, 
respectively. This is consistent with the fact that atorvastatin is metabolised by 
CYP3A4 to a lesser extent. However, in the same study, nelfinavir resulted in a 
massive increase in the AUC and Cmax of simvastatin (505% and 517% 
respectively) while Fitchtenbaum et al demonstrated a rise in AUC of 3059% 
and a 30 fold rise in Cmax of simvastatin. Both studies thus clearly
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demonstrate that simvastatin metabolism will be affected greatly when used 
with potent inhibitors of CYP3A4.
Rosuvastatin and pravastatin, being largely excreted unchanged, are ideal 
statins to use concomitantly with Pis, with little or no clinically relevant 
interactions expected. However, PK studies have shown unexpected changes 
in these statins. The unexpected increased levels (Cmax and AUC) of 
rosuvastatin might be attributable to a change in bioavailability mediated by 
changes in drug transporters at the level of the intestine and liver. 
Rosuvastatin is a substrate for OATP1B1 and BCRP and these transporters 
play a role in the distribution and elimination of this drug (Hsiang et al. 1999; 
McTaggart 2003; Simonson et al. 2004; Zhang et al. 2006; Kiser et al. 2008). 
LPV and/or RTV may possibly be inhibiting rosuvastatin uptake by BCRP and 
OATP1B1 in the intestine and the liver (Kiser et al. 2008); indeed ritonavir has 
been shown to inhibit BCRP and OATP1B1 (Gupta et al. 2004; Hirano et al. 
2006; Neuvonen et al. 2008). ATV and APV (the active moiety of FPV) have 
been shown in an in vitro study to be inhibitors of BCRP and ATV was the 
more potent inhibitor than APV (Weiss et al. 2007; Busti et al. 2008). CYP450 
interactions are unlikely to play a major role in these unexpected findings 
because previous studies have shown no relevant drug-drug interactions with 
rosuvastatin involving CYP2C9, CYP2C19 or CYP3A4 (Cooper et al. 2002; 
Cooper et al. 2003a; Cooper et al. 2003b; van der Lee et al. 2007). The 
conflicting rosuvastatin Cmin results (increased in one study and unchanged in 
another) could be due to differences in methodology although where the Cmin
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remained unchanged could reflect what is expected about this statin, i.e, there 
should be no significant interactions with Pis.
The three studies summarised in this review that evaluated the PK of 
pravastatin showed unexpected reduction in the AUC and Cmax in the 
presence of RTV boosted SQV or NFV while the Cmin remained unchanged in 
the presence of ATV, APV and LPV (Fichtenbaum et al. 2002; Aberg et al. 
2006; Aslangul et al. 2010). This is in contrast with data from 2 studies 
presented at conferences which showed a 30% increase in Cmax and AUC of 
pravastatin with co-administration with RTV boosted LPV though this was not 
statistically significant (Carr 2000) and increases in AUC of 81% and Cmax of 
63% when pravastatin was coadministered with RTV boosted DRV in healthy 
volunteers (Sekar 2007). These variable findings could be due to several 
factors. Non-CYP3A4 oxidation and glucuronidation are involved in the 
metabolism of pravastatin, and RTV is believed to be an inducer of 
glucuronidation, which could explain the reduced level of pravastatin (Kim et 
al. 1998; Wang et al. 2001; Williams and Feely 2002; Aberg et al. 2006; Pal 
and Mitra 2006). Additionally pravastatin is a substrate of the drug transporters 
OATP1B1 and P-glycoprotein which are involved in its bioavailability and 
elimination. Pis are also substrates and inhibitors of these drug transporters, 
as such, complex interactions at this level could explain the reduction or 
increase in plasma levels of pravastatin with concomitant use with some Pis 
(Kim et al. 1998; Wang et al. 2001; Williams and Feely 2002; Aberg et al. 
2006; Pal and Mitra 2006). The reduction in levels of pravastatin may have
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clinical implications in that it may result in reduction in lipid lowering efficacy. 
Indeed studies have shown an attenuation of lipid lowering effects of statins 
with smaller proportions of HIV patients on HAART reaching targeted 
reductions in the various lipid fractions compared to HIV negative individuals 
(Silverberg et al, 2009).
With regard to atorvastatin, the findings of moderately raised levels in the 
presence of Pis is consistent with the known PK profile of this statin, that is, it 
is metabolised less extensively by CYP3A4 as such its levels would not be 
increased to the same extent as, for example, simvastatin.
All the studies that evaluated the PK of Pis when co-administered with statins 
found no significant changes in AUC, Cmax and Cmin of the Pis (Hsyu et al. 
2001; Fichtenbaum et al. 2002; Moyle et al. 2002; Benesic et al. 2004; Hoody 
2007; van der Lee et al. 2007; Kiser et al. 2008; Aslangul et al. 2010). The 
lack of effect of statins on PI drug levels is consistent with what is known about 
statin metabolism, in that they are substrates rather than inhibitors or inducers 
of CYP450 enzymes (Fichtenbaum and Gerber 2002).
Clinical and laboratory adverse effects were commonly reported in the studies 
included in this review. The most commonly reported were Gl effects such as 
nausea, vomiting, diarrhoea and abdominal pain. These were mostly mild to 
moderate in severity and did not result in discontinuation from the studies. It is 
important to note that Gl AEs could be attributable to the expected adverse 
effects of the individual Pis and statins, rather than as a result of the combined
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use as detailed in the package inserts of some of the drugs in this review 
(Bristol-Myers-Squibb 2007; Pfizer 2009; Abbott 2010; Bristoi-Myers-Squibb 
2010; GlaxoSmithKline 2010; Merck 2010; Merck(a) 2010). Muscle problems 
reported were mostly miid or moderate and did not progress to 
rhabdomyolysis. CPK increases were also mostly not clinically significant, and 
these were not exclusively reported with simvastatin use but rather with the 
rest of the statins. These findings are in agreement with the results of most of 
the efficacy and safety studies in which few AEs were reported with 
concomitant use of Pis and statins (Baldini et al. 2000; Moyle et al. 2001; 
Doser et al. 2002; Palacios et al. 2002; Aberg et al. 2005). However, a case of 
life threatening rise in CPK and 2 cases of liver toxicity reported in this review 
highlight the dangers posed by these drugs which although uncommon, could 
lead to serious consequences as has been reported by Aboulafia et al, 
Schmidt et al, Hare et al and Mikhail et al (Aboulafia and Johnston 2000; Hare 
etal. 2002; Schmidt et al. 2007; Mikhail et al. 2009).
The risk or likelihood of an adverse outcome in an individual on Pis and statins 
depends on other factors apart from the known metabolising pathways. These 
include individual variation in the intestinal and hepatic expression of CYP 
isoenzymes and efflux transporters, concomitant use of other drugs with 
inhibitory or inducing effects which would have additive or synergistic effects 
leading to marked changes in PK parameters of the affected substrate drug, 
use of alcohol (a substrate and inducer of some CYP isoenzymes) as well as 
genetic polymorphisms and racial differences in the genes coding for the efflux
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transporters such as SLC01B1 gene (encoding OATP1B1) (Sweeney and 
Bromilow 2006; Ho et al. 2007; Kivisto and Niemi 2007; Schmidt et ai 2007; 
Neuvonen et al. 2008)
There are several limitations identified with regard to studies analysed in this 
review. Firstly, sample sizes were mostly small and the duration of the studies 
was short. Secondly, in most studies, there was lack of a randomized control 
group and lack of information on concomitant medication. Thirdly, diet, 
geographical and racial differences could influence drug handling by the 
intestines and liver; however, these were not reported in the studies. The 
different populations in the studies, each with their own population coefficient 
of variation with regards to the results would also affect the generalizability of 
the results. Most studies did not report on smoking status or intake of alcohol, 
both of which have effects on the CYP450 enzyme system (Sweeney and 
Bromilow 2006). Fourthly, the methodology, drug doses and dosing schedule 
as well as analytical methods were different in the studies. And lastly, data 
were extracted from the publications of the studies which are included in this 
review but the authors were not contacted for their primary data. These would 
affect the generalizability of the results and largely precluded the undertaking 
of a meta-analysis as there was the need to review data on concommittant use 
of a number of statins and Pis in current clinical use in HIV patients.
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5.6 CONCLUSIONS
Polypharmacy in HIV patients is common due to the complex nature of the 
disease. Physicians caring for HIV patients would need to be vigilant when 
prescribing drugs in this population on complex polypharmacy because of the 
potential for harmful interactions. To avoid pharmacokinetic alterations, they 
would need to have information about the metabolizing enzymes and 
transporters involved in the pharmacokinetics of all manner of drugs used in 
this population. This information may not be readily available within the clinic 
setting of many physicians; particularly as most would have time constraints. 
Access within the clinics to national formularies detailing possible interactions 
between various drugs would help physicians to avoid potentially dangerous 
combinations of drugs. Additionally, an internet based program such as the 
one provided by the University of Liverpool (http://www.hiv- 
druainteractions.org/ ) allows clinicians to quickly check for possible harmful 
interactions before prescribing drugs. However, many clinicians working in 
resource poor settings may not have internet access or comprehensive 
national formularies may not exist and additionally, access to alternative safe 
drugs to treat many of the complications of HIV and its treatments may be 
limited by financial constraints. As such, most HIV patients on polypharmacy 
will be at risk of potentially harmful drug-drug interactions. The harms that can 
result are demonstrated by the many case reports that have been published 
showing how interactions, for example, between statins, particularly 
simvastatin, and Pis have caused severe rhabdomyolysis resulting in acute 
renal failure which in some cases caused patient deaths. Complex and
unpredictable interactions can occur between different statins and Pis.
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Increased levels can lead to increased risk of adverse effects while decreased
levels can lead to attenuation of the lipid lowering effects of the statins.
On the whole, the choice of statins for use in HIV patients taking Pl-based 
regimens as recommended by current guidelines are consistent with the 
known interactions demonstrated by this systematic review. However, while 
the studies did not find any unexpected or unsual results due to some 
unknown interactions; some contradictory findings which cannot be explained 
easily could be due to many reasons such as the ones detailed i.e. multiple 
pathways for metabolism, drug doses, diet, race amongst others. Research 
needs to continue particularly in drug development to identify new drugs using 
different pathways of metabolism from those used by Pis or other antiretroviral 
drugs, but also to explore the effects of race, geographical differences or diet 
to see if these have significant impact on drug interactions. This could then be 
used to formulate guidelines tailored to different population groups in-order to 
maximise the benefits of concommittant use of these drugs while minimising 
the risk of dangerous interactions.
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CHAPTER SIX
CONCLUSIONS
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HAART has dramatically changed the management and outlook of HIV 
infection, with the disease moving from a nearly always fatal outcome to a 
chronic manageable disease. However, this success comes at a price, with the 
development of unwanted adverse effects mostly due to the drugs. These can 
be early or late after commencing the drugs. The late adverse effects have 
gained much interest in recent years, particularly the metabolic and 
morphological effects as they have now been shown to increase the risk of 
development of CVD (Friis-Moller et ai 2003(b); Friis-Moller et al. 2007; Pere 
et al. 2008, Sabin et al. 2008; Worm et al. 2010). Many studies have 
demonstrated the occurrence of dyslipidaemia, insulin resistance, glucose 
intolerance or frank diabetes, increased inflammatory state and fat 
redistribution with use of ART drugs, with some drugs or class of drugs having 
a higher association with these adverse effects than others (Behrens et al. 
1999; Carr et al. 1999; Heath et al. 2001; Jones et al. 2005a; Moyle et al. 
2006, Friis-Moller et al. 2007; Pere et al. 2008). Some life style risk factors 
such as smoking are more frequent in the HIV infected populations than in the 
general population (Friis-Moller et al. 2003(a); Pere et al. 2008). The findings 
of the studies and audits in this thesis confirm some of these effects, especially 
with particular ART drugs used within HAART. Some of our findings were 
however unexpected.
We have shown that thymidine NRTIs AZT and D4T are associated with fat 
loss which is reported less upon switching to non-thymidine drugs. Our 
patients did not report fat gain after switching per se but a DEXA scan or a CT 
scan may have characterised this better as was demonstrated by others
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(Gallant et al. 2004; Moyle et ai 2006; Shlay at al. 2008; Shlay et al. 2009). 
Patients who were on a non-thymidine regimen from baseline to the end of the 
study variably reported fat loss and fat gain, with no discernible pattern, which 
probably means fat loss was not a prominent problem. Notably, more patients 
in this group had previous exposure to D4T and older Pis such as IDV, SQV 
and NFV; as such the expectation was that this group would mostly be 
reporting fat gain. This was not reported with any consistency even at the 
individual patient level, which could be due to many reasons including the fact 
that the patients may not have detected any changes, failed to report any 
changes or no changes were occurring.
The lipids in our cohort were unchanged over the 12 month follow-up period 
and were not different between those that continued on a thymidine regimen, 
those that remained on a non-thymidine regimen and those that switched from 
a thymidine to a non-thymidine regimen. An adverse lipid profile on a 
thymidine regimen which improves on switching drugs was not observed, 
which is in contrast to the findings in other switch studies (Gallant et al. 2004; 
Moyle et al. 2006; Pozniak et al. 2006). Of interest is the finding of a high 
TC:HDL-C ratio in patients remaining on a non-thymidine regimen, which was 
even higher than that in patients on a thymidine regimen. This worsened over 
the duration of the studies. Though the total cholesterol was within normal 
range in this group, this could reflect a gradual reduction in levels of the HDL-C 
denominator, and the worsening TC:HDL-C ratio could explain the fact that a 
significant proportion of patients in this group who initially had a low calculated 
CV risk (<10%) at baseline later on in the study moved to the moderate risk 
bracket (10-20%). Obviously other factors were at play in the non-thymidine
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regimen group (which should have had a better lipid profile) such as previous 
exposure to drugs with a worse effect on lipids. It should be noted that 10 of 
the 27 patients in this group were on ABC. Whether this could explain the 
worsening CV risk percentage, with what has already been reported about 
ABC being associated with increased CVD risk is difficult to say because the 
numbers in our studies are smalt, though it should be pointed out that more 
recent data now suggests that ABC does not increase CVD risk (Bedimo R 
2009; Durand M 2009).
There was no perturbation in glucose homeostasis in our studies. The glucose 
levels, p-cell function and insulin levels remained unchanged at 12 months 
compared to baseline and were comparable to levels in the general population. 
There was also no difference between the thymidine, non-thymidine or switch 
groups. Others have demonstrated insulin resistance and glucose intolerance 
development with use of NRTIs and Pis (Hadigan et ai 1999; Hadigan et al. 
2000; Brown et al. 2005; Tien et al. 2008). The small sample sizes in our 
studies could explain these differences.
We have demonstrated high levels of the proinflammatory cytokine TNF-a in 
our cohort similar to that found by others (Ross et al. 2009), further showing 
that serum levels of this cytokine are higher in patients with HIV infection than 
in HIV negative people. We did not demonstrate significant differences in TNF- 
a levels between the drugs used. We can only summise that having HIV 
infection per se causes a rise in the levels of this cytokine regardless of drugs 
used or that the differences with other studies was due to differences in
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methodology. Our findings regarding IL-6 were unexpected, with levels at the 
end of the study in those on a thymidine regimen being lower than those in 
patients who switched to a non-thymidine regimen and the levels being 
comparable to those found in HIV uninfected people in the study by Ross et al 
(Hsue et al. 2009a; Ross et al. 2009). This is in contrast to the findings of 
studies which demonstrated higher levels of this cytokine induced by thymidine 
analogues (Lagathu et al. 2004; Jones et al. 2005b; Lagathu et al. 2007). We 
cannot draw firm conclusions from these results regarding IL-6, as our results 
may have been skewed by unexpected and unexplained high levels of this 
cytokine in a couple of patients. Our finding of declining levels of adiponectin in 
patients on a thymidine is in agreement with what is known about the effects of 
this group of drugs on this cytokine (Lindegaard et al. 2004; Jones et al. 
2005c). However, the lack of improvement in the levels of this cytokine upon 
switching from a thymidine to a non-thymidine regimen in this study could be 
due to the fact that these patients switched mostly because of LD; as such, 
they may not have gained enough adipose tissue mass to cause an increase 
in this cytokine. Reduced adipose tissue mass has been shown to contribute to 
reduced levels of adiponectin by Sweeney et al (2007). On the whole, most of 
the unexpected findings in the levels of the cytokines in this study could be due 
to the fact that patients who had been on non-thymidine drugs such as TDF 
may also have had previous exposure to older Pis, thymidines and DDI, whose 
negative effects may not have reversed completely.
Our patients maintained normal renal function. Renal toxicity was not observed 
at all even though usage of TDF was common. However, we did not check for 
urine protein and additionally serum phosphate testing became routine when
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the studies were elready significantly underway. Urine protein and low serum 
phosphate are the earliest features of TDF renal toxicity before overt 
derangement of renal function tests. However, our findings are in agreement 
with the findings of others (Moyle et al. 2006; Pozniak et al. 2006).
Our audits conducted in large HIV treatment centres in the Northwest of 
England showed that physicians treating HIV patients face the complexity of 
treating the infection, but must now also be vigilant to the occurrence of 
potentially serious long term effects. We were able to show that various risk 
factors of OVD are common in patients with HIV and on ART. These include 
higher rates of smoking than in the local population which is in agreement with 
the findings of others (Friis-Moller et al. 2003(a); Pere et al. 2008). High rates 
of raised or high lipids were also found though the levels did not differ 
significantly between the drugs used except with the use of NNRTIs in which 
the lipids were higher than those in patients on a PI. Additionally, patients had 
CVD risk factors either occurring singly or in combination namely smoking, 
hypertension and family history of pre-existing CVD or dyslipidaemia. The 
majority of our patients had a low risk of developing CVD over 10 years (<10% 
risk). However, a good proportion (15% and 23% in Audit 1 and 2 respectively) 
were at high risk of CVD (CV risk>20%) and therefore warranted intensive 
therapy. Of particular interest is our finding in both audits that patients on ABC 
were nearly twice more likely to have a moderate or high risk of CVD than 
patients not on this drug. Though our numbers are small, they are in 
agreement with the larger studies previously described which reported 
increased CVD risk with ABC use (Lundgren 2008; Sabin et al. 2008), but as 
previously stated, recent evidence has thrown into doubt this association
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(Bedimo R 2009; Durand M 2009). The physicians in our audit on the whole 
clinically assessed and instituted biochemical tests to identify various side- 
effects or existing medical conditions associated with development of CVD and 
instituted the management of the conditions identified. In some instances, 
these actions were not complete, i.e. not all patients had complete 
documentation, received lifestyle advice, drug treatment or were referred on for 
further management by appropriate specialties. These omissions were most 
likely due to lack of awareness of existing guidelines for management of these 
conditions, or lack of availability of proformas to standardize documentation so 
that physicians could be alerted if abnormalities were picked up which needed 
attention. Similar findings by the nationwide British HIV Association audit as 
detailed previously shows that physicians treating HIV need to be particularly 
aware of the need to actively look for and manage appropriately risk factors of 
CVD in this population (BHIVA2006).
Adding to the complexity of treating HIV infection are drug-drug interactions. 
The concommittant use of statins and Pis can result in such interactions. 
However, the data summarised in the systematic review in this thesis shows 
that most interactions are predictable with the current knowledge of 
metabolising pathways of these two groups of drugs. Unexpected 
derangements in the PK levels of the statins could actually be explained by 
other known pathways of drug disposition such as drug transporter changes, 
and other factors such as race or diet could also be playing a role. Indeed the 
systematic review findings support the current guidelines’ choice of safe statins 
to use in HIV patients on Pis.
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There are several limitations in this thesis that would affect the generalisation 
of our results. The sample sizes in our longitudinal studies were small and we 
studied a number of drugs which makes the drawing of firm conclusions from 
our lipid, glucose, insulin and cytokine results from such small numbers 
difficult. The two audits in the thesis had different designs, making it difficult to 
combine and analyse the data as one entity, thereby weakening the impact of 
the results. The studies included in the systematic review were mostly small, 
the methodology, drug doses and populations were different and did not 
include randomised control groups which probably contributed to the variable 
results. But on the whole, some of our results were in agreement with findings 
of published work looking at CVD, its markers and risk factors as well as the 
management of some of the risk factors.
There’s a lot of data now on pathophysiology of HIV LD and CVD. Research 
needs to focus on new ARV drug design, aiming at drugs that will not cause 
these problems. However, due to issues of tolerability and resistance 
mutations, some patients will remain on drugs that will cause the physical and 
metabolic effects of LD and ultimately CVD. As such research also needs to 
focus on development of drugs that will ameriorate the physical effects of LD or 
the treatable risk factors of CVD, but at the same time ensuring that the cost 
and pill burden of such drugs are kept to the minimum and that ease of 
administration is taken into account. Development and regular updating of 
web-based programs will be important to allow physicians to assess the 
likelihood of drug-drug interactions during clinics.
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In conclusion, this work shows that lipodystrophy and CVD risk factors are 
common in HIV patients on ART. Underlying cytokine derangements are not 
easy to reproduce in different studies but a chronic inflammatory state and 
adipose tissue dysfunction in these patients are evident and need further 
studies to help find therapies to stop progression to CVD. Dyslipidaemia is one 
of the most well known adverse effects of ART and its treatment may be 
complicated by serious toxicities as a result of drug-drug interactions with Pis. 
Finally, physicians treating HIV patients need to be aware of current guidelines 
for treating metabolic complications of ART and also need to be aware of 
referral routes for further management of these complications because the 
management of HIV patients who develop these problems needs a 
multidisplinary approach.
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Appendix 1
LIPODYSTROPHY QUESTIONNAIRE
For each body part described please indicate whether you currently have body shape changes that have occurred 
since you were diagnosed with HIV and if YES, note the nature of the change as of today and the current severity of 
any change.
Severity is to be described as:
Mild (noticeable only when specifically looked for) 
Moderate (readily obvious to the patient)
Severe (obvious to the other people)
Fat gain refers to a general increase in fat in a 
specific region. Lipomata are localised fatty lumps 
under the skin.
1. Is there any fat loss in your 
face?
No □ Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □ 
Duration
2. Is there any fat gain in your 
face?
No □ Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
3. Is there any fat loss in the 
front or sides of your neck? 
No □ Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
4. Is there any fat gain in the 
front or sides of your neck? 
No □ Yes a
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
5. Is there any fat loss in the 
back or base of your neck? 
No □ Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate a Severe □
6. Is there any fat gain in the 
back or base of your neck? 
No □ Yes a
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
7. Is there any fat loss on your 
arms?
No □ Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
8. Is there any fat gain on your 
arms?
No □ Yes □ 
if yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
9. Has the size of your breasts 
increased?
No □ Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
10. Has the size of your breasts 
decreased?
No □ Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
11. Has the size of your waist 
decreased?
No □ Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
12. Has the size of your waist 
increased?
No □ Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
13. Has the amount of fat on your 
buttock decreased?
No o Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
14. Has the amount of fat on your 
buttock increased?
No □ Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
15. Has the amount of fat on your 
legs decreased?
No □ Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
16. Has the amount of fat on your 
legs increased?
No □ Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
17. Since you were diagnosed 
with HIV have the veins 
on your arms and/or legs 
become more prominent?
No □ Yes □
If yes ticked indicate how 
severe you think it is 
Mild n Moderate □ Severe □
18. Since you were diagnosed 
with HIV have the veins 
on your arms and/or legs 
become less prominent?
No n Yes □
If yes ticked indicate how 
severe you think it is 
Mild □ Moderate □ Severe □
19. Since you were diagnosed 
with HIV have you developed 
any fat lumps (lipomata)?
No □ Yes □
Tick the Regions below 
where the fat lumps have 
developed:
Site:
Head □
Front/sides of Neck □
Back/base of neck □
Breasts □
Trunk □
Arms □
Legs □
Other □
20. Total Duration of symptom: L 
Date completed: | |
Completed by Patient (initials): [
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Appendix 2
ADHERENCE QUESTIONNAIRE
Study Title: Effects of switching a thymidine nucleoside reverse transcriptase inhibitor 
(zidovudine (ZDV) or stavudine (D4T)), or didanosine (DDI), on lipid profiles, 
adipocytokines and insulin resistance in HIV positive patients.
Patient ID Patient Initials Date
Please answer the following questions by ticking the boxes as appropriate. Please answer each 
question truthfully. The way you are treated will not be affected if you answer that you do not 
take medication all the time as instructed:
1. Do you ever forget to take your medicine?
Yes □ No □
2. Are you careless at times about taking your medicine?
Yes □ No □
3. If at times you feel worse, do you stop taking your tablets?
Yes □ No □
4. Did you miss any of your medications last weekend?
Yes □ No n
5. Thinking about last week, how often have you miss taking your medicine? (Please tick 
one as applicable)
A: Never □
B: 1-2 □
C: 3-5 □
D: 6-10 □
E: More than 10 □
6. How many days have you missed taking all your medicines during the past 3 months?
Days:__________________________________________________________________
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Appendix 3 (audit proforma)
Audit 1: Dyslipidaemia and Highly Active Antiretroviral drugs in HIV positive 
patients AuditNorth Manchester General Hospital - Infectious Diseases Research 
Unit
/ /Date:_______
Demographics:
Age (years):!
HAART:
Ethnicity: White □
Other (specify)
Sex: M □ F □ 
Biack-African □
Doctors Initials
Afro-Caribbean □ Asian □
Current combination:
NRTI Backbone: _______________
Pl(s): ______________
NNRTI: _______________
Total Duration of current HAART (months): 
Previous exposure to: NRTIs □ Pis □ 
Duration of All ART (Years):_________
Lipids/Biood Sugar: Lab results previous 1 year
NNRTO
Date
TC
LDL
HDL
Fasting TGs
TC:HDL
Blood sugar
TC £5 at any time point
Cardiovascular Risk Factor:
Smoking
Yes
□
No
□
FHx of IHD □ □
Diabetes n □
Raised BP □
Dyslipidaemia □ □
Blood Pressure (when
CV Risk % |-----
Management aspects: 
Life style advice given
well) I i
YesHU No n
Drugs Given Yes
If yes Specify 
□ No □
if yes Specify: LLA (type eg. statins, fil
GTT done? Yes Q No HU
BP not recorded □
CV Risk not calculated I—l
Antihypertensives 
Antidiabetics 
Aspirin_______
Referred for further care (eg. lipid clinic, dietician, GP, smoking cessation services, alcohol services, 
cardiologist, diabetologist)
Yes □ No □
If yes Specify
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Appendix 4
SECTION 1
Date:
Patient ID:
Demographics:
Age (years) L
HAART:
SECTION 2
Audit 2: North West HIV Network Audit CVD Risk
Management in HIV Patients on HAART (Nov 14th 2007)
/ / Hospital name/dept: 
Audit number: (1-6 per consultant) No.
Black-African □ Afro-Caribbean □ 
Other (specify)_____________
Sex: M □ F □
Ethnicity: White □
Asian □
Current combination:
NRTI Backbone: _______________
Pl(s): ______________
NNRTI: _______________
Total Duration of current HAART (months): 
Previous exposure to: NRTIs □ Pis Q 
Duration of All ART (Years):_________
NNRTI □
Recorded Not Recorded
Smoker: YesO No D □
Past relevant CVD history (e.g. Hypertension, IHD, CVA and DM, dyslipidaemia etc):
YesD NoD □
FHx of CVD 1° relatives ($<65y, <$<55y):
Yesn No □ □
Total Choi: Highest level past 1 year (mmol/L):
AND
HDL-Chol level (any) (mmol/L):____________
OR
Total Chol:HDL Ratio, highest past 1 year:___
Euglycaemic (glucose < 6.0) d Raised Glucose d Borderline d
BP: /_____ mmHg No record in notes □
SECTION 3:
Do you use the Joint British Societies’ Guidelines on the Prevention of Cardiovascular 
Disease in Clinical Practice (Jan 2006)?
NO d please fill in the yellow coloured BOX 1 below ONLY (page 2), then enter the 
consultant name in the box at the bottom of page 3. The questionnaire is then complete.
YESd -* please complete the following subsection on CVD risks, then fill in EITHER the 
purple BOX 2 (<20% CVD risk) on page 2, OR the green BOX 3 (>20% CVD risk) on page 
3. Then enter the consultant name in the box at the bottom of page 3. The questionnaire is 
then complete.______________ _________________________________________________
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BOX 1
JBS Guidelines not used
Smoker Counselled (stop smoking) CH
Referred smok cessn u
Ref to GP/acup/hypno □
Started meds ie (patches) □
BP: Not Recorded □
Normal □
High □U Counselled re salt/exercise YesD NR EH
Ref to GP/BP clinic/medics YesD nrD
Started meds YesD NR EH
Specify:
Lipids: Not Recorded □
Normal □
Abnormal: cu dietary advice given Yes EH NR EH
Ref to GP/lipid clinic/dietician YesD NR EH
HAART changed YesD NR EH
Started meds YesD NR EH
Specify:
Weight Not Recorded □
Normal □
Big/overwt □-> Counselled diet/exercise YesD NR EH
Ref to GP/dietician YesD NR EH
FPG Not Recorded □
Normal □
>6/Diabetic □ -> Counselled diet/exercise Yes EH NR EH
Ref to GP/DM clinic/dietician YesD NR EH
BOX 2 JBS Guidelines used
Patients at <20% risk of CVD over next 10 years
Life style advice:
• Smoker: Counselled (stop smoking) YesD NR EH
• Diet YesD NR EH
• Exercise Yes EH NR EH
• Wt Reduction (if over-wt) Yes EH NR EH
• Alcohol moderation YesD NR EH
Addressed any isolated high risk factors:
• BP(>160 syst or >100 diast) Yes EH NR EH
• TC/HDL >6 YesD NR EH
• Familial dyslipidaemia Yes EH nrD
Targets reached EH Targets NOT reached EH Action/Referred to (specify):
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BOX 3 JBS Guidelines used
Patients at >20% risk of CVD in next 10 years
Life style advice:
• Smoker: Counselled (stop smoking) YesEH NRC
• Diet YesD Nan
• Exercise YesD NrD
Wt Reduction (if over-wt) YesD NRD
• Alcohol moderation YesD NRD
BP: Not Recorded □
Normal □
High □ -> Counselled re salt/exercise YesD nrD
Ref to GP/BP clinic/medics YesD nrD
Started meds YesC] nrD
Specify:
Lipids: Not Recorded □
Normal □
Abnormal: □ -> Ref to GP/lipid clinic/dietician YesD nrD
HAART changed YesD nrD
Started meds YesD nrD
□
Specify:
RPG Not Recorded
Normal (<6) □
Diabetic(>l 1) Or Impaired Glucose Tolerance (7-11)
u- Counselled diet/exercise YesO nrD
Ref to GP/DM clinic/dietician YesLJ nrD
Targets reached □ Targets NOT reached □ ^Action/Referred to (specify):
Consultant’s Name: Thank you!
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Appendix 5
North Manchester general Hospital Infectious Diseases Department 
Annual Patient Assessment
Patient Name:_______________________ Date:___!__ /
Unit number:________________
Date of birth: / /
Consultant:
CD4 counts and Viral loads previous 1 year:
1 2 3 4 5 6
Dates
CD4 (absolute)
CD4 %
Viral Load
Vaccination Status:
Hep A: Immune Yes 
Non-immune Vaccination given / /
HepB: Immune (Anti-Hbs Ab >100) d
Non-immune Q Vaccination/Booster given: 
Previous infection (HBsAg -/HBcAb+) [13
/
Hep C: Positive Q Negative Q ^ repeat serology date: _____
Influenza vaccination Date:___/__ !____
Renal Function:
Phosphate Normal Q Low □
Creatinine Clearance (ml/min):____________
(Cockcroft-Gault formula for CrCl: M= 1.23x(l 40-age) x Wt(Kg)/creatinine (/.jmol/l); 
F = 1.04 x (140-age) x Wt(Kg)/creatinine (gmol/l)
Urine Dipstick: Normal Abnormal (specity):
Syphilis serology: Date: / / Pos n
Cervical Smear (in Women) Date: / /
Sexual screen Date: / /
BP: / mmHs
Weight: Kg
Cardiovascular Risk Management: 
CV Risks: Smoker: Yes □ No □
tChoI/TGs Yes □ No □
Blood glucose: Normal □
NegD
Diabetes □
OGTT: Results (if performed)
CV Risk %:
(Risk Assessor at http://www.bnf.org/bnf/extra/current/popup/risk.xls OR charts in BNF))
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All CV Risk + established vascular disease (DM, IHD, CVA, PVD):
Life-style advice given:
Smoking cessation □ Wt4. □ Diet □ ExerciseD
CV Risk > 20% or established vascular disease (DM, IHD, CVA, PVD)
If Drug treatment started: tBP □ TLipids Q
Referrals for un-resolving Risk factors/established vascular 
tLipids => lipid clinic
tBP => hypertension clinic/GP/medics
DM => DM clinic/GP
IHD (angina) cardiologist
Smoking => smoking cessation clinic/GP
Participation in clinical trials YesQ No □
DM □
disease
□
□
□
□
□
Signature Name Bleep
•^Alcohol Q 
Aspirin □
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Appendix 6
North Manchester General Hospital Infectious Diseases Department 
New Patient Assessment
***PLEASE COMPLETE ON BOTH SIDES OF THIS FORM***
Patient Name:_______________________ Date: _____
Unit number:________________ Consultant:_________
Date of birth: / /
Demographics:
Age:______ years
Sex: Ml I F I 1
Ethnicity: White [[] Black-African Q Afro-Caribbean | |
Asian [U Other (specify)_____________
Country of Origin________________________
Occupation/Immigration status:_________________________________
Mode of HIV acquisition:
MSM D Heterosexual d IVDU d
Other (specify)_____________
Social: Smoker Yes d (Cigs/day:____) No d
Alcohol Yes d (units/week:____) No d
CV risk factors: DMO HypertensionQ CVAd IHD (angina, Mid
FHx of: IHD 1° relatives ($<65y, (^<55y) d Dyslipidaemia d
BP:_____/_____mmHg Weight: ____ Kg
HIV diagnosis (Date): / /
CD4 Nadir:_____cell/ml %____ Date: _____
Viral Load:_____copics/ml Date: _____
Serologies:
Hep A: Immune (IgG+) I I
Non-immune d => Date vaccinated: 111 , 211_____
Hep B: Positive (sAg+O => e antigen + □ e antigen- d dna Viral load____copies/ml
Negative (sAg-ve/cAb-ve) d
=> Dates vaccinated: III_____, 211_____, 3 / /_____
Previous infection (HBsAg-/HBc+) d
Hep C: Positive Q If CD4 <200: HCV RNA PCR____copies/ml => Genotype:___
Negative Q
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Syphilis: Positive Q Negative □ Date: / /
CMV IgG: Positive Q Negative O Date: / /
Toxoplasma (IgG): Positivd 1 Negative d Date: / /
EBV IgG: Positive □ Negative dl Date: __ /__/_____
Cryptococcal Antigen (if CD4 <100):
Positive Q Negative QJ Date: / /
VZV IgG: Positive n Negative d Date: __ /__L_____
If lived in tropics, Tropical screen (Strongyloides, Schistosomiasis):
Positive C] Negative I I
Haemoglobinopathy Screen (if appropriate) _____________
Urine Dipstick: Normal D Abnormal O (specify):
CXR: Date / / Comment: ____________ ______ ________________
ECG: Date / / Comment:
Last Cervical Smear (in Women) Date:
Sexual screen Date: / /_____
CV RISK % | | (if >20% follow Joint British Guidelines for CVD prevention)
(To assess CVD risk: Need age, sex, smoking history, systolic BP, TC/HDL ratio then use graph 
at back of BNF or risk calculator program to calculate CVD risk)
Signature _________________________
Name __________________________
Bleep
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